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ABSTRACT 
Since the approval of the first monoclonal antibody (mAb) drug in 1986, mAbs have developed 
into a major class of therapeutic agents due to their unique properties. Compared to traditional 
small molecule drug products, the actions of the antibodies are more specific leading to generally 
fewer off-target related side effects. Also antibodies may be conjugated to another therapeutic 
entity for efficient delivery of this entity to a target site, thus reducing potential side effects. On 
the other hand, due to the structural complexity and the dependence of stability of the antibodies 
on the conformation and structure, antibodies are subject to multiple degradation pathways 
induced by a variety of factors encountered during antibody production, purification, 
development, manufacturing, storage, shipping and delivery to the patients. The exposure of 
antibodies to redox-active metal ions and/or light during processing and use is inevitable, and 
may result in antibody degradation. Although abundant information on metal-catalyzed oxidation 
(MCO) and photo-degradation of peptides and small proteins is documented in the literature, 
very limited research has been performed on IgG oxidative modifications and physical 
instability. The research covered in this dissertation focused on two major degradation 
mechanisms for IgG therapeutic mAbs: chemical and physical instability induced by redox-
active metal ions and photo-degradation. Redox-active metal ion-induced instability was first 
examined by a comprehensive study of IgG oxidation induced by MCO. The oxidation of the 
amino acids, especially Phe and Tyr in IgG1 was first identified, and subsequently a fluorogenic 
derivatization methodology was developed for their detection. Secondly, a systematic study of 
the conformational change and intrinsic thermal stability of IgG revealed that metal ions 
perturbed IgG tertiary structure resulting in decreased intrinsic thermal stability. Lastly, metal 
chelators were examined to protect the IgG from MCO-induced degradation. This dissertation 
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also documents the formation of carbon-centered radicals due to homolytic cleavage of disulfide 
bonds upon photo-irradiation and an UPLC-MS method was developed to simultaneously 
separate and characterize IgG1 photo-degradants. The ultimate goal of this research is to gain 
better understanding of IgG degradation mechanism, thereof, providing guidance to develop a 
therapeutic mAb drug product with desired attributes for unmet medical needs.   
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1.1 Introduction 
Since the approval of the first monoclonal antibody (mAb) product, OKT-3 in 1986, IgG 
antibodies represent a rapidly growing biotherapeutic class in the biopharmaceutical industry for 
the treatment and prevention of diseases by recognizing and eliminating pathogenic and disease 
antigens [1-3]. Prior to delivery of a therapeutic IgG product to the patients, the antibody 
undergoes a variety of stresses during each step of antibody production, purification, 
development, manufacturing, shipping, storage and delivery. These stresses include but are not 
limited to pH, temperature, leachables, freeze/thaw, shaking, shearing, absorption, ionic strength, 
reactive oxygen species, impurities from the exicipients and/or light exposure, etc. Each stress 
may induce IgG physical and chemical instability, resulting in potentially significant negative 
consequences, such as reduced potency [4],  formation of subvisible/visible particles [5], and 
immunogenicity [6]. Among these stresses, the exposure of IgG to the contamination of redox-
active metal ions and/or light is inevitable in developing a biotherapeutic drug product, which is 
the focus of this dissertation.   
Abundant information on the degradation mechanisms of metal-catalyzed oxidation 
(MCO) of peptides and small proteins, especially the oxidative modifications of His, Cys, Met 
and Trp can be found in the literature [7-15]. However, few studies have focused on the impact 
of metal ions on IgG conformation / thermal instability and chemical instability, especially the 
oxidative modifications of Phe and Tyr.  
Light testing is an integral part of stress testing for submission in registration application 
for new molecular entities and associated drug products by regulatory agencies [16]. The current 
literature has focused on investigating the degradation mechanisms of photo-instability on model 
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peptides and/or small proteins [17-20]. Due to the structural complexity of IgG, so far, very 
limited knowledge on photo-initiated degradation mechanism(s) of IgG can are available.  
The limited understanding of IgG degradation mechanism(s) leads to less efficient design 
of stable antibodies and/or formulations to provide first-class therapeutic IgG products to the 
patients. The focus of this dissertation is to investigate IgG with respect to i) physical and 
chemical instability induced by redox-active metal ions and formulation strategies to prevent 
metal-catalyzed degradation, and ii) photo-degradation mechanism(s) by studying the formation 
of carbon-centered (C-centered) radicals upon photo-irradiation and developing a methodology 
allowing simultaneous separation and characterization of IgG photo-degradation products. The 
ultimate goal is to address these two major concerns encountered in developing IgG therapeutic 
agents. Prior to introducing any detailed aspects of these two projects, it is necessary to review 
IgG structure, therapeutic significance, instability and development challenges in general.    
1.1.1. Overview of IgG  
1.1.1.1 Structure 
IgG antibody is a protein, composed of primary sequence and higher order secondary, 
tertiary and quaternary structure. Primary sequence is defined as the amino acid sequence 
composed of 20 amino acids. Different regions of the primary sequence form local regular 
secondary structure consisting of α helices, β strands and/or random coils. The tertiary structure 
is formed by packing the secondary structure into one or several compact globular domains. The 
final protein may contain several polypeptide chains arranged in quaternary structure. Protein 
stability and its functions depend not only on its primary sequence but also on its high order 
structures. 
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Antibodies belong to a family of globular proteins called immunoglobulins. 
Immunoglobulins comprise antibody molecules and molecules having patterns of molecular 
structure (antigenic determinants) in common with antibodies. They are roughly Y-shaped 
molecules or combination of such molecules, consisting of variable region (Fv) defining antigen-
binding properties and constant region (Fc) interacting with effector cells and molecules. Based 
on the differences in the Fc region, immunoglobulins are divided into five classes of IgA, IgD, 
IgE, IgM and IgG. IgGs (~150 kDa) contain two identical heavy chains (~50 kDa) and two 
identical light chains (~25 kDa). IgGs are further divided into four subclasses of IgG1, IgG2, 
IgG3 and IgG4 based on the number and location of the inter-chain disulfide bonds and the 
length of the hinge region.  
The IgG light chain consists of two domains and the heavy chain contains four domains, 
respectively. Each domain is of about 110 amino acids (~12 kDa in size) [21]. All these domains 
display similar folded structures of β barrels, which comprise the immunoglobulin fold. Each 
domain is stabilized by a disulfide bond and hydrophobic interactions. These individual domains 
interact with one another and fold into three equal-sized spherical shapes linked by a flexible 
hinge region. The stability of the antibody is a result of balance between destabilizing and 
stabilizing forces. The destabilizing forces are mainly due to the large increase in entropy of 
unfolding, and the stabilizing forces are provided by covalent/non-covalent interactions. The 
presence of a significant number of disulfide bonds and intimate domain-domain interactions in 
antibodies make them relatively more stable and resistant to moderate thermal stress compared to 
other proteins. Unlike small-molecule drugs, the large size, compositional variety, and 
amphipathic characteristics of the IgG constitute specific behavior such as folding, 
conformational stability and unfolding/denaturation. 
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1.1.1.2 Therapeutic significance  
Since the first IgG product, OKT-3 came on the US market in 1986, approximately 30 
antibodies have been approved by Food and Drug Administration (FDA) to become 
commercially available therapeutic products in the US alone by 2011. Antibodies have gained 
popularity for commercial development as therapeutic agents because i) compared to small 
molecule drugs, mAbs are highly specific, thereby reducing side effects or having fewer; ii) 
antibodies may be conjugated to other therapeutic entities for efficient delivery of these entities 
to the target sites, thus reducing potential side effects [22]; iii) antibodies may be conjugated to 
radioisotopes for specific diagnostic purposes; and iv) technology advancement has made fully 
human mAbs available, which are less immunogenic. On the other side, mAbs exhibit 
significantly lower stability due to the strong dependence of their physical-chemical properties 
on the structure and conformation. Like other proteins, antibodies are prone to a variety of 
physical and chemical degradation pathways. Their instability can be observed in liquid, frozen 
and lyophilized states. In many cases, multiple degradation pathways can occur at the same time 
and the degradation mechanisms may change depending on the stress conditions [23].  
1.1.1.3 Chemical and physical instability 
Even though multiple degradation pathways are present, in general, the degradation 
pathways are divided into two major categories: chemical and physical instability. Chemical 
instability is defined as any process that involves covalent bond formation and/or breakage, 
yielding new chemical entity whereas physical instability does not involve any covalent 
modification. However, chemical degradation can also lead to physical instability. Both chemical 
and physical instability can be induced by a variety of factors, such as pH, reactive oxygen 
species, temperature, shaking, ionic strength, vortexing, and surface/interface adsorption, etc. 
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Chemical instabilities reported for proteins of therapeutic interest are deamidation, Asp-
isoAsp interconversion, racemization, proteolysis, β-elimination, oxidation, disulfide exchange, 
formation of diketopiperazine (DPK) ring, condensation reaction, formation of pyroGlu (pGlu) 
and hydrolysis [24]. Any protein containing His, Met, Cys, Trp, Tyr and Phe amino acids can be 
potentially damaged by reactive oxygen species (ROS) [13, 25-26].  
Physical instability refers to the changes in the antibody high order structure of 
secondary, tertiary and/or quaternary due to the polymeric nature and ability of antibody in 
adapting to different forms without alteration in its chemical compositions. This includes 
denaturation, aggregation, precipitation, and surface absorption. Denaturation denotes the loss of 
the globular or three-dimensional structure that most proteins adopt, that is, a disruption of the 
tertiary and secondary structure. Once unfolded, the polypeptide chains can undergo further 
inactivation by association with surfaces (absorption), aggregation with other protein molecules, 
or some chemical reactions. The process by which aggregation leads to macroscopic ensembles 
is termed “precipitation”. Aggregation may result from chemical degradations or modifications 
and subsequently exposure of the hydrophobic surface(s). Physical and chemical aggregation 
may occur simultaneously. The most common physical instability is protein aggregation.  
1.1.1.4 Challenges in developing IgG therapeutics  
One of the most challenging tasks in the development of protein pharmaceuticals is to 
deal with physical and chemical instability. During biotherapeutic product development, 
manufacturing, shipping, storage and delivery process, the biotherapeutic products inevitably 
experience various stresses, resulting in degradation. Aggregation and oxidation represent two 
prominent degradation pathways [7, 12-13, 15, 27-30].  
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Aggregation has received much attention from industry, academia, as well as regulatory 
agencies for a number of reasons. First, aggregates may have reduced activity and more 
importantly, have the potential to induce immunogenicity [31-32]. Immunoglobulin aggregates 
have been reported to cause serious renal failure [33] and anaphylactoid reactions, such as 
headache, fever, and chills [34]. Second, the presence of aggregates may reduce the potency of 
the products, since their biological activity may be compromised due to conformational change. 
Lastly, aggregates, especially insoluble aggregates, can form subvisible and visible particles to 
make a solution turbid or physically precipitate from the solution, thus reducing its 
pharmaceutical elegance and resulting in a loss of quality of the product.  
Oxidation is another major concern. Oxidative modifications of the amino acid residues 
may have significant impact on protein functions. A loss of binding and biological activity was 
observed for IgG monoclonal antibodies due to light oxidative modifications [35-36]. Oxidation 
can further induce formation of aggregates [35, 37]. Oxidation of proteins can be classified into 
two general categories: i) site specific reactions, i.e. metal-catalyzed oxidation; and ii) non-site 
specific reactions, i.e. photo-oxidation and free radical cascades. Metal-catalyzed oxidation can 
induce both physical and chemical instability [11, 13].  
1.2. Overview of this dissertation 
Instability of IgG induced by redox-active metal ions and photo-exposure is commonly 
encountered during the production and use of biotherapeutic products. Understanding the 
underlying degradation mechanisms would provide valuable insights to stabilize protein 
pharmaceuticals and/or to design more stable proteins. In light of the above discussion, specifics 
of this study will now be addressed. In this dissertation, seven themes are discernible throughout 
the research presented in Chapters 1 through 8 to help address these two major concerns. The 
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dissertation covers Part I: chemical and physical instability of IgG by redox-active meta ions by 
examining i) the origin of metal leachables, ii) chemical modifications and their 
detection/characterization, iii) physical instability, conformational change and aggregation,  iv) 
thermal instability and v) formulation strategy to protect IgG from degradation; and Part II: 
photo-instability by studying vi) formation of carbon-centered radicals in IgG and vii) 
developing a methodology to allow simultaneous separation and characterization IgG photo-
degradants. The first five themes in Part I are designed to address the IgG instability concerns 
induced by redox-active metal ions and the last two to gain understanding in IgG photo-
instability. Finally, Chapter 9 offers general conclusions as well as a critical assessment of the 
research presented, and suggestions for future research directions.  
1.2.1. Instability of an IgG1 mAb induced by redox-active metal ions 
1.2.1.1. Origin of metal ions 
Metal ions can be inadvertently introduced into biotherapeutic products from different 
resources, such as excipients, and/or leachables from the contact materials. The level of metal 
ions present in parenteral grade excipients is generally at part per billion (ppb) or below. In this 
dissertation, metal leachables from the stainless steel are the major focus. Chapter 1 and 2 
evaluate the capacity of the biologic formulation factors in leaching metal ions from stainless 
steel by first studying the impact of the commonly used individual formulation factors and then 
the combination of the formulation factors by the approach of design of experiments (DOE).  
1.2.1.2. Chemical and physical instability of an IgG1 induced by metal ions  
Metal ion induced chemical and physical instability of an IgG1 is the main focus through 
Chapters 3-5. Chapter 3 addresses the chemical instability, more specifically the oxidative 
modifications induced by MCO and their detection/characterization. Chapter 4 focuses on the 
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physical instability, mainly the conformation instability and the resulting aggregation whereas 
Chapter 5 targets another aspect of physical instability, that is, thermal instability. Chapter 6 
examines the practical aspects of formulation in evaluating the metal chelators to prevent metal-
catalyzed degradation which would be directly applicable to biotherapeutic product 
development.  
Chapters 3-6 are designed in a way to systematically address an IgG1 physical and 
chemical instability induced by metal ions encountered in developing biotherapeutic products 
and formulation strategies. 
1.2.2. Photo-instability 
Photo-irradiation induced instability is the second subject of this dissertation. Photo-
instability is first examined by investigating the formation of carbon-centered radicals in IgG1 
and IgG2 exposed to ultra-violet (UV) irradiation (chapter 7) and then chapter 8 focuses on 
developing a method capable of simultaneous detection and characterization of IgG1 photo-
degradants.   
1.3. Remarks 
IgG mAbs represent an important class of biotherapeutic agents. Since the exposure of IgG to 
redox-active metal ions and/or photo-irradiation is inevitable, understanding of degradation 
mechanisms of IgG mAb induced by the two stresses would have significant impact in 
developing first-class biotherapeutic products to cure the patients in need.   
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1.1 Introduction 
Metal ions occur widely in association with proteins both in vivo and in vitro via direct 
covalent binding or electrostatic interactions. Alkali and alkaline earth metals bind proteins 
primarily through electrostatic interactions while the transition metals, such as Fe(II/III), Co(II), 
Cu(II), Al(III), and Mn(II), bind covalently to proteins [1] because the protein ligands donate an 
electron pair to form coordinate covalent bond with transition metals. The most common metal-
binding amino acids are cysteine, histidine, aspartate, glutamate, and more rarely, glutamine, 
serine, methionine, threonine, and tyrosine because they contain electron donor elements, such as 
sulfur, nitrogen, or oxygen. The coordination numbers vary from one to eight among different 
metals. The solution pH and ionization state of the amino acid residue play an important role in 
determining the coordination number. Metal ions mediate in vivo biological functions of about 
one third of the known proteins via directly binding to either protein catalytic sites or structural 
sites [1]. Metal ions in proteins serve a variety of functions, including stabilizing protein 
structure and assisting protein function by inducing conformational changes. On the other hand, 
excessive metal ions introduced into biological systems have been implicated in the aggregation 
of proteins responsible for the pathophysiology of several neurodegenerative diseases, such as 
Alzheimer and Parkinson disease [2]. 
Although metal ions play a critical role in modulating physiological functions through 
binding to proteins in vivo, they can have a profound negative impact on biotherapeutic products 
when present as inadvertent contaminants. Trace levels of metal ions can induce biotherapeutic 
product degradation which potentially jeopardizes the quality of the products by altering 
physicochemical properties as well as reducing stability and shelf life. Metal ions migrating from 
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rubber stoppers into a therapeutic protein liquid formulation have been reported to induce N-
terminal degradation [3]. Barium leached from glass vials reacted with sulfate in the formulation 
to form visible particles [3]. Salts of tungsten oxide were shown to migrate from prefilled 
syringes into the drug product, where they triggered protein oxidation followed by aggregation to 
produce visible particles [4]. 
Contamination by leachables raises concerns about the safety and efficacy of the product 
due to the potential to cause acute toxicity or long-term health issues through chronic exposure. 
In the USA, the requirement for the proper evaluation of extractables and leachables (E&Ls) is 
governed by the FD&C Act as codified in 21 Code of Federal Regulations parts 210 and 211. 
Current Good Manufacturing Practice in Manufacturing, Processing, Packing or Holding of 
Drugs: General and Current Good Manufacturing Practice for Finished Pharmaceuticals, Subpart 
D-211.65 which states that “equipment shall be constructed so that surfaces that contact 
components, in-process materials, drug products shall not be reactive, additive, or adsorptive so 
as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official 
or other established requirements.”  
Specific guidance has been issued for monitoring and control of leachables as part of 
requirement for the documentation of primary packaging of drug product [5–9]. Orally inhaled 
and nasal drug products as well as injection (solution and powder) products are of the highest 
degree of concern. The likelihood of interaction between packaging and dosage form is 
considered high for solutions or suspensions and medium for powders. Biological products are 
predominately formulated as liquid or freeze-dried products delivered by injection, which fall 
into the category of highest concern.  
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In biopharmaceutical drug product manufacturing and storage processes, the contact 
materials can be classified into three main categories: plastics/elastomers, glass, and stainless 
steel. Plastics/elastomers are by far the biggest source of extractables and leachables. Extensive 
research has been devoted to leachables/extractables from plastic materials [10–19]. The strategy 
and guidance for selecting, evaluating, and qualifying appropriate container closures as well as 
strategies for safety evaluation have been reported [20–23]. Other leachables/extractables from 
glass have also been studied [21, 22]. However, very limited research has been carried out on 
metal leachables/extractables. Metals can leach out from drug substance and/or product 
contacting equipment in the manufacturing, packaging, shipping, and storage process, especially 
from stainless steel surfaces. Some plastic packages, glass vials, and/or rubber stoppers can also 
be the sources of metal leachates [24]. Stainless steel is a typical contact material used for 
biologics product manufacturing, shipping, and storage. The stainless steel commonly used in 
biopharmaceutical applications is of the grade 316L and is an alloy containing mainly iron, 
nickel, and chromium with minor amounts of manganese and molybdenum. The grade 316L is a 
low-carbon formulation of austenitic stainless steel 316, and this modified chemistry is designed 
to reduce the propensity of the alloy to sensitize. Sensitization is the precipitation of chromium 
carbides (actually mixed iron/chromium carbides) along grain boundaries of stainless steel. This 
precipitation depletes the volume of metal near the grain boundaries of chromium in solution, 
thereby diminishing its corrosion resistance. The precipitation rate can be reduced by keeping 
carbon below 0.03%. The objective of this work is to elucidate the effect of various biologics 
formulation factors (e.g., buffer species, fill volume per unit stainless steel contact surface area, 
metal chelators, and pH) on the quantity of metal leachables from 316L stainless steel over time 
at different storage conditions. 
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1.2 Materials and methods 
1.2.1 Materials  
As shown in Fig. 1, the rectangular shape 316L stainless steel defined as coupons were 
utilized for this study. Prior to use, the coupons were chemically passivated by first immersing 
them in the solution of 1:4 (v/v) of CitruSurf solution (50%; Stellar Solution, McHenry, IL, 
USA; http://www.citrisurf.com) to milliQ water for 30 mins at 50–70°C and then were 
autoclaved after thorough rinsing with water. Two different sizes of stainless steel coupons were 
utilized, defined as type A and B. Type A had a surface area of 3.52 cm2 with the dimensions of 
1.55 cm (length) × 0.7 cm (width) × 0.3 cm (thickness) while type B had a surface area of 6.0 
cm2 with the dimensions of 2.5 cm (length) × 1.0 cm (width) × 0.15 cm (thickness). The 30-mL 
type I glass vials with 20 mm neck were purchased from Abbott Laboratories (Chicago, IL, 
USA). The 10-mL type I glass vials with 20 mm neck and serum stoppers were obtained from 
West Pharmaceutical Services (Lionville, PA, USA). USP/EP grade L-histidine and L-histidine 
mono hydrochloride, analytical grade acetate acid, monobasic sodium phosphate, dibasic sodium 
phosphate, citric acid (anhydrous), and sodium citrate dihydrate, acetate acid and sodium acetate 
trihydrate, succinic acid, FeCl3, disodium edentate (Na2EDTA), and 
diethylenetriaminepentaacetic acid (DTPA) were obtained from Sigma-Aldrich Chemical Co. 
(St. Louis, MO, USA). Polyvinylidene fluoride, 0.22 μm, filters were obtained from Millipore 
Inc. (Billerica, MA, USA). 
1.2.2 Methods 
1.2.2.1 Inductively coupled plasma-mass spectrometry (ICP-MS) 
Metal ion concentrations in the testing solutions were quantitated by an inductively 
coupled plasma–mass spectrometry (ICP-MS) method which utilized an Agilent 7500 CX ICP-
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MS system equipped with an autosampler. The instrument was qualified and calibrated with 
certified standard multi-element solution (BDH 10 ppm-Aristar) and maintained regularly. The 
accuracy of the method was evaluated by spiking recovery and inter-lab comparison with 
external GLP lab in Galbraith Laboratories, Inc. (Knoxville, TN, USA). All vessels, pipettes, and 
other laboratory equipment that came in direct contact with solutions used in the analysis were 
made of plastic. Samples were analyzed in the “hydrogen mode” and 10× diluted certified 
standard multi-element solution (BDH10 ppm-Aristar) was used as the internal standard. An 
external calibration curve for each element measured was established before analyzing the 
samples. A linear response curve between 1 and 500 ppb was established for iron, and 1–100 ppb 
for chromium and nickel. The limit of quantitation of iron, chromium and nickel was 1 ppb. A 
50-ppb iron standard was analyzed every six samples to ensure the system performance. Samples 
were injected directly without dilution unless the metal ion concentration was outside the linear 
range as specified above. The sample volume required was 3.0 mL, and 1.5 mL aliquots were 
injected.  
1.2.2.2 RP-HPLC analyses for chelator concentration 
The concentrations of both Na2EDTA and DTPA in the formulations were determined 
using an Agilent 1100 system coupled to a diode array detector. The system was calibrated and 
maintained regularly. The method accuracy was evaluated by spiking recovery. The separation 
was achieved isocratically on an Agilent Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm) at a 
flow rate of 1 mL/min at ambient temperature. The mobile phase consisted of 30 mM sodium 
acetate, 2 mM tetrabutylammonium hydroxide, and 5% (v/v) methanol in water (pH 3.15). 
Excessive FeCl3 (5 mM final concentration) was added to both samples and standards. External 
calibration was established with varying levels of Na2EDTA and DPTA simultaneously. Of the 
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sample, 20 μL was injected onto the column and the separation was monitored by UV detection 
at 254 nm. 
1.3 Experiments 
To assess the effect of the five buffers on metal leachates from passivated 316L stainless 
steel at storage temperatures of −40°C to 25°C, the relationship between the testing solution 
volume (mL) and the coupon surface area (cm2) was controlled at 5 mL/cm2. All buffer solutions 
were prepared at 20 mM (pH 5.5) and sterile filtered with 0.22 μm polyvinylidene fluoride 
filters. Aliquots of 17.6 mL of the filtered buffer solutions were added into 30 mL type I glass 
vials with or without type A stainless steel coupons and sealed with serum stoppers and flip-off 
aluminum seals. The vials were stored in the stability chamber at either −40°C, −20°C, 2–8°C, or 
25°C/60%RH separately for over 34 weeks. The vials without type A stainless steel coupons 
served as negative controls. The testing solutions and storage conditions are summarized in 
Table 1. The selected buffer types, concentration, pH, and storage conditions were chosen 
because these are commonly used conditions in biotherapeutic drug substance and/or product 
development. To evaluate the impact of contact surface area on metal leachates, commonly used 
20 mM histidine–HCl buffer at pH 5.5 was selected as a testing solution. The testing solution 
volume (mL) per unit stainless steel contact surface area (cm2) was selected to be between 1 and 
5 mL/cm2, with 1 mL/cm2 as the worst case scenario for a stainless steel minitank used as a 
model for stability studies. The testing solution was prepared and processed as previously 
discussed. Aliquots of the testing solution of 17.6 mL for 5 mL/cm2, 14.08 mL for 4 mL/cm2, 
10.56 mL for 3 mL/cm2, 7.04 mL for 2 mL/cm2, and 3.25 mL for 1 mL/cm2 were individually 
added to the vials with or without type A stainless steel coupons and stored at 25°C/60% RH in a 
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stability chamber over the time period of 26 weeks. The vials without stainless steel coupons 
served as negative controls. 
Many parenteral biologics drug products include metal chelators to improve product 
stability. To assess the effect of chelators on metal leachates, DTPA and Na2EDTA were tested 
as chelators at three concentrations of 0.0, 0.134, and 0.268 mM in 20 mM histidine–acetate 
buffer at pH 6. At this pH, DTPA (H5A), polyamino polycarboxylic acid, exists in equilibrium 
between H2A
3− and H3A
2−; however, in presence of metal ions, DTPA forms the metal 
complexes of MA3−/MA2− at equal molar ratios. For simplicity, the term DTPA and Na2EDTA 
are used in the text, regardless of their ionization forms. Here, the concentration of 0.134 mM is 
equivalent to 0.05 mg/mL Na2EDTA and 0.053 mg/mL DTPA. Similarly, the concentration of 
0.268 mM is equivalent to 0.1 mg/mL Na2EDTA and 0.106 mg/mL DTPA. These two 
concentrations were selected because they are typical concentrations applied in parenteral 
formulations. The samples without chelators served as controls. The stainless steel coupons 
utilized in this experiment were of type B due to unavailability of the previously used type A 
coupons. In order for the coupons to be fully immersed in the solution, 10 mL type I glass vials 
were used as the sample containers. The fill volume of the testing solutions (mL) per unit 
stainless steel contact surface area (cm2) was controlled at 1 mL/cm2. The testing vials were 
filled with 6.0 mL of solution in glass vials with or without stainless steel coupons and were then 
stored in a 25°C/60% RH stability chamber for 34 weeks. The vials without stainless steel 
coupons served as negative controls.  
It is well known that pH plays a major role in protein stability. To evaluate the effect of 
pH on metal leachates, 20 mM histidine–acetate solutions, of pH values ranging from 5.0 to 9.0, 
were tested. The stainless steel coupons, glass vials and fill volumes were the same as those 
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utilized for the chelator evaluation in the previous experiment. The vials filled with testing 
solutions (6.0 mL) with or without stainless steel coupons (type B) were stored in a 25°C/60 RH 
stability chamber over the time period of 34 weeks. The vials without stainless steel coupons 
served as negative controls. 
1.4 Results 
The amount of metal ions leaching into biologics products is subject to multiple 
variables, such as formulation components, pH, contact materials, drug substance/drug product 
contact surface area with stainless steel, surface area processing procedure, contact duration and 
temperature, etc. In this paper, commonly utilized buffers, the relationship of the solution 
volume and contact surface area, chelators, and pH were studied individually to explore their 
impact, if any, on metal leachates from 316L stainless steel coupons. 316L (US: S31603) is an 
alloy, mainly composed of iron (62–72%), Cr (16–18.5%), and Ni (10–14%) [25]. Thus, in this 
study, all these three metals in the testing solutions were monitored by ICP-MS to evaluate the 
concentrations of metal ions potentially introduced into the products. Each measured metal ion 
concentration in the testing solution was corrected by subtracting the average amount detected in 
negative control solutions not containing stainless steel coupons. This allowed compensation for 
any metals possibly introduced from the glass and raw materials [26]. Each sample was tested in 
triplicate and the relative standard deviation (RSD) for the triplicate measure was within 0.5%, 
thus the average was utilized here. 
1.4.1 Effect of buffers 
Buffers are added to a formulation to adjust the pH to optimize protein solubility and 
stability. Phosphate, citrate, acetate, histidine, and succinate are the most commonly used buffers 
in parenteral products. In this study, in order to compare the effect of the buffer species on metal 
33 
 
leachates from stainless steel with time and storage conditions, the buffer concentration and pH 
were fixed at 20 mM and 5.5, respectively. Iron, nickel, and chromium were monitored in the 
media in contact or no contact with stainless steel coupons over 34 weeks. The sample storage 
temperatures were −40°C, −20°C, 2–8°C, and 25°C at 60% RH, the commonly accepted DS/DP 
storage or stressed conditions. At each time point, an individual vial was pulled for metal ion 
determination. The vials containing no stainless steel coupons served as negative controls. Due 
to glass vial breakage, the metal leachables data for 20 mM succinate buffer at the time points of 
26 and 34 weeks stored at −40°C are not available. The concentrations of iron, nickel, and 
chromium leached from stainless steel coupons were very low. Nickel was not measurable 
quantitatively since its concentrations were below its limit of quantitation. Chromium was only 
determined quantitatively in the samples stored at 25°C at 60%RH. Among these three metal 
ions, iron was the most abundant and its concentrations were quantitatively determined by ICP-
MS in all samples as shown in Fig. 2. Each buffer exhibited a different pattern on iron leachates. 
To further explore the differences in the impact of each buffer, the iron leachable data in each 
tested buffer were analyzed individually with the aid of John’s Macintosh Project (JMP; SAS 
Institute Inc., Cary, NC, USA), a statistical data analysis software. 
1.4.2 Effect of contact surface area 
During drug substance manufacturing and the storage process, drug substances are in 
contact with stainless steel at different fill volume per unit contact surface area. In this study, the 
worst scenario has been chosen as 1 mL/cm2. Most practical situations will be significantly better 
than this, i.e., larger volume per unit surface area. The metal leachable data for iron, nickel, and 
chromium after 26 weeks at controlled room temperature are shown in Fig. 3. 
1.4.3 Effect of metal chelators 
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The metal chelator Na2EDTA has been commonly used in parenteral formulations. DTPA 
has also been used in several approved parenteral products. The efficiency of Na2EDTA and 
DTPA at inhibiting iron-induced degradation of an antibody was reported to be equivalent [27]. 
Thus, in this study, the effect of the two chelators on metal leachates at two concentrations was 
explored. The testing solutions containing no chelators served as controls. The iron concentration 
data are plotted in Fig. 4 and that for chromium in Fig. 5. No data analysis was performed on 
nickel since the observed levels were either below or at the limit of quantitation. 
1.4.4 Effect of pH 
In this study, the typical pH values of 5.0, 6.0, 7.0, and 9.0 were chosen as testing 
conditions to evaluate the impact of pH on metal leachates. The storage temperatures were 2–
8°C and 25°C/60%RH. The amounts of iron, chromium, and nickel leaching out from the 
stainless steel coupons at 25°C are shown in Fig. 6 while data for 2–8°C are presented in Fig. 7. 
A comparison of the amounts of iron, chromium, and nickel leaching out from stainless steel at 
storage temperatures of 2–8°C vs. 25°C for 34 weeks is shown in Fig. 8. 
1.5 Discussion 
1.5.1 Effect of buffers on metal leachables 
Chromium was quantitatively determined only at 25°C/60%RH storage over 34 weeks. 
Histidine–HCl, histidine–acetate, and phosphate behaved similarly (about 3.5 ppb Cr), and better 
than succinate buffer (4.6 ppb Cr). The highest levels of leachables are observed for citrate 
buffer (7.1 ppb Cr). The leached amount of Cr did not exhibit direct relationship with its 
corresponding salt solubility in the buffers. Cr(III) phosphate salt is slightly soluble in water and 
Cr salt of histidine, succinate, and citrate are water soluble. Similarly, the leached amount of 
Nickel ion did not exhibit dependence on its salt solubility. Ni(II) phosphate salt is insoluble in 
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water with solubility product constant of 4.74×10−32 at 25°C while its salt of histidine, citrate, 
and succinate are water soluble [28]. Nickel levels were below the limit of quantitation for all 
tested conditions. Among three monitored metal ions, iron was the most abundant even though 
the highest concentration observed is less than 40 ppb over 34 weeks. Therefore, in this section, 
only the iron data were analyzed to explore each buffer behavior. As indicated in Fig. 2, each 
buffer exhibited its own properties over the time course of 34 weeks studied here. Thus, 
temperature/time impact on iron leachates is discussed for each individual buffer first, followed 
by a discussion of the comparison among the five buffers.  
For histidine–acetate buffer at pH 5.5 (Fig. 2a), temperature seemed to exert an effect on 
iron leachables. Storage temperature of -20°C exhibited the highest levels of iron leachates 
followed by 25°C, −40°C, and 2–8°C at time points of 12 and 22 weeks. No good explanation 
can be provided for this counterintuitive result. However, when the storage time increased to 34 
weeks, the temperature effect diminished. Further statistical data analysis was performed by JMP 
to explore whether temperature or time makes a significant contribution to iron leachates. With a 
95% confidence level, the probability factor of less than 0.05 indicates that the factor is 
significant. The calculated probability factor for time is 0.0262 while the calculated probability 
factor for temperature is 0.9029 which indicates that within a 95% confidence level, time is the 
significant factor that impacts the iron leachates.  
For histidine–HCl buffer at pH 5.5 (Fig. 2b), the levels of iron leakage for the storage 
temperature of 25°C are significantly higher than those for lower storage temperatures of −40°C, 
−20°C, and 2–8°C, which was further confirmed by JMP statistical data analysis. The calculated 
probability factor of 0.0178 means a significant difference at the 95% confidence level. 
However, no significant difference in iron leachates was observed when storage temperatures 
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range from −40°C to 2–8°C. Further data analysis by JMP indicated that, again, time plays a 
significant role in affecting iron leaching from the stainless steel because the calculated 
significant factor is 0.0909. 
For 20 mM phosphate buffer at pH 5.5 (Fig. 2c), leached iron amounts at 25°C storage 
temperature exhibited the highest level over the tested time period, as expected, followed by the 
levels for a storage temperature of −40°C. The iron amount leached at the storage temperature of 
2–8°C is the lowest among the tested conditions. That the iron amount detected for storage at 
−40°C is much higher than for storage at 2–8°C is probably due to the fact that the pH of 
phosphate buffer can drop significantly upon freezing [29]. The significance of the temperature 
impact on iron leachates cannot be calculated by JMP because the iron leachates concentrations 
are similar for temperature of 25°C and −20°C. However, as Fig. 2c indicates, the iron leachates 
at 25°C or −20°C are significantly higher than those at −40°C and 2–8°C. Also, iron leachates at 
−40°C are three times of that at 2–8°C. The iron leachates at −40°C, 2–8°C, and 25°C did not 
significantly increase over the tested time course, which was confirmed by JMP data analysis. 
However, iron leachates at the storage temperature of −20°C increased about 2.5 times over the 
time period of 22 weeks. The trend is significantly different from the other three tested 
conditions. 
For citrate buffer at pH 5.5 (Fig. 2d), the highest iron levels were seen at 25°C, followed 
by −20°C, 2–8°C, and −40°C. With 95% confidence level, time makes significant contribution to 
iron leachates observed for the four tested conditions, especially at the storage temperature of 
25°C, which was suggested by JMP calculated probability factor of 0.0148. 
For succinate buffer, because of the sample loss at −40°C due to vial breakage, this 
temperature was not evaluated. Storage temperature had a significant impact on the iron 
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leachates: levels of iron leachates at 25°C were highest, followed by those for 2–8°C, and then 
−20°C (Fig. 2e). Further data analysis by JMP (probability factor of 0.0265) suggested that at the 
95% confidence level, temperature is a major factor in affecting iron leaching from stainless 
steel. Here, within the 95% confidence level, time has no major impact on iron leachates for 
succinate buffer over all the tested conditions since the calculated probability factor is 0.7476. 
All five buffers were tested at four different storage temperatures to explore the 
difference of their capacity at affecting iron leaching from stainless steel. The comparison was 
performed for each individual condition by calculating probability factors based on buffer 
species using SAS data analysis. Within the 95% confidence level, a probability factor of less 
than 0.05 indicates that a significant difference is observed. Over the tested time course of 34 
weeks, at −40°C storage temperature, a calculated probability factor of 0.002 indicates that 
significant differences exists among the four buffers (no data for succinate buffer). Phosphate 
buffer shows the highest impact on iron leachates, followed by citrate buffer, and histidine–
acetate buffer. Histidine–HCl buffer exhibited the least impact at leaching iron from stainless 
steel at −40°C. Similarly, significant differences with a probability factor of 0.013 was observed 
among five buffers at the storage temperature of 25°C. The ability to induce iron leaching from 
stainless steel decreases in the following order: citrate buffer >phosphate buffer, succinate buffer 
> histidine–HCl buffer >histidine–acetate buffer. This trend is not consistent with iron salt 
solubility in water at 25°C. Fe (II)/(III) phosphate salt is least soluble (Ksp for FePO4 is 
1.3×10−22 and Fe3(PO4)2 is 10
−36) while its citrate, histidine, and succinate salt are water soluble 
[28]. However, at storage temperatures of −20°C and 2–8°C, no clear trend was observed. Thus, 
the effect of buffer on iron leachates is determined by multiple factors, such as buffer species, 
storage temperature, and contact time, etc. 
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1.5.2 Effect of contact surface area on metal leachables 
Solution fill volume per unit contact surface area between 1 and 5 mL/cm2 were 
investigated in this study. Fig. 3 shows that, as expected, the lower the fill volume (mL) per unit 
stainless steel contact surface area (cm2), the higher the relative levels of metal ions leached. 
However, no linearity was observed at the studied relationship range between fill volume and 
contact surface area over the tested time period of 26 weeks. A plateau was observed when the 
fill volume per unit stainless steel contact surface area reached 3 mL/cm2. 
1.5.3 Effect of metal chelators on metal leachables 
The effect of the metal chelators Na2EDTA and DTPA on metal leachables was explored 
for the storage temperature of 25°C over 34 weeks. Both chelators at the concentrations of 0.134 
and 0.268 mM showed a dramatic impact on iron leachates as shown in Fig. 4. Compared to the 
solutions without chelator, the concentration of leached iron from stainless steel in the buffer 
with Na2EDTA increased more than 20-fold over the 17 weeks, and increased more than 10-fold 
over 34 weeks (Fig. 4a). It was reported previously that EDTA facilitated the migration of metal 
ions into the solution from metal contact surfaces [30]. A similar trend was observed for DTPA. 
Compared to the solutions without any chelator, leached iron ion concentrations in the buffer 
containing DTPA increased more than 10-fold for both the 17 and 34 weeks time period (Fig. 
4b). However, increase in concentration of Na2EDTA did not have a significant impact on 
leached iron ion concentrations over 34 weeks unlike increased DTPA levels which exhibited a 
significant effect on iron leaching. Doubling the concentration of DTPA from 0.134 to 0.268 
mM increased the concentration of leached iron ions by a factor of 1.7. A linear increase in 
leached iron ion concentration with the increased concentration of DTPA was also observed in 
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both cases (R2 is 0.9971 when the solutions contain 0.134 mM DTPA while R2 is 0.9829 when 
DTPA is 0.268 mM). 
The data in Fig. 5a suggest that the presence of Na2EDTA in the solutions increased 
chromium ions leaching from stainless steel but the concentration of the chelator did not make a 
difference under the tested conditions. An effect of DTPA on chromium leachates was not 
observed until 34 weeks (Fig. 5b). Similar to Na2EDTA, no DTPA concentration effect was 
observed for chromium leachates.  
Since iron is the major metal leachate compared to chromium and nickel, it was used to 
explore the capacity difference affecting metal leachates between Na2EDTA and DTPA. At 
equal molar concentrations of Na2EDTA and DTPA over 34 weeks at 25°C, Na2EDTA 
facilitated iron leaching from stainless steel faster than DTPA as shown in Fig. 9. This can be of 
concern since it has been shown that Na2EDTA and DTPA cannot protect protein degradation if 
the ratio of the molar concentration of the metal chelators to iron in solution is less than 1:1 [27]. 
1.5.4 Effect of pH on metal leachables 
Similar to previously discussed results, the major leached metal ions at the tested pH of 
5.0, 6.0, 7.0, and 9.0 is iron, at temperatures of 2–8°C and 25°C. At 25°C, chromium and nickel 
could not be quantitated (levels were below the limit of quantitation) until a contact time with 
stainless steel of over 17 weeks. Thus, in Fig. 6b and c, only the data for 17 and 34 weeks time 
points were plotted. Fig. 6 suggests that iron, chromium, and nickel leached most at pH 5.0 while 
between pH 6.0 and 9.0, no pH effect was observed. At 2–8°C, pH affected metal leaching from 
stainless steel differently compared to 25°C. For iron, the sequence of impact from high to low is 
pH 5.0 >> pH 9.0 > pH 6.0 pH 7.0 (Fig. 7a). Acidic conditions of pH 5.0 produced about 4- 
fold higher iron leachate compared to pH 9.0. It has been reported that ferric/ferrous salts of 
40 
 
sulfate, gluconate, and citrate exhibit much higher solubility in acidic conditions than neutral and 
basic conditions [31]. At close to neutral and neutral conditions, no pH impact was observed. 
The effect of pH on chromium shows decreasing leakage in the following order: pH 9.0 > pH 5.0 
> pH 6.0 > pH 7.0, that is, both basic and acidic conditions have impact on chromium leachables 
but not at neutral pH 7.0 conditions as shown in Fig. 7b. Similar to chromium, basic condition 
(pH 9.0) produced strongest impact on nickel leachables, followed by pH 5.0, then pH 6.0 (Fig. 
7c). At neutral pH 7.0, no pH impact was observed over 34 weeks. 
To further explore the temperature impact at pH 5.0–9.0, the concentrations of each 
leachate were compared using the 34 weeks time point as shown in Fig. 8. For iron, at the acidic 
pH 5.0, the lower temperature of 2–8°C storage produced a stronger impact than at 25°C while 
for neutral conditions of pH 7.0, the 25°C storage condition impact was stronger than 2–8°C. At 
pH 6.0 and 9.0, no temperature impact was observed. For chromium leachables, at acidic to 
neutral condition of pH 5.0–7.0, the higher temperature of 25°C exerted a stronger impact. In 
contrast, at basic condition of pH 9.0, the lower temperature of 2–8°C produced more leachables. 
For nickel leachables, lower temperatures produced much more metal leachates except at neutral 
condition of pH 7.0 which had no obvious impact. 
1.6 Conclusions 
Among the three monitored metal leachates of iron, chromium, and nickel, iron is the 
most abundant. However, overall metal leachates observed are at the ppb level. Multiple factors 
such as buffer species, the amount of testing media fill volume per unit stainless steel contact 
surface area, formulation excipients such as metal chelator type and/or concentration, pH, 
storage temperature, and contact duration with stainless steel, play an important role in affecting 
the concentrations of metal ions leaching from contact with stainless steel. Each studied factor 
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exhibited its own capacity at leaching metal ions from contact with stainless steel. The 
commonly used buffers of histidine–acetate, histidine–HCl, phosphate, citrate, and succinate 
exhibited different properties at storage conditions of −40°C to 25°C with time at same 
concentration and pH. Furthermore, with the same buffer species and concentration, pH 
impacted the capacity to leach metal ions from stainless steel. Solution fill volume per unit 
stainless steel contact surface area above 3 mL/cm2 did not further decrease the concentration of 
metal iron leachates. Compared to the other factors tested in this study, commonly present metal 
chelators in parenteral formulations, metal chelator Na2EDTA and DTPA, produced the most 
significant impact on metal leachates, especially iron leachates. However, Na2EDTA and DTPA 
behaved differently. Na2EDTA produced a much stronger impact compared to DTPA over the 
tested 34 weeks at 25°C. Increase in concentration of Na2EDTA present in the formulations did 
not increase iron leachates. In contrast, the concentration of iron leachates increased significantly 
with an increase of DTPA concentration. Therefore, to minimize metal leaching from stainless 
steel during drug substance and/or drug product manufacturing, storage, and shipping processes, 
multiple factors have to be evaluated to balance the risk and benefit to achieve the desired drug 
product shelf life. Large-scale production tanks generally have much higher volume per unit 
surface areas than those tested here (of the order of 10 mL/cm2 or higher), which significantly 
reduces the risk if proper maintenance procedures are followed. 
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Table 1. Experimental conditions to assess the effect of buffer species and storage conditions on 
metal leachates from 316 L stainless steel coupons with a surface area of 3.52 cm2 in 30 
mL type I glass Vials  
 
Storage condition 
(oC)/ Test solutions 
-40oC -20oC 2-8oC 25oC 
20 mM Histidine-
Acetate at pH 5.5 
1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 
1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 
20 mM Histidine-
HCl at pH 5.5 
1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 
1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 
20 mM Phosphate at 
pH 5.5 
1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 
1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 
20 mM Citrate at 
pH5.5 
1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 
1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 
20 mM Succinate at 
pH 5.5 
1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 
1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 
20 mM Acetate at 
pH 5.5 
1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 1 vial w/ ss 
1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 1 vial w/o ss 
 
Note:  
1. The test solution fill volume is 17.6 mL 
2. ss stands for stainless steel coupon 
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Fig. 1. Appearance of stainless steel coupons used 
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Fig. 2. Iron leachate average concentrations for five different buffers (20 mM) at pH 5.5 stored at 
−40°C, −20°C, 2–8°C, and 25°C over 34 weeks (triplicate measurement with RSD of 
0.5%). a for histidine-acetate, b for histidine–HCl, c for phosphate, d for citrate, and e for 
succinate buffer 
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Fig. 3. Metal leachates average concentrations in 20 mM histidine–HCl buffer solution at pH 5.5 
at different solution fill volumes per unit contact ss surface area (triplicate measurement 
with RSD of 0.5%) 
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Fig. 4. Iron leachate average concentrations in 20 mM histidine–acetate buffer solutions (pH 6.0) 
containing Na2EDTA and DTPA at the concentrations of 0, 0.134, and 0.268 mM over 34 
weeks stored at 25°C (triplicate measurement with RSD of 0.5%). a for Na2EDTA and b 
for DTPA  
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Fig. 5. Chromium leachate average concentrations in 20 mM histidine–acetate buffer solutions 
(pH 6.0) containing Na2EDTA and DTPA at the concentrations of 0, 0.134, and 0.268 
mM over 34 weeks stored at 25°C (triplicate measurement with RSD of 0.5%). a for 
Na2EDTA and b for DTPA 
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Fig. 6. a–c Iron, chromium and nickel leachates average concentration in 20 mM histidine–
acetate buffer solution at pH 5.0, 6.0, 7.0, and 9.0 stored at 25°C over 34 weeks (triplicate 
measurement with RSD of 0.5%) 
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Fig. 7. a–c Iron, chromium, and nickel leachates average concentration in 20 mM histidine–
acetate buffer solution at pH 5.0, 6.0, 7.0, and 9.0 stored at 2–8°C over 34 weeks 
(triplicate measurement with RSD of 0.5%) 
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Fig. 8. a–c Comparisons of the average concentrations of metal leachates of iron, chromium and 
nickel in 20 mM histidine buffer at pH 5.0, 6.0, 7.0, and 9.0 when stored at 2–8° vs. 25°C 
over 34 weeks time points (triplicate measurement with RSD of 0.5%)  
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Fig. 9. Iron leachates average concentration comparison between Na2EDTA and DTPA in 20 
mM histidine-acetate buffer solutions (pH 6.0) when metal chelator concentrations at 0, 
0.134, and 0.268mMstored at 25°C over 34 weeks (triplicate measurement with RSD of 
0.5%) 
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Chapter 2: Metal Ion Leachables Induced by Combined Biologics Formulation Factors 
by Design of Experiment 
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2.1. Introduction 
Biotherapeutic products are predominately formulated as liquids or freeze-dried products 
delivered by injection, and therefore fall into the category of parenteral formulations. In order to 
develop a stable formulation with an acceptable shelf life, excipients such as solvents/cosolvents, 
polymeric and surface-active compounds, chelating agents, anti-oxidants, preservatives, buffers, 
bulking agents, protectants, and tonicity adjusters, have been used in parenteral formulations. 
The majority of biologics products consist of a buffer, a tonicity modifier, a cryo- or 
lyoprotectant, and a surfactant [1–4]. In some cases, a metal chelator and an antioxidant are also 
added to the formulation to protect the protein from oxidation. Polysorbate 80 and 20 are the 
most commonly used surface-active compounds. The concentration of polysorbate 80 employed 
in most biologics formulations is ≤ 0.2 mg/mL. To complex the trace amount of metal ions 
inadvertently present in parenteral formulations, salts of EDTA (mainly sodium edentate; 
Na2EDTA.2H2O), have been used as chelating agents. The content of Na2EDTA.2H2O in 
pharmaceutical preparations is generally between 0.005% and 0.1% (w/v, 0.05–1 mg/mL) [5]. 
Diethylenetriaminepentaacetic acid (DTPA) is an alternative metal chelator approved for 
parenteral use and has demonstrated a comparable capacity to inhibit metal-induced mAb 
instability [6]. L-methionine has been used as an antioxidant to protect labile methionine residues 
in proteins from oxidation. L-histidine buffer is commonly used to adjust the formulation pH for 
optimal stability and solubility. 
Trace amounts of metal ions are invariably introduced into biotherapeutic bulk solution 
during drug substance and/or drug product manufacturing, shipping, and storage. The metal ions 
inadvertently introduced into products either arise from the excipients or leach into solution from 
contact with manufacturing equipment. Even though parenteral grade excipients are used, 
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residual amounts of metal ions are present, mostly at part per billion (ppb) levels or below. Some 
plastic packages, glass vials, and/or rubber stoppers can also be the sources of metal leachates 
[7]. Salts of tungsten oxide were reported to migrate from prefilled syringes into a biotherapeutic 
protein product [8]. Barium was also observed leaching from glass vials [9]. However, the major 
source of the metal contamination in biotherapeutic drug products is the contact with stainless 
steel during drug substance and/or drug product manufacturing, as well as during shipping and 
storage processes, such as transfer tanks, cryotanks, compounding tanks, stainless steel piping, 
header tanks, and filling needles. 
Trace amount of metals can have a profound negative impact on the stability of the 
product. Site specific metal-protein binding can induce secondary and tertiary structural changes 
resulting in the formation of protein aggregates [10, 11]. Metals can induce product degradation 
reactions, such as oxidation [6, 12–14], fragmentation [6, 13], and aggregation [6, 12, 15]. Such 
degradation reactions can potentially jeopardize the quality of the products by altering 
physicochemical properties as well as reducing stability and shelf life. In addition, excessive 
metal ions, especially heavy metal ions, introduced into a biological system may lead to safety 
concerns. Although metal ions are too small to induce an immune response, they can conjugate 
with proteins to form metal–protein complexes, potentially resulting in immunogenicity [16]. 
Iron has been implicated in the aggregation of proteins responsible for the pathophysiology of 
several neurodegenerative diseases, such as Alzheimer and Parkinsons [15]. 
Biotherapeutic products are predominately delivered by intravenous injection. 
Additionally, the majority of biological products are formulated as a liquid or as a lyophilized 
dry powder and packaged in vials. The likelihood of an interaction between packaging and a 
liquid solution dosage form is considered high and considered medium for a powder product. 
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Therefore, biotherapeutic products fall into the category of highest concern from an extractables 
and leachables perspective [17–19]. In the USA, the requirement for the proper evaluation of 
extractables and leachables is governed by the Federal Food, Drug, and Cosmetic Act as codified 
in 21 Code of Federal Regulations, parts 210 and 211. Furthermore, specific guidance for 
monitoring and control of leachables as part of requirements for the primary packaging of drug 
products has been issued by the regulatory authorities [17, 19]. 
The stainless steel grade commonly used in biopharmaceutical applications is called 
316L, a low-carbon (<0.03%) alloy containing mainly iron, nickel, and chromium. This grade is 
called austenitic stainless steel and the alloy is designed to reduce its propensity for corroding by 
reducing the precipitation of chromium carbides (actually mixed iron/chromium carbides) along 
grain boundaries of stainless steel by keeping carbon below 0.03%. 
Since the biologic drug product in solution interacts with the manufacturing equipment, it 
is useful to understand their role in the leaching process. The impact of individual biotherapeutic 
formulation factors, commonly utilized buffers, the relationship of the solution volume and 
contact surface area, metal chelating agent concentration and type, and solution pH, on metal 
leachables from 316L stainless steel was studied, respectively [20]. In this paper, six major 
formulation factors: protein concentration, solution pH controlled by L-histidine, metal chelator 
concentration and type (Na2EDTA.2H2O vs. DTPA), antioxidant (methionine), and surfactant 
(polysorbate 80), were investigated to elucidate the effect of the biotherapeutic formulation 
component in the presence of other components on the quantity of metal leachables from 316L 
stainless steel over time at storage temperatures of −40°C, 2–8°C, and 25°C. The presence of 
multiple factors makes it efficient to study their impact by a design of experiments (DOE) 
approach. Such DOE studies are in accordance with the principles of quality by design as 
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suggested in ICH Q8 [21] since the impact of multiple factors and their potential interaction can 
be evaluated, thus providing an understanding of product during all phases of production and 
enhance the probability of developing a robust formulation. 
2.2. Materials and Methods 
2.2.1. Materials 
As in our previous work [20], rectangular 316L stainless steel coupons were utilized for 
this study. Prior to use, the coupons were chemically passivated as described earlier [20]. The 
dimensions of the coupons were 2 cm (length) ×1 cm (width) × 0.1651 cm (thickness) with a 
surface area of 5 cm2. The 10-mL type I Schott glass vials and serum stoppers (West 4432/50 
Gray B2-40 and Flurotec coated, West Pharmaceutical Services, Lionville, PA, USA) were used 
after they were cleaned and autoclaved. An IgG2 monoclonal antibody produced in-house was 
used in this study. The mAb was formulated in 20 mM histidine at pH 5.5. USP/EP grade L-
histidine and L-histidine hydrochloride monohydrate, analytical grade FeCl3, Na2EDTA 
dihydrate, and DTPA were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 
EP/USP grade polysorbate 80 was obtained from J. T. Baker (Meriden, CT, USA). USP/F.C.C. 
grade L-methionine was obtained from J. T. Baker (Phillipsburg, NJ, USA) and parenteral grade 
α,α-trehalose dihydrate (low endotoxin) was obtained from Ferro Pfanstiehl Laboratories, Inc 
(Cleveland, OH, USA). Polyvinylidene fluoride (PVDF), 0.22 μm, filters were obtained from 
Millipore Inc. (Billerica, MA, USA). 
2.2.2. Methods 
2.2.2.1. Inductively coupled plasma - mass spectrometry 
Metal ion concentrations in the testing solutions were quantitated by an inductively 
coupled plasma-mass spectrometry (ICP-MS) method which utilized an Agilent 7500 CX ICP-
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MS system equipped with an auto-sampler according to our published method [20]. The 
instrument was qualified, calibrated, and maintained regularly to ensure the system suitability. 
Prior to analyzing the samples at each time point, an external calibration curve for each element 
measured was revalidated. The same linear range as in previous work [20], 1–500 ppb for iron 
and 1–100 ppb for chromium and nickel, was maintained. 
2.2.2.2. UV spectrophotometer for mAb concentration 
The mAb concentrations in the formulations were determined using a Cary UV 
spectrophotometer coupled with a diode-array detector (Varian Inc., Lake Forest, CA, USA). 
The extinction coefficient of 1.43 (1 mg/mL at 280 nm) was determined by the Edelhoch method 
[22]. The system was calibrated and maintained regularly. Quartz cuvettes with a 1 cm path 
length were utilized. The formulations were gravimetrically diluted to 0.5 mg/mL using the 
corresponding placebo and then equilibrated to room temperature before testing. The 
corresponding placebo was used as the reference solution to zero the instrument. The absorptions 
for the formulations were measured at the fixed wavelength of 280 nm. 
2.2.2.3. RP-HPLC analysis for chelator concentration 
The concentrations of both Na2EDTA and DTPA in the formulations were determined 
using an Agilent 1100 system coupled to a diode array detector [6, 20]. The system was 
calibrated and maintained regularly to ensure the system suitability. The method accuracy was 
evaluated by a spike recovery test. Prior to sample analysis, external calibration was 
reestablished with varying levels of Na2EDTA and DPTA simultaneously. The separation was 
monitored by UV detection at 254 nm. 
2.2.2.4. Experimental design 
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The experiment was designed by StatEase Design Expert® (v7.1.6) (Stat-Ease Inc., 
Minneapolis, MN, USA). In this study, six formulation factors of protein concentration, pH, anti-
oxidation agent, metal chelator, metal chelator concentration, and surfactant concentration were 
investigated. In order to reduce the substantial resources needed for the full design of 26 (64) 
formulations, a fractional factorial design, 2(6–2), of 16 formulations was adopted. This design is 
shown in Table 1. Five of the formulation factors (factors A–E) are continuous while factor F, 
chelator type, is a categorical factor. The design incorporated 16 boundary runs (F1–F16) along 
with seven additional formulations, five of which were center points (F17–F21), and the other 
two formulations (F22–F23) were controls not containing any protein while other components at 
center points. The drawback for this design is that there could be aliasing between the significant 
factors which would require additional knowledge or experiments to deconvolute as to which 
interaction is actually significant. 
The formulations were prepared in 20 mM histidine buffer with 84 mg/mL α,α-trehalose 
dihydrate, except the formulations F20 and 21, which were included to explore the effect of 
sugar. The mAb concentration ranged from 5.0 to 20.0 mg/mL with 12.5 mg/mL as center point. 
These concentrations were confirmed by UV absorption at 280 nm. The formulation pH was 
controlled at 5.5–6.5 (due to consideration of protein stability) with the center point at pH 6.0, 
and these were confirmed by a pH meter at ambient room temperature. The concentrations of 
methionine ranged from 0.0 to 0.1 mg/mL with 0.05 mg/mL as the center point. The surfactant 
(polysorbate 80) concentration ranged from 0.0 to 0.2 mg/mL with the center point of 0.1 
mg/mL. The metal chelator concentration ranged from 0.0 to 0.1 mg/mL with 0.05 mg/mL as the 
center point, as confirmed by RP-HPLC. The chelator was either Na2EDTA or DTPA. At a pH 
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of 5.5–6.5, DTPA (H5A) exists in equilibrium between H2A
3− and H3A
2− [23]. For simplicity, 
from here on, the term DTPA is used regardless of its ionization form. 
The formulations were sterile filtered through a 0.22 μm PVDF filter. Aliquots of 5 mL 
were filled into 10 mL autoclaved glass vials containing stainless steel coupons as the samples 
accompanied by the vials containing no coupons as negative controls. The vials were sealed with 
the autoclaved stoppers and placed upright in stability chambers maintained at −40°C over 6 
months, as well as 2–8°C and 25°C over 3 months. During storage, the testing solutions were not 
allowed to come into contact with the stoppers eliminating the potential leachables from the 
stoppers confounding the study. 
ICP-MS was performed on each formulation sample at the initial time point and 3 months 
for the storage temperature of 2–8°C and 25°C, and at both 3 and 6 months for storage 
temperature of −40°C to explore the impact of the formulation components on metal leachables 
from 316L stainless steel. 
2.3. Results and Discussion 
The amount of metal ions leaching into biological products is dependent on many 
variables, such as formulation components, solution pH, contact materials, drug substance/drug 
product contact surface area with stainless steel, surface area processing procedure, contact 
duration and temperature, etc. The leaching capacity of individual biotherapeutic formulation 
factor, commonly utilized histidine/HCl, histidine/acetate, succinate, acetate and citrate buffers, 
the relationship of the solution volume and contact surface area of 1–5 mL/cm2, metal chelator 
Na2EDTA vs. DTPA at the concentration of 0.0–0.1 mg/mL, solution pH 5.0–9.0, on metal 
leachables from 316L stainless steel was studied, respectively [20]. In this paper, the focus was 
to investigate the effect of each formulation component in the presence of others, as described in 
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Table 1, on metal leachables from 316L stainless steel. All stainless steel coupons used in this 
study were made from the same sheet of stainless steel to ensure consistency of the material. The 
316L stainless steel was made in the USA (US: S31603), composed of 62–72% iron, 16–18.5% 
chromium, and 10–14% nickel, along with a trace amount of carbon, magnesium, manganese, 
silicon, nitrogen, phosphate, and sulfur [24]. Three major components, iron, chromium, and 
nickel in the testing solutions were quantified by ICP-MS to evaluate the amounts of metal ions 
introduced into the product. The other elements such as magnesium, manganese, silicon, 
phosphate, and sulfur were not monitored in this study because our feasibility study suggested 
that the amount of these leached into solution was several order of magnitudes lower than that of 
three major elements (iron, chromium, and nickel). Silicon can also arise from packaging such as 
stoppers in greater amounts than via leaching from stainless steel containers and was thus not 
monitored. 
At each time point, both the sample vial (containing the stainless steel coupon) and its 
negative control (containing no stainless steel coupon) were pulled for metal ion determination. 
Prior to ICP-MS analysis, the samples were equilibrated to ambient room temperature by storing 
them in the laminar airflow hood overnight at ambient room temperature. In order to eliminate 
the interference of any metals possibly introduced from the glass and raw materials [25], each 
measured metal ion concentration in the testing solution was corrected by subtracting the amount 
detected in the negative control. All the samples were tested in triplicate and the relative standard 
deviation was within 0.5%, thus the average was utilized here. 
Analysis of variance was used to explore the impact of the experimental factors on the 
metal ions. For each of the tested metals at their individual storage temperatures, a mathematical 
model was fitted to the experimental data. Formulation factors not included in the predictive 
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equations were either not statistically significant or were concluded to be of far lesser importance 
than the included factors. The relative impact of the statistically significant factors over the range 
tested can be assessed by the magnitude and sign of their coefficients. The magnitude is the 
indication of their relative impact and the sign is the indication of the impact direction relative to 
that of variables. A positive sign indicates that the impact changed in the same direction as the 
change of the variables and the negative sign indicated the opposite trend. 
The equation provides a quantitative prediction tool in assessing metal amounts of the 
untested formulations given the formulation components are within the specified testing ranges. 
The visual representations as well as the coefficients make it easy to compare the relative impact 
of the significant factors within the ranges tested. Given the need for higher protein 
concentration formulations and longer storage time, caution must be taken in applying the 
prediction model to the formulations outside of the tested ranges since the models may no longer 
hold true. In each data analysis, adjusted R2 and root mean square error (RMSE) are also 
provided. The adjusted R2 is used to indicate the percentage of the total variation in the data 
explained by the model, adjusted for the number of terms in the model. The closer the adjusted 
R2 is to 1.00, the better the model fits the experimental data. The RMSE is calculated from the 
difference between the experimental and predicted values (residuals). This number can be 
interpreted as the standard deviation of the residuals. For most of the models, we would expect 
about 95% of the observed values to lie within ±2 times the RMSE of the predicted values. The 
data on each storage condition are addressed individually. 
2.3.1. Six months storage at -40oC 
Over 6 months in contact with the coupons at −40°C, iron ions leaching into the testing 
solutions ranged from 3 to 276 ppb with a mean value of 49 ppb. Chromium ions ranged from 
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below limit of quantitation to 17 ppb with a mean value of 5 ppb, while nickel ions increased 
from below limit of quantitation to 13 ppb with a mean value of 5 ppb. As expected, iron ions are 
the most abundant leachates among the three monitored metal ions, consistent with our previous 
findings [20].  
A natural logarithmic transformation was applied to the data for iron, chromium, and 
nickel leachates as these data at 6 months were significantly higher and more variable compared 
to those at the initial time point. The prediction equations with the adjusted R2 and RMSE (in 
natural logarithmic scale) for all three leachates are provided in Table 2. The adjusted R2, 70% 
with RMSE of 0.57% for iron leachates, 73% with RMSE of 0.45% for chromium, and 90% with 
RMSE of 0.35% for nickel, suggest that the models fit the experimental data reasonably well. 
The factors included in the models are only the statistically significant factors: metal chelator 
concentration, protein concentration, and contact time for iron leachates while protein 
concentration and contact time for chromium and nickel leachates. Other formulation factors, 
namely solution pH, the presence of methionine and polysorbate 80, and the metal chelator type 
(for iron leachates), or metal chelator concentration (for chromium and nickel) leachates, are not 
statistically significant. The coefficients of each significant factor for iron, chromium, and nickel 
leachates are positive, indicating that the amount of all three metal leachates increased 
accordingly with the increased amount of the significant factors. The impact of respective 
response surface plots: Fig. 1a, b for iron leachates, Fig. 1c for chromium, and Fig. 1d for nickel. 
Because no curvature and no interactions are observed among the significant factors, the models 
for all three metal leachates are additive. Consequently, the relative impact of the individual 
significant factor can be compared quantitatively over the range studied.  
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For iron leachates, the impact (per unit) of metal chelator is 19-fold of that of contact 
time and 91-fold of that of protein concentration within all ranges tested. The overall impact of 
contact time was about twice as much as that of protein concentration and three times of that of 
metal chelator concentration as shown in Fig. 1a, b. Note these magnitudes are relative to ranges 
tested. Fig. 1a shows the impact of contact time and protein concentration in the formulations 
without any chelating agent while Fig. 1b shows the effects in the formulations with 0.1 mg/mL 
metal chelator. The highest levels would be predicted at 6 months, for the highest protein 
concentration tested (20 mg/mL) and the highest chelator concentration (0.1 mg/mL). This is 
represented by the elevation of the surface towards the back on the right side in Fig. 1b.  
For chromium leachates, the impact of contact time is three times of that of protein 
concentration in per unit term within the ranges tested. However, over the tested ranges, the 
overall impact of contact time is approximately equal to that of the protein concentration as 
shown in Fig. 1c. The highest amounts of chromium leachates would be predicted for 6 months 
in formulations containing 20 mg/mL protein, as represented by the elevated surfaces towards 
the back on the right side in Fig. 1c.  
As with iron and chromium, the impact on leached nickel by contact duration of the 
solution with stainless steel is thirteen times as much as that by protein concentration in per unit 
terms. In relative terms, the overall impact of contact time is about five times as high as that of 
protein over the ranges tested as shown in the response surface plot displayed in Fig. 1d. The 
highest amount of nickel leachates occurred in formulations containing the highest concentration 
of protein (20 mg/mL) over 6 months contact with stainless steel, represented by the elevated 
surface towards the back on the right side in Fig. 1d.  
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Compared to the iron leachates in the solutions, the concentrations of chromium and 
nickel were significantly lower, by about 1 order of magnitude. Considering all three metals, 
potentially migrating from stainless steel into the drug substance and/or product from the contact 
stainless steel, we see that contact time and protein concentration, as well as metal chelator 
concentration for iron leachates are the statistically significant factors. Their contribution to the 
total amount of metal leachates in the final products depends on the formulation compositions 
and contact duration. Ranked by the contribution per unit, milligram per milliliter for 
concentration and months for contact time, metal chelator concentration is the most significant 
factor, followed by contact time and protein concentration for leaching iron, while contact time 
followed by protein concentration is the most significant parameter for chromium and nickel 
leachates. 
2.3.2. Three months storage at 2-8oC 
The iron leachates ranged from 3 to 229 ppb with a mean of 69 ppb. The chromium ion 
leachates increased from below limit of quantitation to 17 ppb with a mean of 5 ppb and nickel 
increased from below limit of quantitation to 23 ppb with a mean of 5 ppb. The overall levels of 
all three metal leachates are higher than those at −40°C. As stated previously, due to higher and 
more variable values at the 3 months compared to initial time point, a natural logarithmic 
transformation was utilized for the data analysis. 
The prediction equations with the adjusted R2 and RMSE (in the natural logarithmic 
scale) for all three leachates at 2–8°C are also listed in Table 2. The adjusted R2, 82% with 
RMSE of 0.51% for iron leachates, 77% with RMSE of 0.42% for chromium, and 94% with 
RMSE of 0.31% for nickel are better than those observed at −40°C. The enhanced-adjusted R2 
and RMSE suggest that the models fit experimental data very well. As discussed previously, only 
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the statistically significant factors are included in the models. Other formulation factors are not 
statistically significant. The models for all three metal leachates of iron, chromium, and nickel are 
additive and the combined impacts of significant factors on metal leachates are presented in the 
response surface plots: Fig. 2a, b for iron leachates, Fig. 2c for chromium, and Fig. 2d for nickel.  
As shown for the analysis of storage at −40°C, the significant effects for the three metal 
leachates at 2–8°C also arise from protein concentration and contact time, and includes metal 
chelator concentration for iron leachates. All three have positive coefficients: metal leachates 
increase as any of these factors and/or the combination thereof increases.  
For iron leachates, as shown in Fig. 2a and b, the impact coefficient (per unit) of metal 
chelator concentration is about 110-fold of that of protein concentration and 9-fold of contact 
time. Over the ranges tested, the relative contributions for leaching iron decrease in the following 
order: contact time was about 2.5 times of that of protein concentration, and 3 times of that of 
chelator concentration. This is the same trend as observed for −40°C storage except that the 
magnitudes are higher. The highest amounts of ion leachates occurred in the formulation 
containing 20 mg/mL protein and 0.1 mg/mL metal chelator over 3 months contact with the 
stainless steel, as indicated by the elevation of the surface towards the back on the right side in 
Fig. 2b (note that Fig. 2a shows the impact of time and protein concentration in formulations 
containing no metal chelator while 2b shows the same effect in formulations with 0.1 mg/mL 
metal chelator.) 
For chromium leachates, as shown in Fig. 2c, the impact (per unit) of contact time was 
about 7-fold that of protein concentration. Within the tested ranges, the overall impact of the 
contact time is 1.3 times that of protein concentration. The highest levels occurred at 3 months in 
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the formulations containing 20 mg/mL protein, represented by the elevation of the surface 
towards the back on the right side in Fig. 2c.  
For nickel leachates, the contribution of the contact duration (per month) of the solution 
with stainless steel is about 20-fold that of protein concentration (per milligram/per milliliter). 
Within the tested ranges, the overall impact of contact time is about 4 times of that of protein 
concentration as shown in the response surface plot in Fig. 2d. The formulation containing 20 
mg/mL protein stored over 3 months exhibited the highest levels of nickel leachates, represented 
by the elevation of the surface towards the back on the right side in Fig. 2d. 
Similar to the results at −40°C, iron leaching occurs to a much higher extent than the 
leaching of chromium and nickel. In the parameter ranges studied, the impact coefficient (impact 
per unit) indicated that metal chelator concentration showed the most significant contribution for 
the leaching of iron from stainless steel, followed by contact time and then protein concentration, 
while contact time followed by protein concentration was most important for chromium and 
nickel leachates. 
2.3.3. Three months storage at 25oC 
As expected, iron ion leaching increased much more at 25°C compared to that at −40°C 
or 2–8°C. The iron leachates ranged from 3 to 550 ppb with a mean of 165 ppb, almost twice the 
amount of iron leachates at −40°C and 2–8°C. The chromium leachates increased from below the 
limit of quantitation to 27 ppb with a mean of 8 ppb, and nickel increased from below the limit of 
quantitation to 23 ppb with a mean of 8 ppb, a slight increase compared to the data at −40°C and 
2–8°C. A natural logarithmic transformation was utilized for data analysis. The prediction 
equations along their R2 and RMSE (in natural logarithmic scale) at 25°C are presented in Table 
2. The R2, 96% with RMSE of 0.34% for iron leachates, 95% with RMSE of 0.28% for 
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chromium, and 98% with RMSE of 0.22% for nickel suggest that the models fit experimental 
data with high accuracy. 
As discussed previously, only the statistically significant factors are included in the 
models. Even though protein concentration, metal chelator concentration, and contact time of the 
tested solutions with the stainless steel are still the only three statistically significant factors 
within the testing parameter ranges, interactions between contact time and protein concentration, 
and metal chelator concentration are observed for all three metal leachates. The interactions 
greatly increased the prediction model complexity because of the inherent inadequacy due to the 
partial factorial design of 2(6–2) (16 formulations) instead of the full factorial design of 26 (64 
formulations). This partial DOE design was adopted to balance the required resources and the 
benefit. In this design, the individual contribution of the interacting factors cannot be separated 
from the combined effect as the interactions are present. In order to mathematically quantify the 
dependency of one factor on another, a more thorough investigation is needed which is outside 
the scope of the work reported here. Therefore, in our data analysis, the interactions of the 
contact time with the protein concentration, and metal chelator concentration do not allow 
ranking of the relative contribution of the three major factors affecting three metal ion leachates. 
For iron leachates, protein concentration, metal chelator concentration, and contact time 
are the three statistically significant factors and their individual impact coefficients are positive. 
However, interactions between metal chelator concentration and contact time, and between 
protein concentration and contact time are also observed. The combined effect of metal chelator 
concentration and contact time enhanced metal ion leaching, comparable to their individual 
effects. Thus, the overall effect of increased metal chelator concentration was to increase metal 
iron leachates in the solution, as shown in Fig. 3a and b. In contrast, the interaction between 
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protein concentration and contact was opposite to the direction of their individual impact so that 
it is hard to quantify the individual final impact. However, the overall contribution of each 
parameter is qualitatively presented in Fig. 3a and b. The overall consequences of contact time 
were to increase metal ion leachates over the increased contact duration while no significant 
impact from protein concentration was observed. Despite the complexity of the interactions in 
the models, the overall impact of metal chelator concentration is more significant than that of 
contact time and protein concentration, that is, the amount of iron ion leachates increased much 
more dramatically in the formulations containing 0.1 mg/mL metal chelator (Fig. 3b) than the 
formulations containing no metal chelator (Fig. 3a). The highest amounts of iron leachates 
occurred in the formulations containing 5 mg/mL protein (lowest studied level) and 0.1 mg/mL 
metal chelator (the highest studied levels) over 3 months, represented by the elevation of the 
surface towards the front on the right side in Fig. 3b.  
For chromium leachates, the model shown in Table 2 suggests that within the tested 
parameter ranges, besides protein concentration, metal chelator concentration and contact time as 
the significant factors, solution pH also played an important role. The lower pH of 5.5 increased 
chromium leaching more than pH 6.5. The interactions of contact time with protein 
concentration and with metal chelator concentration make it infeasible to quantify the individual 
contributions of protein concentration, metal chelator concentration, and contact time. However, 
over the tested ranges, an increased contact time and metal chelator concentration increased 
chromium leachates as shown in Fig. 3c–f. As a consequence of the combined effects, the 
amount of chromium leachates increased most significantly in the formulations at pH 5.5 (lowest 
tested pH) containing 0.1mg/mL metal chelators (highest tested level), as shown in Fig. 3f. This 
indicates that a decrease of pH and an increase in metal chelator concentration increase the 
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capacity of the formulation for leaching chromium from stainless steel. The highest amount of 
chromium leachates occurred in the formulations at pH 5.5 containing the lowest protein 
concentration of 5 mg/mL protein, and 0.1 mg/mL metal chelator over 3 months, represented by 
the elevation of the surface towards the front on the right side in Fig. 3f, the worst case scenario. 
The chromium leaching pattern observed at 25°C is dramatically different from that observed at 
lower storage temperatures of −40°C and 2–8°C. 
For nickel ion leachates, protein concentration, metal chelator concentration, and contact 
time are still the three statistically most significant factors. As for iron and chromium leachates, 
the complicated interactions between the contact time and protein concentration, and the 
interaction with metal chelator concentration make it infeasible to quantify each individual 
impact. However, the overall impact of the significant factors as exhibited in Fig. 3g and h, the 
increased contact duration and metal chelator concentration increased nickel leachates in the 
formulations. The nickel leachates changed more significantly in the formulations containing 0.1 
mg/mL metal chelators as shown in Fig. 3h which indicates that the metal chelator plays an 
important role. The highest amount of nickel leachates occurred in the formulations containing 
the lowest protein concentration of 5 mg/mL protein, and highest metal chelator concentration of 
0.1 mg/mL over 3 months, represented by the elevation of the surface towards the front on right 
side in Fig. 3h. Analogous to the data for chromium leachates, the observed nickel leaching 
pattern from stainless steel at 25°C is also dramatically different from that observed for lower 
storage temperatures of −40°C and 2–8°C. 
Compared to the leaching patterns of iron, chromium, and nickel at −40°C and 2–8°C, 
more complex metal leaching patterns were observed at 25°C, which indicates that temperature 
plays an important role. Regardless of the interactions, under the three tested storage conditions, 
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metal chelator concentration, protein concentration, and contact time are the three major 
statistically significant factors for leaching iron, chromium, and nickel from stainless steel. The 
statistically significant and insignificant formulation components affecting metal ion leachates at 
storage temperature of −40°C, 2–8°C, and 25°C are summarized in Table 3. 
Protein concentration ranges vary widely in biopharmaceutical products. Our observation 
that protein concentration controls the capacity for metal leaching from stainless steel is 
consistent with previous findings [26–28]. It was reported that the presence of proteins had a 
significant impact on the passivation behavior of the metals and alloys [26–28]. Acting as 
complexing agents for dissolved metal ions, the protein stimulated the dissolution rate of a base 
metal in a structure-dependent manner, and, consequently, suppressed the formation of the 
protective oxide layer [27]. Brown and Merritt reported that the presence of protein produced 
pitting corrosion on the surface of stainless steel [26]. The same phenomenon was also observed 
by us during protein drug product storage in 316L stainless steel minitanks. Woodman 
demonstrated that in the presence of protein, the leached nickel and chromium predominately 
formed metallo-organic complexes with the protein [28]. In addition, serum protein in vivo and 
in vitro fluids also showed a significant capacity at increasing cobalt, chromium and nickel 
leaching from 316L stainless steel [28] and the leaching pattern was quantitatively fitted into a 
mathematical model. 
In approved biotherapeutic drug products, metal chelators such as Na2EDTA and DTPA 
are present at relatively low concentrations. EDTA was reported to facilitate metal leaching from 
contact stainless steel into solution [20, 27], consistent with the present study. However, our 
observation of no significant difference between Na2EDTA and DTPA is different from previous 
observations when the leaching capacity was investigated only in 20 mM histidine buffer [20]. 
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The impact of contact time was reported to play a significant role in leaching metal ions 
from stainless steel when the impact of individual component of buffer species, and metal 
chelator in 20 mM histidine was investigated [20], a similar phenomenon as observed in this 
study. 
We note here that this study was performed with histidine buffer which is commonly 
used in biotherapeutics drug products. Histidine buffer has a significant temperature coefficient 
(~0.022 K−1) such that formulations prepared at ambient room temperature ( 25°C) will 
experience a pH approximately 0.4 units higher at 2–8°C [29]. Thus samples at 2–8°C actually 
underwent leaching at a slightly higher pH than stated. However, this represents exactly the 
situation that would occur in practice. 
In the current competitive market, the need for high concentration biotherapeutic drug 
products has increased dramatically to improve dosing and storage convenience. A protein 
concentration of 100 mg/mL and higher has been seen in some approved biotherapeutic products. 
In most cases, protein concentration in drug substance has to be even higher than the finished 
drug product due to the dilution effect of excipients which must be added afterwards. Also, the 
storage duration of the drug substance can be over 24 months. Therefore, the overall impact of 
protein concentration, metal chelator concentration, and contact time needs to be carefully 
evaluated with respect to the formulation composition and the storage duration. We expect that if 
different ranges of the factors had been studied, the relative magnitudes of impact would not be 
the same. However, it can be generally expected that the presence of metal chelators and long 
contact time at higher temperatures will always contribute to more leaching of metal ions. 
2.4. Conclusions 
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Biotherapeutic formulation factors of protein concentration, metal chelator 
concentration/type, solution pH, the presence of methionine and surfactant of polysorbate 80, 
and contact time were studied for their capacity to promote metal leaching from contact stainless 
steel in a defined formulation matrix. Among them, metal chelator concentration, protein 
concentration, and contact time are the three statistically most significant parameters affecting 
metal leaching from the contact with 316L stainless steel at storage temperatures of −40°C, 2–
8°C, and 25°C. Furthermore, temperature is an important factor affecting metal leaching pattern. 
Increased temperature dramatically increased metal leaching amount, probably simply because 
of higher mobility of ions and reduced viscosity of the disaccharide solutions. The higher 
mobility enables leached ions to be transported away from the metal surface and thus maintains a 
higher driving force for leaching compared to that at lower temperatures. Regardless of the 
interactions among factors, increased metal chelator concentration and contact duration enhanced 
metal leaching into the solution for all three tested conditions. However, the complexity caused 
by the interactions makes the impact of protein concentration more complicated at storage 
temperature of 25°C. At −40°C and 2–8°C, the increased protein concentration increased the 
metal leachates. Within the tested pH range of 5.5–6.5, solution pH played a minor role for 
facilitating chromium leaching from stainless steel into the product only at 25°C. No statistically 
significant impact is observed for anti-oxidant (methionine) and the surfactant (polysorbate 80). 
During biotherapeutic product development, each formulation component, and potential storage 
duration and temperature must be carefully evaluated for its impact to reduce the risk, 
consequently, to optimize the biotherapeutics formulation to achieve the target drug product 
shelf life with acceptable quality. 
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Table 1. Biotherapeutic formulation components studied to explore their capacity in leaching 
metal ions from 316L stainless steel  
Formulation 
ID 
A B C D E F 
Comment: 
Sugar 
mAb 
Conc. 
(mg/mL) 
pH 
Chelate 
Conc. 
(mg/mL) 
Methionine 
Conc. 
(mg/mL) 
Polysorbate 
80 (mg/mL) 
Chelator 
type 
F1 5.0 5.5 0.0 0.0 0.0 DTPA Trehalose 
F2 5.0 5.5 0.0 0.1 0.0 Na2EDTA Trehalose 
F3 20.0 5.5 0.0 0.1 0.2 Na2EDTA Trehalose 
F4 20.0 5.5 0.0 0.0 0.2 DTPA Trehalose 
F5 20.0 5.5 0.1 0.0 0.0 Na2EDTA Trehalose 
F6 20.0 5.5 0.1 0.1 0.0 DTPA Trehalose 
F7 5.0 5.5 0.1 0.1 0.2 DTPA Trehalose 
F8 5.0 5.5 0.1 0.0 0.2 Na2EDTA Trehalose 
F9 20.0 6.5 0.0 0.1 0.0 DTPA Trehalose 
F10 20.0 6.5 0.0 0.0 0.0 Na2EDTA Trehalose 
F11 5.0 6.5 0.0 0.1 0.2 DTPA Trehalose 
F12 5.0 6.5 0.0 0.0 0.2 Na2EDTA Trehalose 
F13 5.0 6.5 0.1 0.1 0.0 Na2EDTA Trehalose 
F14 5.0 6.5 0.1 0.0 0.0 DTPA Trehalose 
F15 20.0 6.5 0.1 0.0 0.2 DTPA Trehalose 
F16 20.0 6.5 0.1 0.1 0.2 Na2EDTA Trehalose 
F17 12.5 6.0 0.0 0.05 0.1 Na2EDTA Trehalose 
F18 12.5 6.0 0.05 0.05 0.1 DTPA Trehalose 
F19 12.5 6.0 0.05 0.05 0.1 Na2EDTA Trehalose 
F20 12.5 6.0 0.05 0.05 0.1 DTPA None 
F21 12.5 6.0 0.05 0.05 0.1 Na2EDTA None 
F22 0.0 6.0 0.05 0.05 0.1 DTPA Trehalose 
F23 0.0 6.0 0.05 0.05 0.1 Na2EDTA Trehalose 
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Table 2. Three metal ions of iron, chromium and nickel leaching prediction model along with 
adjusted R-squared (R2) and root mean square error (RMSE) in natural logarithmic scale 
Storage 
Temperature 
(oC) 
Metal 
leachates 
Prediction Models 
Adjusted 
R2 (%) 
RMSE 
(%) 
-40oC 
Iron Ln (Fe) = 1.827 + 0.0525 * [protein conc.]  + 4.812 * [metal 
chelator conc.] + 0.251 * contact time 
70 0.57 
Chromium Ln (Cr) = -0.0825 + 0.0628 * [protein conc.] + 0.195 * contact 
time 
73 0.45 
Nickel Ln (Ni) = -0.364 + 0.0262 * [protein conc.] + 0.353 * contact 
time 
90 0.35 
2-8oC 
Iron 
Ln (Fe) = 1.754 + 0.0539 * [protein conc.]+ 5.998 * [metal 
chelator conc.] + 0.657 * contact time 
82 0.51 
Chromium 
Ln (Cr) = -0.0746 + 0.0621 * [protein conc.] + 0.410 * contact 
time 
77 0.42 
Nickel 
Ln (Ni) = -0.493 + 0.0374 * [protein conc.] + 0.755 * contact 
time 
94 0.31 
25oC 
Iron 
Ln (Fe) = 1.476 + 0.0906 * [protein conc.] + 3.035* [metal 
chelator conc.] + 1.164 * contact time - 0.0327 * contact time 
*[protein conc.] + 3.553 * [metal chelator conc.]* contact time 
96 0.34 
Chromium 
Ln (Cr) = 2.098 + 0.0887 * [protein conc.] – 0.404 * pH - 
1.031 * [chelator conc.] + 0.901 * contact time – 0.0306 * 
[protein] * contact time + 3.064 * [chelator conc.] * contact 
time 
95 0.28 
Nickel 
Ln (Ni) = -0.721+ 0.0601 * [protein conc.] - 0.649 * [chelator 
conc.] + 1.106 * contact time – 0.0217 * [protein conc.] * 
contact time + 1.170 * [chelator conc.] * contact time 
98 0.22 
Note: 
1) Unit for protein and metal chelator concentration: mg/mL; 
2) Unit for contact time: month 
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Table 3. Summary presentation of statistically significant and insignificant factors impacting 
metal leachability at storage temperatures of -40oC, 2-8oC and 25oC  
Storage Temperature 
(oC) 
Leachables Significant factors Insignificant factors 
-40oC 
Iron 
Protein conc., metal chelator conc. 
and contact time 
pH, metal chelator type, 
anti-oxidant and 
surfactant 
Chromium 
Protein conc. and contact time 
pH, metal chelator conc. 
/type, anti-oxidant and 
surfactant Nickel 
2-8oC 
Iron 
Protein conc., metal chelator conc. 
and contact time 
pH, metal chelator type, 
anti-oxidant and 
surfactant 
Chromium 
Protein conc. and contact time 
pH, metal chelator conc. 
/type, anti-oxidant and 
surfactant Nickel 
25oC 
Iron 
Protein conc., metal chelator conc. 
and contact time 
pH, metal chelator type, 
anti-oxidant and 
surfactant 
Chromium 
Protein conc., metal chelator conc., 
contact time and pH 
Metal chelator type, anti-
oxidant and surfactant 
Nickel 
Protein conc., metal chelator conc. 
and contact time 
Metal chelator type, pH, 
anti-oxidant and 
surfactant 
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Fig. 1. The impact of the statistically significant formulation factors on metal ion leachates 
from stainless steel at the storage temperature of −40°C (a and b the impact on iron 
ion leachates: a for the formulations containing no metal chelator and b for the 
formulations containing 0.1 mg/mL metal chelator; c for the impact on chromium ion 
leachates in natural logarithmic scale and d for the impact on nickel ion leachates in 
natural logarithmic scale) 
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Fig. 2. The impact of the statistically significant formulation factors on metal ion leachates 
from stainless steel at the storage temperature of 2–8°C (a and b the impact on iron 
ion leachates: a for the formulations containing no metal chelator and b for the 
formulations containing 0.1 mg/mL metal chelator; c for the impact on chromium ion 
leachates in natural logarithmic scale; and d for the impact on nickel ion leachates in 
natural logarithmic scale)  
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Fig. 3. The impact of the statistically significant formulation factors on metal ion leachates 
from stainless steel at the storage temperature of 25°C (a and b the impact on iron 
leachates: a for the formulations containing no metal chelator and b for the 
formulations containing 0.1 mg/mL metal chelator; c–f the impact on chromium ion 
leachates: c for the formulations at pH 6.5 containing no metal chelator, d for the 
formulations at pH 6.5 containing 0.1 mg/mL metal chelator, e for the formulations at 
pH 5.5 containing no metal chelator, and f for the formulations at pH 5.5 containing 
0.1 mg/mL metal chelator; g and h the impact on nickel ion leachates: g for the 
formulations containing no metal chelator and h for the formulations containing 0.1 
mg/mL metal chelator) 
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Fig. 3. continued 
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Chapter 3: Chemical instability of IgG1 induced by metal-catalyzed oxidation: 
fluorogenic tagging methodology applied to characterize oxidized tyrosine and 
phenylalanine in an immunoglobulin monoclonal antibody 
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3.1 Introduction 
Immunoglobulin G (IgG) monoclonal antibodies (mAbs) represent a rapidly growing 
biotherapeutic class in the biopharmaceutical industry for the treatment and prevention of 
diseases by recognizing and eliminating pathogenic antigens [1-3]. Compared to small-molecule 
drugs, mAbs are highly specific, reducing potential side effects. On the other side, mAbs exhibit 
significantly lower stability due to the strong dependence of their physical-chemical properties 
on conformation. Oxidation represents a prominent degradation pathway of proteins [4-11], 
potentially changing potency or causing other undesired pharmaceutical consequences.  
The detection and identification of oxidized proteins has been an analytical challenge due 
to their potentially low abundance and structural complexity. With high demands for the 
development of biotherapeutic products, the need for an efficient and sensitive analytical tool to 
detect and identify oxidative protein modification(s) is becoming imperative.         
Currently, in proteomic research and the biopharmaceutical industry, mass spectrometry 
(MS) is a dominant tool to characterize protein structural features, including amino acid 
sequences, disulfide bond linkages, carbohydrate structures and profiles, post-translational 
modifications, and in-process and in-storage degradation. Reverse-phase liquid chromatography 
(RPLC), size exclusion chromatography (SEC) and sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) are generally used to separate proteins prior to MS analysis. 
Despite the advantages of mass spectrometry, sample separation, purification and digestion, and 
data analysis and interpretation are very time-consuming and resource-intensive processes. The 
complexity of these processes and the expertise necessary to utilize mass spectrometry for 
protein analysis, in general, require a dedicated expert team. In the pharmaceutical industry, RP-
90 
 
HPLC coupled to UV detection has served as a routine analytical method to monitor Met 
oxidation as an indicator of IgG oxidation. However, this method does not provide a complete 
picture of oxidation, or may mislead the assessment of protein degradation; for example, in the 
heavy chain Met is not the best representative residue to monitor mAb oxidation.  
In biotherapeutic product development, manufacturing and during storage, trace amounts 
of metal ions are inadvertently and inevitably introduced into the product from excipients and 
contact materials. Even trace amount of metal ions can be sufficient to induce metal-catalyzed 
oxidation (MCO) [10].  Generally, for the evaluation of a protein’s susceptibility towards MCO, 
a combination of L-ascorbic acid/Cu(II)/O2 or L-ascorbic acid/Fe(III)/O2 has been used as a 
model system, to predominately study reaction mechanisms and to identify oxidation-sensitive 
amino acids [5, 10, 12-17] . Protein primary sequence, structure and the geometry of the metal-
binding sites, as well as the particular oxidation mechanisms inherent to various oxidizing 
species, play important roles in transitional metal-induced oxidative modifications. The 
predominantly oxidized amino acids are either directly involved in metal-binding or located at or 
in close vicinity of metal-binding sites [5, 10, 12, 13, 15]; thus, the reaction sites are not 
necessarily exposed to the surface. Amino acids sensitive to MCO are mainly Met, His, Trp, Cys, 
Lys and Arg [5, 10, 13, 14]. The chemical modifications generated in an IgG2 mAb were 
thoroughly studied under different stress conditions, including MCO [14], and only oxidative 
modifications of Met, Trp and His were identified. No oxidative modifications of Tyr and Phe in 
IgGs are reported to date, even though Tyr oxidation in small proteins and peptides was reported 
[18-20]. Under MCO, Tyr was oxidized to different products, such as Tyr hydroxylation (DOPA) 
and 2-amino-3-(3,4-dioxocyclohexa-1,5-dienlyl) propanoic acid (DOCH) [18] and dityrosine 
[19, 20]. Tyr and Phe oxidation was also identified in covalent aggregates of insulin induced by 
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MCO [18]. Despite the fact that Tyr can be oxidized to different products, Tyr oxidation in IgG 
and its detection have not received much attention in accelerated stability studies of protein 
pharmaceuticals.    
Specific oxidation products of Tyr and Phe, DOPA and DOCH, can be successfully 
derivatized with 4-(aminomethyl)-benzenesulfonic acid (ABS), where the resulting benzoxazole 
[21] exhibits a characteristic fluorescence with excitation and emission maxima at 360±2 nm and 
490±2 nm, respectively [18]. Thus, fluorescence can serve as a fast and sensitive approach to 
detect and characterize Tyr and/or Phe oxidation because of the specificity of the resulting 
benzoxazole derivatives. To date, no study has been reported to utilize this fluorogenic tagging 
method to monitor and characterize oxidative degradation of IgG mAbs. 
Since IgG mAbs represent a major class of biopharmaceutical products, and the exposure 
of antibodies to redox-active metal ions is inevitable and inadvertent, the screening for oxidative 
modifications induced by MCO would provide a valuable approach in evaluating antibody 
instability during biotherapeutic product development. Here, we provide a fluorogenic 
derivatization methodology to detect oxidized Phe and Tyr in IgG1 to monitor IgG1 oxidation 
induced by MCO.   
3.2 Experimental 
3.2.1 Materials 
IgG1 mAb stock solution at 37 mg/mL was supplied by Amgen Inc. (Seattle, WA, USA). 
The purified antibody was stored in formulation buffer at -80oC. Dithiothreitol (DTT), 
iodoacetamide (IAM), sodium phosphate dibasic (Na2HPO4), sodium phosphate monobasic 
(NaH2PO4), copper dichloride (CuCl2), L-ascorbic acid, potassium ferricyanide (K3Fe(CN)6), 
and sodium chloride (NaCl) were purchased from Sigma Aldrich (St. Louis, MO, USA). 
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FabRICTATOR® was purchased from Bulldog Bio, Inc. (Portsmouth, NH, USA), a distributor of 
Genovis (Lund, Sweden). All analytical and HPLC grade organic solvents were purchased from 
Sigma (St. Louis, MO, USA) or VWR Scientific (West Chester, PA, USA). SDS-PAGE running 
buffer (100 mM Tris, 1.92 M Glycine and 0.1% (w/v) SDS at pH 8.3), sample buffer (100 mM 
Tris, 100 mM Tricine, and 0.1% (w/w) SDS at pH 8.25) and Precision Plus Protein dual color 
standards were purchased from Bio-Rad (Hercules, CA, USA). Sequencing-grade trypsin and 
Glu-C were obtained from Promega Corp. (Madison, WI, USA). ABS was synthesized according 
to a published protocol [21].    
3.2.2 Metal-catalyzed oxidation (MCO) 
The IgG1 stock solution was exchanged into milliQ H2O at 2-8
oC using an Amicon® 
ultra-0.5 centrifugal filter device with a 10 kDa filter membrane (Millipore Inc., Bedford, MA, 
USA). An aliquot of the IgG1 stock solution in water was diluted to 1.5 mg/mL with 20 mM 
sodium phosphate buffer (pH6.5). IgG1 oxidation was induced by MCO under air in the presence 
of Cu(II)/L-ascorbic acid. The concentration of Cu(II) varied from 10 µM to 5 mM [14, 16]. 
Considering the relevance to biological and biopharmaceutical conditions [12, 22-24], most 
experiments were performed with 10 µM of Cu (II) and 1 mM L-ascorbic acid. An aliquot (1.5 
mL) of 1.5 mg/mL IgG1 in 20 mM phosphate (pH6.5) was incubated with 10 µM CuCl2 and 1 
mM L-ascorbic acid over 6 hours in a 2 mL Eppendorf vial at 37oC in a water bath. An aliquot of 
oxidized IgG1 solution was sampled at 0, 2, 4, and 6 hours. The reaction was quenched by the 
addition of 100 µM disodium EDTA. In this paper, we will use several terms that need to be 
explicitly defined. First, the term “control” will refer to an IgG1 sample, which was treated 
identically as the MCO sample, but without the addition of CuCl2 and L-ascorbic acid. Second, 
the term “reference standard” will refer to an IgG1 solution which was freshly diluted from the 
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IgG1 stock solution and not subject to any manipulation related to MCO. The control and the 
reference standard, respectively, were used to evaluate i) the impact, if any, of the in-process 
manipulation on IgG1 instability and ii) the method to monitor the IgG1 quality. In the 
discussion, the same definitions were applied to the control and reference standard. 
3.2.3 MCO monitored by size exclusion chromatography (SEC) 
The MCO of IgG1 was monitored by SEC coupled to a diode array detector. The 
separation of monomer and degradation products, aggregates (high molecular weight species, 
soluble aggregates) and fragments (low molecular weight species), was achieved by an isocratic 
elution at 0.7 mL/min over 40 minutes with a Shimadzu ultra performance liquid 
chromatography (UPLC) system equipped with TSK-GEL® G3000SWXL and G2000SWXL 
columns (7.8 x 300 mm, 5 µm) (Tosoh Biosciences, King of Prussia, PA, USA) connected in 
line. The mobile phase consisted of 200 mM phosphate and 50 mM NaCl at pH 7.0. An aliquot 
of 20 µL of the IgG1 sample was injected onto the column. The IgG1 stock solution was diluted 
to 1.5 mg/mL with the mobile phase and used as the reference standard to evaluate the system 
performance. The elution was monitored by a diode array detector, allowing for the recording of 
UV spectra in the region between 200-800 nm.  
3.2.4 Cleavage, reduction and alkylation of IgG1 
An aliquot of the MCO-treated IgG1 was cleaved at the hinge region using 
FabRICATOR® at a ratio of 1:1 (w/w) (IgG1/ FabRICATOR®) for 30 minutes at 37oC. Then the 
disulfide bonds were reduced by DTT (4 mM) by incubating the samples for another 30 minutes 
at 37oC. The thiols resulting from the reduction of the disulfide bonds were alkylated with 10 
mM iodoacetamide for 45 minutes, in the dark, at room temperature. An aliquot (20 µL) was 
sampled for RPLC/MS analysis. The remaining solution was used for ABS derivatization (see 
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below). The IgG1 reference standard and the control were cleaved, reduced and alkylated 
according to the same protocol to evaluate the impact, if any, on IgG1 instability in the absence 
of MCO reagents.   
3.2.5 Analysis of MCO-induced degradation by RPLC-mass spectrometry (RPLC-MS) 
A 20 µL aliquot of IgG1 as well as its control and reference standard after cleavage, 
reduction and alkylation, were purified by an Amicon® ultra-0.5 centrifugal filter device 
(Millipore Corp., Bedford, MA, USA) with 50 mM NH4HCO3 (pH8.0). The purified samples 
were analyzed to evaluate IgG1 degradation induced by MCO using RPLC-MS according to our 
developed procedure (unpublished data). Briefly, an aliquot of 10 µL purified sample was 
injected onto a non-porous column (15 cm x 0.5 mm C18, 2 µm) (Imtakt Corp., Philadelphia, 
PA, USA) on an Acquity RPLC chromatography system (Water Corp., Milford, MA, USA). The 
chromatographic separation was achieved by a combination of several linear gradients of H2O 
and acetonitrile (ACN) containing 0.1% formic acid: a linear increase of from 15% to 25% B 
between 0 and 3 min and from 25% to 35% B between 3 and 20 min at a flow rate of 5 μL/min; 
and a further increases from 35% to 65% B between 20 and 35 min and from 65% to 95% B 
between 35 and 45 min at a flow rate of 7 μL/min. Each chromatographically separated 
component was analyzed by means of a SYNAPT G2 high definition mass spectrometer (Waters 
Corp. Milford, MA, USA). The spectra were acquired using a mass range of 900-3000 amu 
(amu: atomic mass unit). The data were accumulated for 0.7 sec per cycle and processed using 
the software MassLynx (Waters Corp. Milford, MA, USA). To characterize the polypeptides, the 
mass-to-charge (m/z) ratio distributions were analyzed by maximum entropy (MaxEnt) 
processing. 
3.2.6 Feasibility and optimization of fluorogenic tagging of intact and cleaved IgG1 
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After MCO, the intact IgG1 as well as the control and reference standard were dialyzed 
into 100 mM sodium phosphate buffer (pH 9.0) using Amicon® ultra-0.5 centrifugal filter 
devices (Millipore Corp. Bedford, MA, USA) for ABS fluorogenic tagging. The feasibility and 
optimization of ABS tagging of oxidized IgG1 were performed by incubating the oxidized IgG1 
with ABS derivatization reagents in the dark at room temperature under the following 
conditions: i) molar ratios of K3Fe(CN)6/ IgG1 ranged from 5:1 to 30:1; ii) concentrations of 
ABS were 2 and 10 mM ; and iii) the reaction time spanned over 200 minutes. An aliquot was 
sampled at time points of 0, 60, 90, 150 and 200 min. The formation of the resulting fluorescent 
benzoxazole derivatives of oxidized IgG1 was monitored by a steady-state fluorescence 
spectrometer and SEC coupled to a fluorescence detector. Similar derivatizing conditions were 
applied to the reference standard and the control to monitor any potential derivatization not due 
to MCO. The optimized ABS-derivatization conditions were applied to oxidized IgG1 as well as 
its control and reference standard after cleavage, reduction and alkylation for SDS-PAGE and in-
gel digestion to identify the oxidized amino acids, and the benzoxazole derivatives of the 
oxidized Tyr and Phe residues. 
3.2.7 Steady-state fluorescence spectrometry 
The benzoxazole fluorescence of the ABS-derivatized IgG1 samples was measured by a 
Shimadzu RF-5000U fluorescence spectrophotometer (Kyoto, Japan) equipped with a 1-cm 
quartz cuvette and a 96-well plate model, respectively. The emission and excitation spectra were 
acquired in a 0.5 mL 1-cm quartz cuvette (Hellma, Plainview, NY, USA), and the fluorescence 
intensities at λem = 490 nm (λex = 360 nm) for the ABS derivatized samples as well as the 
reference standards and controls were measured in a 96-well plate. For both modes, the 
excitation and emission slit was set at 5 nm.  
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3.2.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
After cleavage, reduction and alkylation, the oxidized IgG1, its control, reference 
standard and their ABS-derivatized samples were independently mixed with SDS-PAGE sample 
buffer containing 100 mM Tris, 100 mM Tricine, and 0.1% (w/w) SDS at pH 8.25. The samples 
were boiled at 100oC for 2 mins after mixing. An aliquot of 20 µL of each sample was loaded 
onto a Novex 4-20% polyacrylamide gel from Invitrogen Inc. (Carlsbad, CA, USA). Molecular 
Weight Standards, precision plus protein dual color standards from Bio-Rad (Hercules, CA, 
USA), were also loaded onto the same gel as the samples. The gel electrophoresis was run under 
a difference of potential of 250 V for 60 mins using 10-fold diluted running buffer at a 
temperature maintained at 6oC. Fluorescence visualization of ABS-tagged proteins was recorded 
by a UV Transilluminator from Fotodyne Inc. (Hartland, WI, USA). Fluorescent bands of 
interest were excised for in-gel digestion. 
3.2.9 In-gel digestion 
The proteins present in the excised fluorescent bands were digested according to the in-
gel digestion protocol described by Shevchenko et al [25]. Briefly, the gel slices were first rinsed 
twice with 100 mM NH4HCO3 (pH 7.8) in ACN (1:1 v/v) and then rinsed with 100% ACN at 
room temperature. The gel slices were dried using a SpeedVac from Labconco Corp. (Kansas 
City, MO, USA). The dried gel slices were incubated for 1 hour at 4oC in 125 µL of a Promega® 
reconstitution buffer for trypsin, containing 5 µg of sequencing-grade trypsin and 2 µg of Glu-C 
in 1.5-mL Eppendorf vials. An aliquot of 275 µL of 100 mM NH4HCO3 (pH 7.8) was then added 
to the samples prior to protein digestion at 37oC overnight. Upon the completion of digestion, the 
digested protein solutions were transferred into new 1.5-mL Eppendorf vials. The gel slices were 
rinsed three times with 100% ACN and the rinsing solutions were combined with the digested 
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protein solutions in the new Eppendorf vials. The samples were concentrated using the SpeedVac 
to reach a final volume of 20 µL for LC-MS/MS analysis. 
3.2.10 CapLC-ESI-TQ-FT-MS analysis 
The in-gel digested protein samples were subjected to capillary LC-MS/MS experiments 
using an LTQ-FT mass spectrometer (ThermoFinnigan, Bremen, Germany) under conditions 
described by Ikehata et al [26]. In short, peptides were separated on a reverse-phase LC Packings 
PepMap C18 column (0.300 × 150 mm) (Dionex, Sunnyvale, CA, USA) at a flow rate 10 
µL/min with a linear gradient rising from 0 to 65% ACN in 0.06% aqueous formic acid over a 
period of 55 minute s using a LC Packing Ultimate Chromatograph (Dionex, Sunnyvale, CA, 
USA). LC-MS experiments were performed in a data-dependent acquisition mode using the 
Xcalibur 2.0 software (Thermo Scientific, Waltham, MA, USA). The five most intense precursor 
ions in a survey MS1 mass spectrum acquired in the FT-ICR over a mass range of 300–2000 amu 
were selected and fragmented in the linear ion trap by collision-induced dissociation. The ion 
selection threshold was 500 counts.  
The MS/MS analysis was performed using MassMatrix [27-29]. The theoretical 
fragments from the parent ions were generated by MassMatrix and then compared to the 
experimental MS/MS spectra to validate the structures, which were taken into account only when 
the difference between the theoretical and the experimental m/z of the parent ion was within 0.1 
Da. The oxidation of Met (+16, 32 and 48 amu) and Trp (+4, 16, 20, 32 and 48 amu), Phe (+16 
and 32 amu), and Tyr (+14 and 16 amu) and the benzoxazole derivatives of oxidized Tyr and Phe 
(listed in Table 1) were built in a customized IgG1 database for identification of the chemical 
modifications. The elementary compositions of the benzoxazole derivatives of the oxidized Tyr 
and Phe residues are also listed in Table 1. 
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3.3 Results  
3.3.1 Degradation of IgG1 induced by MCO 
In a 2-mL Eppendorf vial, 1.5 mL of IgG1 at a concentration of 1.5 mg/mL in 20 mM 
sodium phosphate buffer (pH 6.5) was incubated with 10 µM CuCl2 and 1 mM L-ascorbic acid 
over 6 hours at 37oC. IgG1 degradation induced by MCO was monitored at 0, 2, 4, and 6 hours 
by SEC coupled to a diode array detector (Fig. 1). Soluble aggregates (tR = 18.0 min) were eluted 
first, followed by monomers (tR = 21.5 min) and fragments (tR = 26.0 min) (Fig. 1). The control 
(Fig. 1, pink) exhibits the same profile as our reference standard (Fig. 1, black). Thus, the 
processing of IgG1 did not induce additional soluble aggregates and fragments. A prolonged 
exposure (over 6 hours) of IgG1 to MCO reagents (CuCl2 /L-ascorbic acid under air) led to the 
formation of more soluble aggregates and fragments as monitored by UV detection at 214 nm 
(Fig. 1, blue, dark red and green).  
To further characterize the MCO of IgG1, the reference standard, control and oxidized 
IgG1 were cleaved, reduced and alkylated as described in the Experimental, section 3.2.4, to 
form Fc-HC, Fab-HC and LC. The resulting polypeptides were analyzed by RPLC-MS. The 
chromatograms, monitored by MS analysis of the reference standard, control, and oxidized IgG1 
are shown in Fig. 2. The chromatograms of the reference standard (Fig. 2A) and the control (Fig. 
2B) exhibited the same pattern, which is different from that of the oxidized IgG1 (Fig. 2C). 
Masses of the polypeptides observed in the control (Fig. 3A) and reference standard (Fig. 3B) 
confirm that the processing of the IgG1 (in the absence of MCO) did not induce detectable 
degradation. Indeed, the acquired molecular weights of 22,982 Da for the LC and 24,457 Da for 
Fab-HC, respectively, match their expected masses after alkylation. Also, the acquired molecular 
weights of 24,996 Da, 25,200 Da and 25,362 Da match the expected masses taking into account 
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the glycosylation heterogeneity of the IgG1 Fc-HC (unpublished data). The MCO of IgG1 results 
in a mass increase of 32 Da (25,201 Da to 25,233 Da and 25,364 Da to 25,396 Da) for the Fc-HC 
(Fig. 4A). Similarly, new species with mass increases of 16 Da and 34 Da (22,983 Da to 22,999 
Da, and 22,983 Da to 23,017 Da) along other products were observed for the IgG1 LC (Fig. 4B). 
No significant new species were observed for the Fab-HC resulting from MCO (Fig. 4C). The 
mass spectrometric analysis of the oxidized IgG1 (Fig. 4) indicates that several amino acids may 
be targeted for oxidative modifications, although the MS1 analysis alone cannot detail which 
amino acid is oxidized. The analysis of oxidized IgG1 as well as its control (Fig. 5) indicate that 
MCO induced not only oxidative modifications in the IgG1 primary sequence, as described 
above, but also induced the formation of fragments and/or aggregates, consistent with the data 
obtained by SEC-UV analysis. For example, a fragment with a mass of 11,492 Da and multiple 
aggregates with masses of 33,212 Da, 45,998 Da and 68,948 Da etc., were formed due to MCO.   
3.3.2 ABS derivatization of oxidized IgG1: feasibility and optimization 
CuCl2 and L-ascorbic acid were removed after oxidation of IgG1 by centrifugation 
through a 10 kDa centrifugal filter (as described in the Experimental, section 3.2.3) prior to ABS 
derivatization. The same procedure was applied to the control. Oxidized IgG1 and its control 
were incubated with 10 mM ABS and 100 µM of K3Fe(CN)6 (molar ratio of 10:1 of K3Fe(CN)6 : 
IgG1) for 1 hour in the dark at room temperature. Prior to and post ABS derivatization, the 
fluorescence emission (370 to 650 nm at λex = 360 nm) and excitation (220 to 470 nm at λem = 
490 nm) spectra (Fig. 6) were recorded. For oxidized IgG1 alone, a maximal emission at λem = 
410 nm (λex = 360 nm) was observed prior to ABS derivatization (Fig. 6A, dotted line). A 
maximal emission at λem = 490 nm with a significantly increased intensity emerged after ABS 
derivatization (Fig. 6A, solid line). Likewise, at λem = 490 nm, a maximal excitation at λex = 360 
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nm (Fig. 6B, solid line) was observed after ABS derivatization besides the maximal excitation at 
λex = 245 nm that was present prior to ABS derivatization (Fig. 6B, dotted line). No change in 
maximal fluorescence emission and excitation wavelengths was observed for the control after 
and prior to ABS derivatization (data not shown). Additionally, we observed that the 
fluorescence emission intensity increased at least by 10-fold (Fig. 6A, solid line) after ABS-
derivatization in comparison to the non-ABS derivatized oxidized IgG1 (Fig. 6A, dotted line). 
The increase of fluorescence intensity observed at λem = 490 nm (λex = 360 nm) of the ABS-
tagged sample is consistent with the formation of a benzoxazole derivative as presented in 
Scheme 1 [18]. Met, His, and Trp are subject to MCO [5, 10, 13, 14]. However, Tyr and Phe are 
also prone to oxidation. In the presence of K3Fe(CN)6 and ABS, DOPA and DOCH can be 
transformed into benzoxazole derivatives via the reactions summarized in Scheme 1. Thus, the 
characteristic fluorescence (λem= 490 nm / λex = 360 nm) observed after ABS derivatization of 
the oxidized IgG1 can be rationalized by the formation of ABS derivatives of DOPA and/or 
DOCH resulting from the oxidation of Phe and Tyr.  
Sharov et al, optimized the ABS derivatization conditions for 3-aminotyrosine (3-AT), 
that is, the optimal molar ratio of K3Fe(CN)6 to the peptide was ≥ 5:1 in the presence of 2 mM 
ABS  at room temperature for the peptide concentrations between 0.1, 1 and 10 μM [21]. 
However, this peptide contained only one 3-AT residue for derivatization. Since IgG1 contains 
twenty seven Tyr and sixteen Phe residues and MS analysis indicated the presence of several 
oxidized amino acids, it was necessary to optimize the ABS derivatization conditions specifically 
for the oxidized IgG1. Samples containing the oxidized IgG1 were mixed with different amounts 
of K3Fe(CN)6 and ABS. The molar concentration of IgG1 was maintained at 10 µM. The 
fluorescence intensity of the samples was monitored over 200 minutes at λem = 490 nm (λex = 
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360 nm) (Fig. 7A). At fixed molar ratios of K3Fe(CN)6/IgG1 of 5:1 and 15:1, the concentrations 
of ABS at 2 mM and 10 mM did not show significantly different fluorescence, indicating that the 
ABS concentration was sufficient for derivatization of the oxidized protein. However, an 
increase of the molar ratio of K3Fe(CN)6/IgG1 resulted in a significant increase of the 
fluorescence intensity. The latter can be rationalized by the fact that multiple oxidized Tyr and 
Phe residues are available for ABS derivatization. The derivatization time also affected the 
fluorescence intensity. A plateau was reached after 150 minutes. Importantly, the incubation of 
the oxidized IgG1 with either ABS or K3Fe(CN)6 did not produce any additional fluorescence 
background monitored by fluorescence spectrometer. Thus, the optimized ABS derivatization 
conditions for oxidized IgG1 are achieved with a molar ratio K3Fe(CN)6/IgG1 of 30:1, and 10 
mM ABS. The derivatization reaction was performed at room temperature in the dark for 60-90 
minutes. 
To confirm the optimized ABS derivatization conditions, SEC coupled to a fluorescence 
detector was employed to analyze oxidized IgG1, a mixture of oxidized IgG1 and K3Fe(CN)6, a 
mixture of oxidized IgG1 and ABS, and ABS-derivatized IgG1 after 90 minutes storage in the 
dark at room temperature. The fluorescence (Fig. 7B) was monitored at λem = 490 nm with λex = 
360 nm. Consistent with our previous results obtained by fluorescence spectroscopy, the 
optimized molar ratio of 30:1 of K3Fe(CN)6/IgG1 resulted in a significant increase of the 
fluorescence intensity (Fig. 7B, dotted line). Moreover, the incubation of IgG1 with either 
K3Fe(CN)6 or ABS alone under the same conditions did not generate additional fluorescent 
products (Fig. 7B. solid lines), consistent with the results obtained by fluorescence spectroscopy.  
3.3.3 ABS derivatization to monitor time-dependent IgG1 oxidation 
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IgG1 was exposed to MCO and an aliquot of the solution was sampled at 0, 2, 4, and 6 
hours to evaluate the reaction progress of MCO through ABS derivatization. The control protein 
was processed in the same way as the oxidized protein. At each time point, the MCO was 
terminated by the addition of EDTA. Prior to ABS derivatization, the reaction mixtures were 
dialyzed into sodium phosphate buffer (100 mM, pH 9.0). The progress of MCO was monitored 
by tagging the IgG1 with ABS using our optimized conditions (see above). The fluorescence 
intensity at λem = 490 nm (λex = 360 nm) was measured prior to and after ABS derivatization of 
the oxidized IgG1 samples and their respective controls. The controls as well as their respective 
ABS treated controls did not exhibit fluorescence. The fluorescence intensities obtained prior to 
and after ABS derivatization of the oxidized IgG1 were plotted against the reaction time (Fig. 8). 
Prior to ABS derivatization, the oxidized IgG1 exhibited very low intrinsic fluorescence. The 
fact that the fluorescence intensity increased significantly after ABS derivatization of the 
oxidized IgG1, indicates that the residues of Tyr and/or Phe were oxidized and subsequently 
derivatized by ABS. Our data show that oxidation of Phe and Tyr occurred within 2 hours of 
MCO.  
3.3.4 SDS-PAGE visualization of ABS-derivatized oxidized IgG1 
SDS-PAGE analysis was performed to visualize ABS derivatization of the oxidized IgG1 
prior to in-gel digestion. The oxidized IgG1, and the control as well as the reference standard 
were first cleaved, reduced and alkylated. An aliquot of each sample was incubated with ABS 
and K3Fe(CN)6 at the optimized conditions for ABS derivatization. An aliquot of 5 μL of the 
Molecular Weight Standards was loaded into lane 1 of the SDS-PAGE gel. Lane 2, 7 and 10 
were left blank to monitor the background. An aliquot of 20 μL of each of the following IgG1 
was loaded onto the gel: i) reference standard prior to and after ABS derivatization, ii) control 
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prior to and after ABS derivatization, and iii) oxidized IgG1 prior to and after ABS 
derivatization. The fluorescence was recorded by an UV Transilluminator (Fotodyne Inc., 
Hartland, WI, USA) as presented in Fig. 9. Clearly, only ABS derivatization of the oxidized 
IgG1 (lane 9) exhibited a strong fluorescence. This observation confirms our results obtained by 
fluorescence spectroscopy and SEC analysis coupled to fluorescence detection. The fluorescent 
lane 9 in Fig. 9 was excised from the gel for in-gel digestion to identify the oxidized amino acids 
and the benzoxazole derivatives of the oxidized Phe and Tyr residues. The fact that no 
fluorescence was observed for ABS derivatized IgG1 reference standard and control is consistent 
with the results obtained by RPLC/MS analysis. That is, the processing of IgG1 did not induce 
any oxidative modifications. Therefore, we can conclude that any oxidative modifications in the 
oxidized IgG1 were induced by MCO. 
3.3.5 Identification of ABS derivatives and oxidized amino acids 
    The fluorescent lane 9 from the SDS-PAGE (Fig. 9) was excised and subjected to in-gel 
digestion. The resulting proteolytic peptides were analyzed by means of capillary LC-ESI-LTQ-
FT-MS. The purpose of this analysis was to map the oxidative modifications and benzoxazole 
derivatives in the primary sequence of oxidized IgG1. The oxidized amino acids identified in 
oxidized IgG1 are summarized in Table 2. Besides the oxidation of His, Met and Trp, we report 
the oxidation of Tyr and Phe residues. In fact, three out of eleven Tyr, two out of three Trp, and 
one out of four Phe residues located in the IgG1 LC, and six out of sixteen Tyr, three out of ten 
Trp, nine out of twelve Phe, five out of ten His and one out of eleven Met residues in the IgG1 
HC were oxidized by MCO when IgG1 was incubated with 10 μM CuCl2/ 1 mM ascorbic acid at 
37oC over 6 hours.  
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Four MS/MS spectra are presented below to illustrate how the oxidative modifications 
were rationalized from the MS/MS analysis of the proteolytic peptides obtained after digestion of 
oxidized IgG1. The b and y fragments used in the discussion below for MS/MS analysis refer to 
the cleavage sites defined by Roepstorff [30].  
i.  Hydroxylation of Phe. MS/MS data displayed in Fig. 10 indicate that Phe [103] in IgG1 
LC is hydroxylated. The b2 fragment shows a mass increase of 16 Da compared to the b2 
fragment of non-oxidized IgG1 indicating that the addition of one oxygen atom is located either 
to Val or Phe. The series of the fragment ions of b4-b6 and y2-y5 show that none of the amino 
acids in the sequence GTGTK, C-terminal to Phe is oxidized. The mass increase of 163 Da (147 
Da for Phe + 16 Da) from the y5 fragment to y6 confirms that Phe in the tryptic peptide 
VFGTGTK is oxidized. We cannot determine the position of the hydroxylation from the 
information obtained here since Phe hydroxylation can occur in ortho, meta or para position [31]. 
Only hydroxylation of Phe at the para position leads to the formation of Tyr.  
ii.  ABS derivatization of oxidized Phe. The formation of benzoxazole derivative of oxidized 
Phe [166] in HC in the sequence of TFPAVLQ is indicated by the MS/MS data presented in 
Fig. 11. The fragment ions y3 and y4 indicate that the sequence of AVLQ is not oxidized and 
derivatized. The presence of the fragment ion y5+16 Da suggests the formation of a hydroxyl 
group at Pro in the HC [32]. Therefore, the additional mass increase of 181 Da is localized to 
the sequence TF. The series of b3-b6 fragment ions also confirm a mass increase of 197 Da in 
the original sequence TFP. The loss of two molecules of H2O from the b4 fragment ion is likely 
due to the presence of two hydroxyl functions within the sequence of the b4 fragment ion. 
Because the non-oxidized peptide generates a b4 fragment ion with only one Thr, the loss of 
the second molecule of H2O from the b4 fragment ion of the oxidized peptide is therefore likely 
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due to the presence of the hydroxylated Pro. Therefore, we can assign the mass increase of 181 
Da to Phe corresponding to the addition of one molecule of ABS. The reaction mechanism 
allowing for the formation of the benzoxazole group is possibly facilitated by the amide 
between the original Phe and the Pro residue. The analysis of the fragment ions is completed by 
the assignment of the fragment ion TF(+181 amu)P(+16 amu)AL with m/z of 743.40 and the 
one with m/z of 725.41 corresponding the loss of one molecular of H2O from TF(+181 
amu)P(+16 amu)AL, respectively. These two fragments are likely formed by neutral lose of 
Val from b6 and b6-H2O, respectively.  
iii.  ABS derivatization of oxidized Tyr. ABS derivatization of oxidized Tyr [403] in IgG1 
HC is characterized by the MS/MS fragmentation of the parent ion DSDGSFFLY(+196 amu) 
(Fig. 12). The presence of the y1 and y2 fragment ions indicates a mass increase of 196 Da on 
the C-terminal Tyr residue. The fragment ion b8 confirms that none of the amino acids in the 
sequence DSDGSFFL is oxidized. The observation of a mass increase of 196 Da suggests that 
Tyr was oxidized and subsequently derivatized by ABS. The structure of the benzoxazole 
derivative is presented in Fig. 12, which contains an amino substituted in the 6-position, 
consistent with the data of Sharov et al [21]. 
iv.  ABS derivatization of oxidized Tyr. MS/MS spectra presented in Fig. 13 demonstrate that 
Tyr [315] in HC is oxidized and subsequently derivatized by ABS. The MS/MS spectrum of the 
tryptic peptide W(+16 amu)LNGKEY(+179 amu)K shows a mass increase of 179 Da located at 
Tyr and 16 Da increase located at Trp. Such peptide should have a m/z of 1232.50. The presence 
of the ion with m/z of 607.99 (assigned to the [M+2H-H2O]
++ ion) along with the observation of 
the series of y2-y6 and b4-b6 fragment ions suggest that i) the oxidized Tyr is derivatized by 
ABS, and ii) the formation of a cyclic product involving Lys [316] (Fig. 13, A). The structure 
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involving the C-terminal Lys [316] is also supported by the formation of the internal fragment 
NGKE (m/z 412.20). Meanwhile, the series of b4, b7 and y4-y6 fragment ions, and internal 
fragment of ABS-derivatized GKEY (m/z 576.36), with a loss of 80 Da (SO3H), suggest that 
ABS derivatization of the oxidized Tyr can also form a cyclic product with Lys [313] (Fig. 13, 
B). This intra-molecular crosslink is the result of the addition of the primary amine (-NH2) from 
the side chain of Lys [316] or Lys [313] to the benzoxazole group located on the original Tyr 
[315]. This observed structure of benzoxazole derivative formed through intramolecular 
crosslink to primary amino functional group in the 6-position is consistent with data of Sharov et 
al [21].  
MS/MS analysis of the tryptic peptides containing Phe [103] (Fig. 10) in the LC confirms 
that Phe is oxidized to hydroxyphenylalanine. MS/MS analyses of the tryptic peptides containing 
Phe [166, HC] (Fig. 11), Tyr [403, HC] (Fig. 12) and Tyr [315, HC] (Fig. 13) confirm that Phe 
and Tyr residues are oxidized and subsequently derivatized by ABS. 
3.4 Discussion 
Oxidative modifications of Trp, His and Met residues induced by MCO are well 
documented [5, 12-14, 16, 17, 33], and specifically His has been identified as a target for MCO 
[12, 13, 16, 17]. Luo et al reported the degradation of IgG2 under different conditions of 
chemical and physical stresses. The authors demonstrated that the residues Met, Trp, and His 
were oxidized by MCO [14]. Consistent with this report, we also observed the oxidation of Met, 
His and Trp residues during the MCO of IgG1. The MS/MS spectra were not presented here for a 
more detailed analysis since they are well known oxidation products.    
To the best of our knowledge, the oxidation of Tyr and Phe residues in IgG has not been 
reported. Furthermore, the feasibility of using a fluorogenic tag to detect the oxidized Tyr and 
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Phe in a mAb is also first reported here. We are able to obtain MS/MS confirmation of 
benzoxazole derivatives of Tyr [315, HC], Tyr [403, HC] and Phe [166, HC], consistent with the 
observed significant fluorescence increase at λem = 490 nm (λex = 360 nm) after ABS-
derivatization. The abundance of other ABS-tagged Tyr and Phe residues may be sufficiently 
high for fluorescence detection, but too low for MS/MS analysis. The mapping of oxidized 
amino acids in the primary sequence of IgG1 indicates that no modifications are identified in the 
IgG1 complementarity determining regions (CDRs) for antigen binding. 
Noteworthy, the quantification of the monomer by SEC-UV has been a well-accepted 
practice to evaluate protein stability in the biopharmaceutical industry. However, as revealed by 
our ABS derivatization procedure, we noticed that the fluorescence signal (due to the 
benzoxazole formation) increased not only for the fragments and soluble aggregates, but also for 
the monomers monitored by SEC-fluorescence detection (Fig. 7B). These observations suggest 
that the monomers also incorporate oxidized Tyr and/or Phe that are derivatized with ABS. 
Therefore, the coupling of our ABS-tagging procedure with SEC-fluorescence analysis provides 
additional information on protein integrity. That is, a stability study monitored by SEC-UV 
analysis does not provide sufficient information to assess the stability of IgG1. Here, the 
application of a variety of techniques of SEC-UV/fluorescence, SDS-PAGE, RPLC-MS and 
MS/MS allowed us to develop a practical fluorogenic tagging approach to monitor and 
characterize oxidized Tyr and Phe amino acids to evaluate IgG1 stability.   
3.5 Conclusions 
Oxidation represents a prominent protein degradation pathway. In this paper, we applied 
fluorogenic tagging approach to detect the oxidized Phe and Tyr in IgG. Fluorescence detection 
108 
 
alone and/or SEC combined with a fluorescence detector would provide a rapid alternative 
approach for additional information to evaluate protein stability.  
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Scheme 1. ABS derivatization of oxidized Phe and Tyr to form fluorogenic benzoxazole 
derivatives   
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Table 1. Structure, elementary composition of the modified amino acids and mass shift for 
the non-oxidized residue which are taken into account for peptide mapping searching of 
ABS derivatives of oxidized Tyr in IgG1 (the structures for ABS derivatives of 
oxidized Phe are the same as listed in the table with additional +16 Da mass shift for 
one atom of oxygen) 
Structure 
Elementary 
compositions 
of 
modifications 
Mass shift 
(Da) 
 
DOPA 
O1 +16 
 
ABS-NH2 derivative 
C7H4N2O3S +196 
 
(ABS)2 derivative 
C14H10N2O6S2 +366 
 
ABS-NH2 crosslink 
C7HO3NS +179 
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Table 2. The oxidized amino acids in oxidized IgG1 by MCO, their oxidation products, positions 
in primary sequence and probability of the oxidized amino acids compared to the same 
amino acids in the primary sequence  
Oxidized residues Oxidation products Location Position 
Oxidized 
probability 
Tyr 
3,4-hydroxyphenylalanine 
(DOPA), quinone 
LC 38, 88, 101 3/11 
HC 
60, 94, 95, 274, 
315, 403 6/16 
Phe 
hydroxyphenylalanine, 
DOPA, quinone 
LC 103 1/4 
HC 
79, 122, 146, 
166, 237, 239, 
271, 401, 419 
9/12 
Trp 
kynurenine, hydroxyl-Trp, 
3-hydroxy kynurenine 
LC 37, 191 2/3 
HC 48, 273, 413 3/10 
His 2-ox-histidine HC 
54, 220, 281, 
306, 431 
5/10 
Met 
methionine sulfoxide, 
methionine sulfone 
HC 248 1/11 
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Fig. 1. SEC-UV Chromatograms (λ = 214 nm) to monitor IgG1 degradation induced by metal- 
catalyzed oxidation (MCO) using CuCl2/L-ascorbic acid/O2 system.  
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Fig. 2. RPLC-MS chromatograms of IgG1 reference standard (A), and the control (B) as well as 
oxidized IgG1 (C) after cleavage, reduction and alkylation.  
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Fig. 3. Identification of the components detected by RPLC-MS for IgG1 reference standard (Fig. 
2A) and the control (Fig. 2B). IgG1 was cleaved at hinge region and disulfide bonds were 
reduced and alkylated. The mass for each detected component was obtained by 
deconvolution of the respective mass to charge (m/z) ion distribution using MaxEntropy.  
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Fig. 4. Identification of the components detected by RPLC-MS for oxidized IgG1 (Fig. 2C). 
IgG1 was cleaved at hinge region and disulfide bonds were reduced and alkylated. The 
mass for each detected component was obtained by deconvolution of the respective mass 
to charge (m/z) ion distribution using MaxEntropy.    
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Fig. 5. Combination of all the MS scans of oxidized IgG1 (A) and non-oxidized IgG1 (B). 
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Fig. 6. Fluorescence spectra for oxidized IgG1 prior to and after ABS derivatization: emission 
spectra at λex = 360 nm (A), and excitation spectra at λem = 490 nm (B).    
B 
A 
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Fig. 7. Optimization of ABS derivatization of oxidized IgG1 by fluorescence at λem = 490 nm (λex 
= 360 nm) at different molar ratios of K3Fe(CN)6 to IgG1 (a) and ABS concentrations (b) 
over the time course of 200 mins (A) and SEC-Fluorescence chromatograms (λem/ λex = 
490 nm/360 nm) (B) (the %RSD is within 0.5% with triplicate measurements) 
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Fig. 8. Fluorescence intensity at λem = 490 nm (λex = 360 nm) acquired by fluorescence 
spectrometer to monitor IgG1 degradation over the time course of 6 hours induced by 
metal catalyzed oxidation by using the optimized ABS derivatization condition: molar 
ratio of 30:1 of K3Fe(CN)6 to IgG1 at presence of 10 mM ABS at room temperature in 
the dark (%RSD is within 0.5% for triplicate measurements). 
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Fig. 9. SDS-PAGE gel and fluorescence visualization of oxidized IgG1 after ABS derivatization. 
Fluorescence was recorded by UV Transilluminator (Fotodyne Inc. Hartland, WI, USA).  
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Fig. 10. Collision induced dissociation (CID) obtained by a FT-ICR MS for the peptide VF(+16 
amu)GTGTK [102:108]. The peptide is the result of the tryptic digestion of oxidized 
IgG1 after ABS derivatization.  
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Fig. 11. Collision induced dissociation (CID) obtained by a FT-ICR MS for the peptide TF(+181 
amu)P(+16 amu)AVLQ. The peptide is the result of the tryptic digestion of oxidized 
IgG1 after ABS derivatization. 
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Fig. 12. Collision induced dissociation obtained by a FT-ICR MS for the peptide, 
DSDGSFFLY(+196 amu). The peptide is the result of the tryptic digestion of oxidized 
IgG1 after ABS derivatization.  
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Fig. 13. Collision induced dissociation obtained by a FT-ICR MS for the peptide W(+16 
amu)LNGKEY(+195 amu)K. The peptide is the result of the tryptic digestion of oxidized 
IgG1 after ABS derivatization.  
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Chapter 4: Physical Instability: Impact of Metal Ions on IgG1 
Conformation and Aggregation 
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4.1 Introduction 
Trace levels of metal ions are inadvertently but inevitably present in biotherapeutic 
products. They either arise from the excipients and/or leach from the contact materials during 
product manufacturing, shipping and/or storage process. Metal ions such as tungsten, iron, 
nickel, zinc, barium, manganese, and chromium can leach from prefilled syringes, glass vials, 
plastic container, rubber stoppers and/or stainless steel [1-7]. In our earlier reports, the 
leaching of iron, chromium and nickel from stainless steel has been systemically examined 
[7-8]. It is well known that trace levels of metal ions can induce protein degradation such as 
oxidation, aggregation, fragmentation and the formation of insoluble particles [9-17].  
In vivo, it is believed that one third of the proteins bind to metal ions such as calcium 
and iron as cofactors in their native conformation so that the proteins are stabilized and/or 
perform their functions properly [18-22]. Excessive metal ions present in biological systems 
have been reported to be related to neurodegenerative diseases, with the associated protein 
aggregation potentially induced by metal ions [10, 15]. Protein conformational change 
induced by metal ions is a viable protein degradation route in vitro [10, 15, 17, 23-24]. The 
structure of recombinant human factor VIII was affected by the presence of metal ions such 
as Al3+, Tb3+, Co2+ and Fe3+, resulting in the acceleration of protein aggregation and 
inactivation [23]. It was proposed that the detectable structural change was a result of binding 
of metal ion to the protein. Serum transferring protein exhibited a different tertiary structure 
upon binding of Fe3+ compared to its native state, characterized by ultraviolet-visible (UV) 
spectroscopy, near UV-circular dichroism (CD) spectroscopy, and small-angle x-ray scatting 
[24]. A conformational change of α-synuclein was observed to be correlated with aggregation 
and fibril formation due to the presence of metal ions such as Al3+, Cu2+, Fe3+, Co2+ or Mg2+  
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[15]. Chen, et al observed that Al3+ and Zn2+, but not Cu2+ and Fe3+, induced amyloid-β (Aβ) 
conformational change, exposing a larger hydrophobic area [55]. The authors concluded that 
this conformational change destabilized αβ, resulting in the acceleration of aggregation. 
Previously, we had evaluated the effect of disodium edetate (Na2EDTA) and 
diethylenetriaminepentaacetic acid (DTPA) as iron chelators to prevent metal-catalyzed 
destabilization of a monoclonal antibody (mAb) [17]. We found that the mAb tertiary 
structure was perturbed when the amount of chelators was not sufficient to bind all the metal 
ions. Even though the tertiary structure perturbation was subtle, it was sufficient to induce 
protein oxidation, aggregation, deamidation and fragmentation. Isothermal titration 
calorimetry (ITC) experiments showed that Fe3+ bound to mAb at a molar stoichiometry of 
20 ±1 per mAb with a Kd of 0.18 mM [17]. The binding was suggested to be responsible for 
mAb tertiary structure perturbation. To further explore the conformational impact of Fe3+ on 
the mAb and the resulting degradation mechanism, we have systematically investigated the 
changes in mAb conformation via Far-UV CD, intrinsic/extrinsic fluorescence, and chemical 
denaturation by guanidine hydrochloride (GdnHCl). Also, the resulting degradation products 
of aggregation were studied in a real-time stability manner. Furthermore, we built a 
homology model of the full length antibody and identified potential Fe3+ binding sites in the 
mAb native structure and their surface exposure. These studies provided us insights into the 
mechanism(s) of mAb and Fe3+ interaction. For simplicity, the testing solution was only 
composed of the mAb and Fe3+ in 20 mM histidine buffer at pH5.5 under deaerated 
conditions. The same therapeutic quality IgG2 mAb as in our previous study [17] was chosen 
as the model compound in this study. 
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Here we report that increasing levels of Fe3+ in the mAb solutions result in greater 
levels of mAb degradation, as monitored by aggregation. The mAb tertiary and quaternary 
structure were perturbed, but not secondary structure. Chemical denaturation of the mAb by 
GdnHCl suggested that the unfolding process changed from a two-step transition to a broad 
single step transition at high molar ratios of Fe3+ to mAb. A homology model of the mAb 
was built. The model showed that Fe3+ binding residue clusters (putative Fe3+ binding sites) 
are spatially and sequentially proximal to aromatic residues and aggregation prone regions 
(APRs) located in the complementarity determining regions (CDRs) of the mAb. Putative 
Fe3+ binding sites were also identified in other parts of the mAb, including the hinge region 
and CH2:CH3 domain interfaces. These molecular level observations help us rationalize the 
experimental results on aggregation of the mAb upon Fe3+ binding. 
4.2 Materials and Methods 
4.2.1 Materials 
An in-house produced therapeutic quality IgG2 mAb in 20 mM histidine (pH5.5) was 
utilized. USP/Ph.Eur. grade L-histidine, analytical grade ferric chloride (FeCl3), bis-ANS 
(4,4’-dianilino-1,1’-binaphthyl-5,5’-disulfonic acid, dipotassium salt), 8M GdnHCl stock 
solution and concentrated hydrochloride acid (HCl) were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA). Polyvinylidene fluoride (PVDF), 0.22 µm, syringe 
filter (33 mm) was obtained from Millipore Inc. (Bedford, MA, USA). 
4.2.2 Preparation of the test solutions 
The mAb solution in 20 mM histidine buffer at pH5.5 was first concentrated to 31.7 
mg/mL using a lab-scale tangential flow filtration (TFF) unit with 50 kDa cut-off membrane 
(Millipore Inc., Barrington, IL, USA). An appropriate amount of 31.7 mg/mL mAb stock 
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solution and 1 mg/mL FeCl3 stock solutions in 20 mM histidine (pH5.5) were compounded 
so that a series of test solutions were obtained at discrete molar ratios of Fe3+ to mAb of 0, 
10, 20, 40, 60 and 80. The mAb concentration in all test solutions was maintained at 5 
mg/mL. The formulations were sterile filtered through a 0.22 µm PVDF filter. The actual 
mAb concentrations in the solutions were measured by UV spectrometry at 280 nm using an 
extinction coefficient of 1.43 au. mL per mg per cm (1 mg/mL at 280 nm) determined by the 
Edelhoch method [25]. 2 mL aliquots of the formulations were filled into 2-mL type I glass 
vials (washed and autoclaved), purged with nitrogen and stopper-sealed. The vials were 
stored in stability chambers maintained at 25ºC over 35 days. At designated time points, 
aggregate quantification and biophysical characterization were performed on the samples 
using three individual vials, to explore the effects of Fe3+ on mAb stability and its structure 
over the monitored time course. An aliquot of 1 mL of the test solutions was filled into 2-mL 
type I glass vials for chemical denaturation by GdnHCl. 
4.2.3 Aggregation determined by size exclusion chromatography (SEC) 
The aggregation of the mAb was monitored by SEC. The separation of monomer, 
aggregates (high molecular weight species, soluble aggregates) and fragments (low 
molecular weight species) were achieved by isocratic elution over 40 minutes (0.7 mL/min) 
on an Agilent 1100 system equipped with G3000SWXL and G2000SWXL columns (7.8 x 
300 mm, Tosoh Biosciences or equivalent) in tandem. The mobile phase consisted of 200 
mM phosphate and 50 mM NaCl at pH 7.0. The mAb was diluted to 1 mg/mL using the 
mobile phase and an aliquot of 20 µL was injected into column. An in-house reference 
standard was injected at the beginning, after every 6 samples, and at the end of the sequence 
to ensure system performance by monitoring both peak area count and monomer elution 
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time. The elution was monitored at 214 nm and the relative percentage of the monomers, 
soluble aggregates and fragments was reported. The soluble aggregates are the total percent 
of high molecule weight species including primarily dimeric and higher order species. The 
limit of quantitation (LOQ) for soluble aggregates was determined to be 0.5% with a 
variability of 0.2%. For each time point, three individual samples were analyzed and the 
results were averaged. 
4.2.4 Sodium sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was employed to evaluate the identity and purity of the mAb. The mAb 
concentration was diluted to 0.8 mg/mL using 2x sample buffer for non-reducing SDS-
PAGE. Mark 12 molecular weight standard was used as the reference standard. An aliquot of 
5 µL of the reference standard, and 10 µL of samples and blanks were loaded onto gel. The 
separation was performed on precast polyacrylamide gels (NuPAGE 4-12% Bis-Tris, 1.0 mm 
x 12 well) using a mini-gel apparatus (Invitrogen Cell SureLockTM) using NuPAGE® MES 
SDS running buffer for 35-45 minutes at a voltage of 200 V. The gel was fixed for 10 
minutes, stained using Colloidal Blue for 12 hours and then destained with MilliQ water for 4 
hours. All reagents and gels utilized here were purchased from Invitrogen (Carlsbad, CA, 
USA). The bands were analyzed using the molecular dynamics personal densitometer 
(PDQC-90) with the FragmeNT software.  
4.2.5 Inductively coupled plasma – mass spectrometry (ICP-MS) 
The concentrations of Fe3+ in the test solutions were measured by ICP-MS utilizing 
an Agilent 7500 CX ICP-MS system equipped with an autosampler. An aliquot of 50 µL of 
mAb samples were hydrolyzed using 70% nitric acid (Omnitrace-NX0407) (EMD Chemicals 
Inc, Gibbstown, NJ, USA) at a volume ratio of 1:3 (sample: nitric acid) for 15 minutes at 80-
134 
 
90°C in a water bath. Upon completion of hydrolysis, the samples were cooled to ambient 
temperature and then diluted to 5 mL with 1% (v/v) nitric acid before analysis. The blanks 
were treated using the same procedure as described above. Scandium (45) was used as the 
internal standard and the “hydrogen mode” was utilized to analyze the samples. Prior to 
sample analysis, an external calibration curve was established, giving a linear range of 1-500 
ppb with a LOD of 1 ppb. A 50 ppb standard was analyzed every 6 samples to ensure system 
performance. 
4.2.6 Circular dichroism spectroscopy (CD) 
Far UV-CD spectra for all the samples were acquired on a ChiraScanTM (Applied 
Photophysics, Leatherhead, Surrey, UK) at ambient room temperature. Samples were diluted 
to 0.2 mg/mL using milliQ water. The blanks were diluted in the same way as the samples. A 
1 mm quartz cuvette was used. The sample volume needed for analysis was 400 µL. The 
spectra of the samples and of the respective blanks were acquired by scanning from 200 to 
260 nm with a scan rate of 20 nm / minute, a resolution of 0.5 nm and a response time of 1 
second. Each acquired spectrum was the average of three individual samples (three 
accumulations for each sample). Sample spectra were corrected by subtracting the 
corresponding blank spectra.  
4.2.7 Intrinsic and extrinsic fluorescence 
Intrinsic and extrinsic fluorescence were studied using a Cary Eclipse Fluorescence 
Spectrometer (Varian Inc, Lake Forest, CA, USA). A 1 cm rectangular cuvette was used. For 
intrinsic fluorescence, the mAb samples were diluted to 0.2 mg/mL using 20 mM histidine 
buffer at pH5.5. The protein was excited at 295 nm and the Trp-dominated emission was 
recorded from 300 to 450 nm. For extrinsic fluorescence, bis-ANS was used as the 
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fluorescence dye. The sample was diluted to 1 mg/mL in 20 mM histidine (pH5.5) containing 
50 µM bis-ANS. The mAb was excited at 385 nm and extrinsic bis-ANS fluorescence was 
recorded from 400 to 600 nm. The excitation and emission slits were set at 5 nm. All the 
spectra were analyzed using the Microcal Origin 7.0 (Piscataway, NJ, USA) software. Both 
Trp-dominated intrinsic and bis-ANS fluorescence spectra of the respective blanks were 
acquired using the same methods as the mAb samples. Each sample spectrum was corrected 
by subtracting its respective blank control spectrum to eliminate the contribution of the 
formulation matrix. At each time point, the spectra reported represent the average of three 
independent samples with three runs for each sample. 
4.2.8 Chemical denaturation of the mAb by GdnHCl 
The mAb chemical denaturation was studied with GdnHCl. 8M GdnHCl stock 
solution in water was spiked into mAb solution and then diluted with 20 mM histidine 
(pH5.5), resulting in a series of test solutions containing 0.4 mg/mL mAb with GdnHCl at the 
concentrations of 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, and 4.5M, respectively. The 
solutions were shaken for 10 minutes at 200 rpm and then incubated for 1 hour at 37°C to 
reach equilibrium. A feasibility study demonstrated that fluorescence intensity did not change 
for incubations up to 48 hours. Denaturation was monitored by intrinsic fluorescence using a 
plate reader of 96-well plate format (Spectra Max M5, Molecular Devices, Sunnyvale, CA, 
USA). The 96-well plate was an optical black plate with clear bottom from Nalge Nunc 
International (Rochester, NY, USA). The mAb was excited at 295 nm and the fluorescence 
was recorded from 310 to 400 nm, 2 nm per step. Before the measurement, the solutions on 
the plate were automatically mixed for 5 second and the settling time was set at 100 
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milliseconds. The plate was incubated at 37oC. The denaturation experiment was repeated 
twice. 
4.2.9 Homology based model building for full length mAb 
The mAb used in this study was a humanized IgG2 mAb. The crystal structure of a 
full length murine IgG2a antibody from the Protein Data Bank (PDB) (www.pdb.org, 1IGT) 
was used as an overall template for this mAb, after replacing its hinge region with that found 
in human IgG2 mAbs [26]. The murine IgG2a structure (1IGT) was chosen over that of a full 
length human IgG1 antibody (1HZH) because its hinge region is more similar in sequence to 
the human IgG2 hinge region. Moreover, all the inter-chain disulfide bonds are intact in 
1IGT and the coordinates of all heavy (non hydrogen) atoms in this region are available. A 
separate model for the Fv (fragment variable) portion of the mAb in this study was built 
using Antibody Modeler under MOE2010.10 and superimposed onto the Fv portion of the 
modified 1IGT template. The high resolution (1.6 Å) crystal structure for the Fc (fragment 
constant) portion of the human IgG (PDB entry 1L6X) was also superimposed onto the one 
of the modified 1IGT template. These superimpositions enabled construction of a chimeric 
template which retained the overall spatial disposition of the domains seen in the murine 
IgG2a mAb. However, some of the individual domains (Fv and Fc) were replaced with the 
human ones.  
One thousand (100 backbone models and 10 side chain models per backbone model) 
intermediate homology models were generated and optimized via energy minimization using 
the homology model module in MOE2010.10. In the calculations, all-atom AMBER99 force 
field was used. A cut off of 12 Å with switching starting at 10 Å was applied to non-bonded 
interactions. Generalized Born implicit solvation was employed and interior and exterior 
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dielectric values were 4 and 80, respectively. The one thousand intermediate models were 
ranked using Generalized Born Volume Integral (GB/VI) score and the best ranked model 
was selected for further optimizations. The final model was checked for stereo-chemical 
precision and was found to be of high quality. This model was used to identify potential Fe3+ 
binding residues and their clusters. Inter-chain disulfide bonds in human IgG2 undergo 
scrambling when subjected to redox potential. A recent molecular dynamic study indicated 
that conformational heterogeneity of human IgG2 hinge region results in potential non-
canonical inter-chain disulfide bond pairings [26]. However, for the purpose of this study, the 
canonical IgG2 disulfide bonding scheme [27] was retained and models with non-canonical 
inter-chain disulfide schemes were not created.    
4.2.10 Prediction of APR 
Potential APRs in this mAb sequences were identified using a combination of Tango 
(Fernandez-Escamilla, 2004) and PAGE (Tartaglia, 2005) as described in an earlier 
publication from our group [28]. To complement the predictions from Tango and PAGE, we 
have also used a relatively new aggregation prediction program, Waltz (VIB, 2010). It uses 
position-specific scoring matrices and performs better at recognizing polar APRs [29].  
4.2.11 Identification of putative Fe3+ chelating sites 
Goyal and Mande [30] have surveyed a large number of protein structures to study 
the characteristics of metal binding residues which coordinate divalent and trivalent metal 
ions. Their survey indicates that Fe3+ primarily binds to Glu, Asp and His residues. Thus, to 
identify potential Fe3+ coordinating sites, we looked for Asp, Glu and His residues in the 
mAb sequence and structure as the primary sites. In the mAb homology model, all Cys 
residues are disulfide bonded. In the disulfide bonded form, Cys is not a major residue 
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involved in Fe3+ binding [56]. However, if the disulfide bonds are broken, Cys residues can 
also bind Fe3+. The primary Fe3+ binding sites, identified in the mAb structure, were 
expanded into Fe3+ binding hot spots by including Cys, Asp, Glu and His residues that are 
spatially proximal (neighboring) to a primary site residue. The criterion for selecting spatially 
proximal residues is as following: a pair of amino acid residues, A and B, are considered to 
be spatially proximal if at least one non-hydrogen (heavy) atom belonging to residue A is 
within 4.5 Å distance from a heavy atom in the residue B. For our purpose, residue A is a 
primary Fe3+ binding residue (Asp, Glu or His) [39]. The expansion of a primary site 
continued until all Fe3+ binding residues spatially proximal to the primary residue were 
accounted for. Two Fe3+ binding hotspots were merged together if they contained at least one 
common residue. The Fe3+ binding hotspots thus obtained are the putative Fe3+ chelating sites 
in the mAb structure and are expected to bind multiple Fe3+ ions. Each putative Fe3+ chelating 
site was evaluated for its solvent exposure to measure its location in the mAb surface. The 
solvent exposure of a putative Fe3+ chelating site was measured by averaging the solvent 
accessible surface areas (SASA) of its residues. A putative Fe3+ chelating site was considered 
to be on surface if its average SASA ≥ 20%. 
4.3 Results and Discussion 
Various levels of Fe3+ were spiked into a mAb solution in 20 mM histidine at pH5.5 
to obtain a series of solutions containing 5 mg/mL mAb with discrete molar ratios of Fe3+ to 
mAb. The actual molar ratios of Fe3+ to mAb (ICP-MS and UV280 determinations) were: 0, 
8, 18, 35, 54 and 75. The solution without Fe3+ served as a negative control. Three individual 
vials for each molar ratio were pulled for aggregate analysis at defined time points from 
storage at 25°C. Intrinsic fluorescence was monitored at each tested time point. Extrinsic 
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(bis-ANS) fluorescence was recorded for samples at the initial and last time points. Similarly, 
far UV-CD spectra were also recorded at initial and final time points.    
4.3.1 Antibody degradation by aggregation  
The levels of aggregates monitored by SEC over 819 hours in the solutions 
containing different molar ratios of Fe3+ to the mAb are shown in Fig. 1. The results are 
plotted as % soluble aggregates versus duration of incubation. At each time point, the 
reported level of soluble aggregates represents the average of three individual samples with 
its relative standard deviation (RSD) shown by an error bar. It appears that at 2 hours after 
formulation preparation, the presence of Fe3+ causes an increase in the levels of soluble 
aggregates. The amounts of aggregates increased over time when molar ratios of Fe3+ to mAb 
increased.  
To further explore the nature of aggregation, SDS-PAGE was performed on the 
samples at two selected time points of 75 and 819 hour exposure. SDS-PAGE at the time 
point of 75 hours (Fig. 2) clearly indicates an increasing molar ratios of Fe3+ to mAb induced 
an increasing levels of aggregates. For molar ratios of Fe3+ to mAb ≥35, multiple high 
molecular weight assemblies of aggregates were formed. The SDS-PAGE results at the last 
time point (data not shown) are similar to those at 75 hour time point. With further 
incubation at 25°C over another 30 days, the aggregation pattern did not change (data not 
shown).  
4.3.2 Impact on mAb conformation: secondary and higher order tertiary structures  
The impact of Fe3+ on the mAb secondary structure was explored by Far-UV CD on 
the stability samples at initial and final time points. The spectra obtained on the stability 
samples at final time point are presented in Fig. 3. These spectra are identical to those 
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collected at the initial time point (data not shown). This result indicates that increasing molar 
ratios of Fe3+ to mAb do not have any significant impact on the mAb secondary structure. 
The impact of Fe3+ on mAb higher order tertiary and quaternary structures was studied by 
both intrinsic and extrinsic fluorescence over twenty six days when stored at 25°C. The 
intrinsic fluorescence spectra are shown in Fig. 4A. The fluorescence spectra represent the 
normalized averages of three samples with three runs of each sample after background 
subtraction. No clear blue to red shift in the wavelength of maximal fluorescence intensity is 
observed, but the Trp/Tyr fluorescence intensity decreased with increased molar ratios of 
Fe3+ to the mAb.  However, as shown in Fig. 4B, no further significant decrease in maximal 
fluorescence intensity over the incubation period of twenty six days is observed, suggesting 
that the impact of the Fe3+ binding on mAb conformation is rapid and not affected by further 
changes in aggregation levels. The change in intensity is thus likely related to the initial rapid 
change in aggregation levels. In order to further explore the impact of Fe3+ on tertiary 
structure, bis-ANS extrinsic fluorescence was utilized which characterizes hydrophobic 
pockets or surfaces in the mAb [31]. The fluorescence properties of bis-ANS strongly depend 
on their interactions with protein molecules [32]. The bis-ANS fluorescence emission is 
sensitive to the polarity of the environment. In hydrophobic environment, an increase in 
quantum yield and a blue shift in the maximum are detected. The extrinsic fluorescence 
spectra acquired are shown in Fig. 5A. Each spectrum represents the average of three 
samples, each with three runs after background correction. Bis-ANS extrinsic fluorescence 
exhibits a similar pattern as observed for Trp/Tyr intrinsic fluorescence: no significant blue 
or red shift in the maximal wavelength, but a decrease in fluorescence intensity for increasing 
molar ratios of Fe3+ to mAb (Fig. 5B). The intensity was reduced by 50% for a molar ratio of 
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18. This corresponds to the 50% reduction of intrinsic fluorescence intensity observed for a 
molar ratio of 18 in Fig. 4B. Unlike the intrinsic fluorescence, the decrease in bis-ANS 
fluorescence intensity reaches a plateau when the molar ratio of Fe3+ to mAb reaches 54. The 
leveling in bis-ANS fluorescence intensity with increased molar ratios of Fe3+ to mAb shows 
that above a certain level of Fe3+, the tertiary structure is disrupted to such a complete extent 
that further increase in Fe3+ amount cannot lead to any further changes. Together, the results 
from SEC, SDS-PAGE, intrinsic and extrinsic fluorescence experiments show that the 
binding of Fe3+ perturbs mAb structure accompanied by the formation of aggregates. The 
perturbation of mAb conformation is seen in Fig. 4 and Fig. 5. The intrinsic (Fig. 4) and 
extrinsic fluorescence (Fig. 5) intensity decrease is observed immediately after the addition 
of Fe3+, indicating that the metal binding-induced structural changes are rapid. 
4.3.3 Chemical denaturation by GdnHCl 
The impact of Fe3+ on chemical denaturation of the mAb was explored by addition of 
GdnHCl at concentrations of 0 - 4.5M. Chemical denaturation studies have been used to 
study the folding-unfolding transitions in proteins and to gain insight into stabilizing and 
destabilizing interactions [33-34]. The mAb denaturation was completed after 1 hour of 
incubation at 37oC.  Intrinsic fluorescence is used to monitor the chemical denaturation. The 
maximal fluorescence intensity for the solution containing no GdnHCl is observed at 346 nm 
with excitation at 295 nm (data not shown), corresponding to Trp/Tyr fluorescence. At 
increasing concentrations of GdnHCl, a progressive red shift in the maximal wavelength is 
observed for all tested molar ratios of Fe3+ to mAb (data not shown). This observation 
suggests the loss of compact structure around some of the Trp/Tyr residues and a progressive 
exposure of these hydrophobic regions to a hydrophilic environment. The intrinsic 
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fluorescence emission at 354 nm was chosen to plot fluorescence intensity against the 
concentrations of GdnHCl, as shown in Fig. 6. The negative control not containing any Fe3+, 
shows a two-transition unfolding process, where the first transition occurs in the range of 0 – 
2M and the second transition in the range of 2 – 3.5M. A similar behavior was also observed 
for the molar ratio of Fe3+ to mAb at 8. For the molar ratios of Fe3+ to mAb > 8, the two-step 
unfolding process changes to a single broad transition. Two-step unfolding in the absence of 
Fe3+or at the molar ratio of Fe3+  to mAb at 8 is also observed in the differential scanning 
calorimetry (DSC) melting curve [17] as well as by differential scanning fluorometry (DSF) 
in our another study (unpublished data). At higher molar ratios of Fe3+ to mAb, increased 
tertiary and higher order structure perturbation (as demonstrated by intrinsic/extrinsic 
fluorescence in Fig. 4 and Fig. 5) reduces the overall stability of the mAb, producing the 
observed broad single transition. The above noted change in mAb unfolding pattern from 
double to single transition is also observed in the wavelength shift of the maximal intensity 
(Fig.7A) and the calculated fractions of unfolded mAb (Fig.7B). This observed unfolding 
pattern change strongly suggests that the mAb tertiary structure is perturbed by the addition 
of Fe3+. The chemical denaturation by GdnHCl also offers further insight for the aggregation 
pattern induced by Fe3+. When the molar ratio of Fe3+ to mAb is 8 or less, the aggregates are 
formed probably due to interactions among the perturbed region(s), which are only 
marginally stable. In the solutions containing higher molar ratios of Fe3+ to mAb, the least 
stable domain of the mAb is rapidly unfolded to expose hydrophobic APRs, which, in turn, 
facilitate aggregation. There could also be a second explanation. The destabilization of mAb 
higher order structure may originate from two different structural domains at low molar 
ratios of Fe3+ to mAb. However, at high molar ratios of Fe3+ to mAb, the domains may be 
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destabilized simultaneously leading to a single broad transition. To locate the potential APRs, 
sequence and structural features of the mAb were analyzed.  
4.3.4 Sequence and structural analysis of mAb 
A full length homology-based three dimensional structural model of the mAb was 
built. This model was used to identify putative Fe3+ chelating sites in the mAb structure (see 
materials and methods). Fig. 8 shows the putative Fe3+ chelating sites in the mAb structure. 
Tables 1 and 2 list all putative Fe3+ chelating sites in the mAb, along with their average 
SASA values which indicate their location in the mAb three dimensional structure. Several 
putative Fe3+ chelating sites could be identified throughout the mAb structure including in 
the CDRs, hinge regions and CH2: CH3 domain interfaces. Fig. 9 maps the potential Fe3+ 
binding residues on the sequences of the mAb light and heavy chains along with predicted 
APR, CDRs, aromatic residues (Trp, Tyr and Phe) and auto/metal catalyzed hydrolysis sites. 
The putative Fe3+ chelating sites in hinge region involve Glu and Asp residues that are 
vicinal to inter-chain disulfide bonds.  
APR prediction is shown in the Fig. 10 and Fig. 11, for the mAb heavy and light 
chains, respectively. Predicted APRs, aromatic residues and putative Fe3+ chelating sites are 
co-localized in the CDRs and adjacent framework regions (the sequence regions separating 
the CDRs in the Fv portion) of the mAb. The following APRs were found to overlap with the 
CDRs and adjacent framework regions: (i) 45-KLLIYAA-51 in framework region 2 and 
CDR loop 2 in the light chains, (ii) 87-YCQQYYS-93 in framework region 3 and CDR loop 
3 in the light chains, (iii) 47- WVAVIWY-53 in framework region 2 and CDR loop 2 in the 
heavy chains and (iv) 103- ATLYYYYYG-111 (Kabat positions 99–100G) in CDR loop 3 in 
the heavy chains. All these APRs are strongly predicted by Tango/Page combination (Fig. 10 
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and Fig. 11) and Waltz.  Several Fe3+ binding residues are also present in the CDRs of the 
mAb. These residues are Asp34 in CDR loop 1 in the light chains, His35 in CDR loop 1 in 
the heavy chains, Asp54 and Asp62 in CDR loop 2 in the heavy chains, Asp99 (Kabat 
position 95) in the framework region 3 in the heavy chains, and Asp113 (Kabat position 101) 
in CDR loop 3 in the heavy chains. Some of these residues are vicinal to aromatic residues, 
Trp and Tyr, in sequence and structure. For example, Asp34 precedes Trp35 and Tyr36 in the 
CDR loop 1 of the light chains. Similarly, His35 precedes Trp36 in CDR loop 1 of the heavy 
chain. Glu46 in framework 2 region of heavy chains precedes the APR, 47-WVAVIWY–53. 
Asp54 succeeds this APR. Three of the seven residues in this APR are Trp and Tyr. Glu46 is 
also part of a putative Fe3+ chelating site (Glu46, Glu89 and Asp90) in both the heavy chains 
and is solvent exposed in one heavy chain but not in the other. On the other hand, Asp54 is 
alone and solvent exposed in both heavy chains. Asp62 in the CDR loop 2 is also solvent 
exposed in both heavy chains. Asp113 (Kabat position 101) is located close to a five-Tyr 
residue cluster in the APR 103-ATLYYYYYG–111 in the CDR 3 of the heavy chains and 
also to Trp115 (Kabat position 103). Asp113 is buried in both heavy chains. Accessible 
surface area calculations show that most of the residues in APR 47-WVAVIWY–53 are 
buried and thus protected from solvent. A majority of the residues in the APR 103-
ATLYYYYYG–111 are solvent exposed and this APR is partially on surface. These 
observations are consistent in both the heavy chains. Accessible surface areas for the Fe3+ 
binding residues that are proximal to the aromatic residues (Trp, Tyr and Phe) in the CDRs 
and adjoining framework regions are summarized in Table 3. Fig. 12 shows solvent 
accessible Fe3+ binding residues along with their proximal aromatic residues in Fv region of 
the mAb. These Fe3+ binding residues may serve as initial anchor sites for Fe3+ and the 
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nearby aromatic residues may report the conformational changes in the fluorescence 
experiments. As stated above, there are APRs in vicinity and Trp47, Trp52, Tyr53 and 
Tyr106 are located within these APRs. Physico-chemical degradations initiated by Fe3+ 
binding in the CDR regions may perturb the mAb tertiary structure and cause additional 
buried residues to become solvent-exposed, thereby, leading to further degradation. These 
observations correlate very well with the experimental observations of perturbation of 
tertiary structures and increased aggregates upon increasing molar ratios of Fe3+ to mAb, and 
indicate that destabilization of Fab/Fv regions may underpin the experimental observations.  
Overall, most of the experimental observations on the mAb in this study could be 
rationalized when its molecular sequence and structural properties were taken into account. 
However, collapse of the double transition step in to a single broad transition step at higher 
molar ratios of Fe3+ to mAb in the chemical denaturation studies could not be readily 
explained. The two transitions at the lower molar ratios of Fe3+ to mAb may be due to the 
differences in conformational stabilities of Fc and Fab portions of the mAb. At higher molar 
ratios of Fe3+ to mAb, both Fab and Fc portions may be destabilized simultaneously leading 
to a single broad transition. There could also be a second possibility. The two transition steps 
seen at lower molar ratios of Fe3+ to mAb may be due to the marginal differences in the 
stabilities of two Fab or Fv portions in the mAb. Crystal structures for the full length mAbs 
available in the PDB [35] (PDB entries, 1IGY, 1IGT and 1HZH) show that the two Fabs in 
the antibody structure are oriented asymmetrically with respect to the Fc Portion. This results 
in imperfect T or Y configurations for the overall mAb three-dimensional structure [29, 36]. 
Moreover, there are conformational differences between the two Fabs even though both the 
Fabs have identical sequences (our unpublished data) [37]. These conformational differences 
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also result in the differences among the putative Fe3+ chelating sites (Tables 1 and 2). Thus, 
at low molar ratios of Fe3+ to mAb, the two Fab/Fv regions may be destabilized to marginally 
different extents. But at the higher molar ratios of Fe3+ to mAb, both Fabs are destabilized to 
similar extents and a single broad transition is observed instead of two. Clearly, this question 
will require further investigation. 
4.4 Conclusions 
The impact of Fe3+ on an IgG2 mAb and its degradation mechanism were 
investigated in solutions which did not contain fenton reagents or fenton-like reagents. 
Aggregation and structural change were monitored in this study. Both modes of degradation 
were correlated with the molar ratios of Fe3+ to mAb.  
The impact of the Fe3+ on mAb conformation studied by far UV-CD, intrinsic/ 
extrinsic fluorescence and chemical denaturation by GdnHCl indicates that the mAb 
secondary structure is not impacted by the presence of Fe3+ but its tertiary and higher order 
oligomeric structures are perturbed. The intrinsic/extrinsic fluorescence intensity 
significantly decreases with increased molar ratios of Fe3+ to mAb even though no detectable 
red or blue shift in the wavelength of the maximum intensity is observed. The perturbation of 
the tertiary structure and the resulting enhanced aggregation is due to the binding of Fe3+ to 
the mAb. An impact on the tertiary and quaternary structures is seen immediately after 
addition of Fe3+, suggesting that the binding occurs at specific regions in such a way that the 
local environment of the aromatic residues, especially, Trp/Tyr, is altered. These 
experimentally measured ‘macroscopic’ observations of the mAb in this study could be 
rationalized on the basis of its ‘microscopic’ sequence and structural properties. Homology 
model of the mAb indicates presence of putative Fe3+ chelating sites throughout the mAb 
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structure, both in the variable (Fv) and constant (Fc) regions. In particular, these putative 
Fe3+ chelating sites are in close sequence and spatial proximity with the aromatic residues, 
especially Trp and Tyr, and APRs located in the CDRs and adjacent framework regions of 
the mAb. This study also demonstrates the utility of predictive methods towards 
understanding degradation of biotherapeutics from a formulation perspective.  
4.5 References 
1. Allain, L., et al., Impact of package leachables on the stability of pharmaceutical 
products. American Pharmaceutical Review, 2007. 10(4): p. 38, 40, 42-44. 
2. Fliszar, K.A., et al., Profiling of metal ions leached from pharmaceutical packaging 
materials. PDA J Pharm Sci Technol, 2006. 60(6): p. 337-42. 
3. Markovic, I., Challenges associated with extractables and/or leachables substances in 
therapeutic biologic protein products. American Pharmaceutical Review, 2006. 9(6): p. 
20-27. 
4. Markovic, I., Evaluation of safety and quality impact of extractable and leachable 
substances in therapeutic biologic protein products: a risk-based perspective. Expert 
Opin Drug Saf, 2007. 6(5): p. 487-91. 
5. Osterberg, R.E., Potential toxicity of extractables and leachables in drug product. 
American Pharmaceutical Review, 2005. 8(2): p. 64-67. 
6. Waterman, K.C., et al., Stabilization of pharmaceuticals to oxidative degradation. Pharm 
Dev Technol, 2002. 7(1): p. 1-32. 
7. Zhou, S., et al., Biologics formulation factors affecting metal leachables from stainless 
steel. AAPS PharmSciTech, 2011. 12(1): p. 411-21. 
148 
 
8. Zhou, S., et al., Biotherapeutic Formulation Factors Affecting Metal Leachables from 
Stainless Steel Studies by Design of Experiments. AAPS PharmSciTech, 2011. 
9. Bee, J.S., et al., Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci, 
2009. 98(9): p. 3290-301. 
10. Chen, W.T., et al., Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, 
oligomerization, and aggregation: amyloid-beta destabilization promotes annular 
protofibril formation. J Biol Chem, 2011. 286(11): p. 9646-56. 
11. Dufield, D.R., et al., Selective site-specific fenton oxidation of methionine in model 
peptides: evidence for a metal-bound oxidant. J Pharm Sci, 2004. 93(5): p. 1122-30. 
12. Kim, K., et al., Nonenzymatic cleavage of proteins by reactive oxygen species generated 
by dithiothreitol and iron. J Biol Chem, 1985. 260(29): p. 15394-7. 
13. Li, S., et al., Aggregation and precipitation of human relaxin induced by metal-catalyzed 
oxidation. Biochemistry, 1995. 34(17): p. 5762-72. 
14. Stadtman, E.R., Metal ion-catalyzed oxidation of proteins: biochemical mechanism and 
biological consequences. Free Radic Biol Med, 1990. 9(4): p. 315-25. 
15. Uversky, V.N., et al., Metal-triggered structural transformations, aggregation, and 
fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's 
disease and heavy metal exposure. J Biol Chem, 2001. 276(47): p. 44284-96. 
16. Zhao, F., et al., Metal-catalyzed oxidation of histidine in human growth hormone. 
Mechanism, isotope effects, and inhibition by a mild denaturing alcohol. J Biol Chem, 
1997. 272(14): p. 9019-29. 
17. Zhou, S., et al., Comparative evaluation of disodium edetate and 
diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed 
149 
 
destabilization of a therapeutic monoclonal antibody. J Pharm Sci, 2010. 99(10): p. 4239-
50. 
18. Akke, M., et al., Three-dimensional solution structure of Ca(2+)-loaded porcine 
calbindin D9k determined by nuclear magnetic resonance spectroscopy. Biochemistry, 
1992. 31(4): p. 1011-20. 
19. Banci, L., et al., A prokaryotic superoxide dismutase paralog lacking two Cu ligands: 
from largely unstructured in solution to ordered in the crystal. Proc Natl Acad Sci U S A, 
2005. 102(21): p. 7541-6. 
20. Degtyarenko, K., Bioinorganic motifs: towards functional classification of 
metalloproteins. Bioinformatics, 2000. 16(10): p. 851-64. 
21. Sun, H., et al.,, Transferrin as a metal ion mediator. Chem Rev, 1999. 99(9): p. 2817-42. 
22. Tainer, J.A., et al., Metal-binding sites in proteins. Curr Opin Biotechnol, 1991. 2(4): p. 
582-91. 
23. Derrick, T.S., et al., Effect of metal cations on the conformation and inactivation of 
recombinant human factor VIII. J Pharm Sci, 2004. 93(10): p. 2549-57. 
24. Thakurta, P.G., et al., Tertiary structural changes associated with iron binding and 
release in hen serum transferrin: a crystallographic and spectroscopic study. Biochem 
Biophys Res Commun, 2004. 316(4): p. 1124-31. 
25. Pace, C.N., et al., How to measure and predict the molar absorption coefficient of a 
protein. Protein Sci, 1995. 4(11): p. 2411-23. 
26. Wang, X., et al., Disulfide scrambling in IgG2 monoclonal antibodies: insights from 
molecular dynamics simulations. Pharm Res, 2011. 28(12): p. 3128-44. 
150 
 
27. Milstein, C., et al., Disulphide bridges of the heavy chain of human immunoglobulin G2. 
Biochem J, 1971. 121(2): p. 217-25. 
28. Wang, X., et al., Potential aggregation-prone regions in complementarity-determining 
regions of antibodies and their contribution towards antigen recognition: a 
computational analysis. Pharm Res, 2010. 27(8): p. 1512-29. 
29. Maurer-Stroh, S., et al., Exploring the sequence determinants of amyloid structure using 
position-specific scoring matrices. Nat Methods, 2010. 7(3): p. 237-42. 
30. Goyal, K., et al., Exploiting 3D structural templates for detection of metal-binding sites 
in protein structures. Proteins, 2008. 70(4): p. 1206-18. 
31. Togashi, D.M., et al.,  A fluorescence analysis of ANS bound to bovine serum albumin: 
binding properties revisited by using energy transfer. J Fluoresc, 2008. 18(2): p. 519-26. 
32. Matulis, D., et al., 1-Anilino-8-naphthalene sulfonate anion-protein binding depends 
primarily on ion pair formation. Biophys J, 1998. 74(1): p. 422-9. 
33. Jennings, P.A., et al., Formation of a molten globule intermediate early in the kinetic 
folding pathway of apomyoglobin. Science, 1993. 262(5135): p. 892-6. 
34. Kim, P.S., et al., Intermediates in the folding reactions of small proteins. Annu Rev 
Biochem, 1990. 59: p. 631-60. 
35. Dutta, S., et al., Promoting a structural view of biology for varied audiences: an overview 
of RCSB PDB resources and experiences. J Appl Crystallogr, 2010. 43(Pt 5): p. 1224-
1229. 
36. Harris, L.J., et al., Comparison of the conformations of two intact monoclonal antibodies 
with hinges. Immunol Rev, 1998. 163: p. 35-43. 
151 
 
37. Zhou, S., et al., Simultaneous separation and identification of IgG1, IgG1 fragments and 
photodegradation product by reverse phase liquid chromatography/ mass spectrometry 
(LC/MS)  submitted, 2012. 
 
 
152 
 
 Table 1. Putative Fe3+ chelating sites in the heavy chains of the mAb 
Residue clusters in 
heavy chain 1 (HC1) 
Structural 
Location 
Average 
SASA (µ±) 
Residue clusters in 
heavy chain 2 (HC2) 
Structural 
Location 
Average SASA 
(µ±) 
HC1.E6, HC1.C22, 
HC1.H35, HC1.C96, 
HC1.D99, HC1.D113 
VH 3.69 ± 7.32 
HC2.E6, HC2.C22, 
HC2.H35, HC2.C96, 
HC2.D99, HC2.D113 
VH 2.77 ± 6.79 
HC1.E46, HC1.E89, 
HC1.D90 
VH 
17.17 ±  
14.93 
HC2.E46, HC2.E89, 
HC2.D90 
VH 11.52 ± 16.71 
HC1.D54 VH 49.48 HC2.D54 VH 49.35 
HC1.D62, LC1.D1 VH:VL 44.42 HC2.D62, LC2.D1 VH:VL 42.57 
HC1.D73 VH 24.61 HC2.D73 VH 23.65 
HC1.E145 CH1 74.08 HC2.E145 CH1 71.33 
HC1.D156 CH1 33.51 HC2.D156 CH1 13.21 
HC1.E160, HC1.D211, 
HC1.H212 
CH1 
12.06 ± 
20.89 
HC2.E160 CH1 2.219 
HC1.H176, LC1.D167, 
LC1.E165 
CH1:CL 9.10 ± 13.08 
HC2.H176,  LC2.E165, 
LC2.D167 
CH1:CL 3.20 ± 5.31 
None   HC2.D211, HC2.H212 CH1 10.09 
LC1.E123, HC1.C208, 
HC1.D220 
CH1:CL 
18.82 ± 
22.25 
HC2.D220, LC2.E123 CH1:CL 36.09 
HC1.E224, LC1.D122 CH1:CL 32.7 
HC2.E224, LC2.D122, 
HC2.E230, HC2.C228, 
HC2.C231, HC2.C234, 
HC1.C234 
Hinge 6.11 ± 7.73 
HC1.E230, HC2.C227, 
HC1.C228, HC1.C231, 
HC2.C228, HC2.C231" 
Hinge 
17.13 ± 
16.76 
None   
HC1.D253, HC1.E262, 
HC1.H314, HC1.D316, 
HC1.E349, HC1.D380, 
HC1.H433, HC1.E434, 
HC1.H437, HC1.H439 
CH2:CH3 
23.07 ± 
27.39 
HC2.D253, HC2.E262, 
HC2.H314, HC2.D316,  
HC2.E349, HC2.D380, 
HC2.H433, HC2.E434, 
HC2.H437, HC2.H439 
CH2:CH3 18.53 ± 25.89 
HC1.D269 CH2 7.632 HC2.D269 CH2 6.8 
HC1.C234, HC1.H272, 
HC1.E273, HC1.D274, 
HC1.E276, HC1.E297, 
HC1.E298 
CH2 
23.28 ± 
19.39 
HC2.H272, HC2.E273, 
HC2.D274, HC2.E276, 
HC2.E297, HC2.E298 
CH2 49.56 ± 21.41 
HC1.D284, HC1.E322 CH2:CH3 34.7 HC2.D284, HC2.E322 CH2:CH3 42.32 
HC1.E287, HC1.H289 CH2 50.46 HC2.E287, HC2.H289 CH2 47.34 
HC1.E337, HC1.C325 CH3 15.765 HC2.E337, HC2.C325 CH3 19.89 
HC1.E360, HC1.E361 CH3 13.73 HC2.E360, HC2.E361 CH3 10.83 
HC1.E384, HC1.E386, 
HC1.E392, HC1.C429 
CH3 9.61 ± 8.29 
HC2.E384, HC2.E386, 
HC2.E392, HC2.C429 
CH3 9.68 ± 7.55 
HC1.D403, HC1.D405 CH3 27.55 HC2.D403, HC2.D405 CH3 29.55 
HC1.D417 CH3 34.8 HC2.D417 CH3 36.22 
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Table 2. Putative Fe3+ chelating sites in the light chains of the mAb 
 
LC1 LC2 
Residue clusters in light 
chain 1 (LC1) 
Structural 
Location 
Average 
AASA (µ ± ) 
Residue clusters in 
light chain 2 (LC2) 
Structural 
Location 
Average AASA   
(µ ± ) 
LC1.D1, HC1.D62 VH:VL 44.42 LC2.D1, HC2.D62 VH:VL 42.57 
LC1.D17 VL 39.75 LC2.D17 VL 40.04 
LC1.D34, LC1.C88 VL 0 LC2.D34, LC2.C88 VL 0 
LC1.D70, LC1.C23 VL 26.84 LC2.D70, LC2.C23 VL 27.1 
LC1.E81, LC1.D82 VL 20.46 
LC2.E81, 
LC2.D82, 
LC2.E105, 
LC2.E165, 
LC2.D167, 
LC2.D170, 
HC2.H176 
VL 10.94 ± 12.77 
LC1.E105 VL 2.702 None   
LC1.D122,LC1.E123, 
LC1.E213, LC1.C214, 
HC1.D220,  HC1.E224, 
HC1.C227 
CL:CH1 27.88 ± 18.63 
LC2.D122, 
LC2.E123,   
LC2.D151, 
LC2.D185, 
LC2.E187, 
LC2.H189, 
HC2.D220, 
HC2.E224 
CL:CH1 25.98 ± 19.46 
LC1.143, LC1.H198 CL 20.33 
LC2.143, 
LC2.H198 
CL 26.7 
LC1.D151, LC1.H189, 
LC1.D185, LC1.D187 
CL 26.23 ± 9.41    
LC1.E161 CL 42.15 LC2.E161 CL 47.23 
LC1.E165, LC1.D167,  
LC1.D170, HC1.H176 
CL 13.78 ± 14.20    
LC1.E195, LC1.C194 CL 4.24 
LC2.E195, 
LC2.C194 
CL 9.65 
LC1.E213, LC1.C214, 
HC1.E224, HC1.C227 
CL:CH1 33.43 ± 18.35 
LC2.E213, 
LC2.C214, 
HC2.C139 
CL:CH1 21.49 ± 22.63 
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Table 3. Fe3+ ion binding residues in the neighborhood of aromatic residues in CDRs and 
adjoining framework regions 
Residue and  structural location Spatially vicinal aromatic residues SASA (%) 
D 34  in L1 loop in LC1 
LC1: W35, Y36, Y49, Y87, Y91 
HC1: Y109 
0 
D 34  in L1 loop in LC2 
LC1: W35, Y36, Y49, Y87, Y91 
HC1: Y109, Y110 
0 
E46 in FR2 region of HC1 
HC1: W47 
LC1: F98 
24.4 
E46 in FR2 region of HC2 
HC2: W47 
LC2: F98 
3.9 
D54 in H2 loop of HC1 HC1: W52, Y53, Y106 49.5 
D54 in H2 loop of HC2 HC2: W52, Y53, Y106 49.4 
D62 in H2 loop of HC1 HC1: W47, Y60 41.8 
D62 in H2 loop of HC2 HC2: W47, Y60 30.4 
D99 in H3 loop of HC1 HC1: Y32, Y108, Y109, Y110 0 
D99 in H3 loop of HC2 HC2: F27, Y32, Y108, Y110 0 
D113 in H3 loop of HC1 HC1: W115 18.3 
D113 in H3 loop of HC2 HC2: W115 16.6 
155 
 
 
 
 
 
Fig. 1. Yield (%) of soluble aggregates of mAb in the formulations containing discrete molar 
ratios of Fe3+ to mAb when incubated at 25oC are plotted versus incubation time. % 
soluble aggregates are the total percent of high molecule weight species quantitated by 
SEC. The values represent the average of three individual samples at each time point. 
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Fig. 2. SDS-PAGE of the mAb formulations at different molar ratios of Fe3+ to mAb (Pl means 
placebo, F1 for negative ctrl and F2-F6 stand for the formulations at molar ratios of Fe3+ 
to mAb of 8, 18, 35, 54 and 75) at a time point of 75 hours  
 
157 
 
 
 
Fig. 3. Secondary structure of the formulations containing different molar ratios of Fe3+ to mAb 
when incubated at 25oC over 35 days by Far UV CD from 190-200 nm at ambient 
temperature. The mAb conc. was at 0.2 mg/mL. The spectra represent the average of 
three samples with RSD < 0.05% 
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Fig. 4. Intrinsic fluorescence (excitation was set at 295 nm) of the solutions containing discrete 
molar ratios of Fe3+ to mAb is presented. (A) Fluorescence spectra at initial time points 
(the spectra represent the average of three individual samples with RSD <0.5%); and (B) 
Maximal intrinsic fluorescence change of the formulations with the molar ratios of Fe3+ to 
mAb over the different incubation period at 25oC. The mAb conc. for all the tested 
solutions was 0.2 mg/mL and experiment was performed at ambient temperature. 
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Fig. 5. Bis-ANS extrinsic fluorescence (excitation wavelength was set at 385 nm) of the 
formulations containing different molar ratios of Fe3+ to mAb is shown. (A) Bis-ANS 
extrinsic fluorescence spectra at final time point (the spectra represent the average of 
three individual samples with RSD < 0.5%); and (B) Maximal bis-ANS extrinsic 
fluorescence change with the molar ratios of Fe3+ to mAb over the incubation at 25oC. 
The mAb conc. for all the tested solutions was 1 mg/mL and the experiment was 
performed at ambient temperature. 
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Fig. 6. Chemical denaturation of the IgG2 mAb by GdnHCl is presented as intrinsic fluorescence 
intensity at 354 nm with excitation at 295 nm versus GdnHCl concentration. The intrinsic 
fluorescence was measured by using 96-well plate reader. The mAb conc. was 0.2 
mg/mL and the experiment was performed at ambient temperature.    
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Fig. 7. Chemical denaturation by GdnHCl in the solutions containing different molar ratios of 
Fe3+ to mAb is presented. (A) Wavelength shift in maximal intrinsic fluorescence 
intensity, and (B) Percentage of unfolded protein. The intrinsic fluorescence was 
monitored by a plate reader with 96-well plate. The mAb conc. was 0.2 mg/mL and the 
experiment was performed at ambient temperature.  
 
A  B 
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Fig. 8.  A three-dimensional homology based model of an IgG2 mAb in this study is shown in 
ribbon representation. Putative Fe3+ chelating sites are shown in CPK. The following 
color code was used: heavy chains, light pink and magenta; light chains, cyan and orange; 
predicted aggregation prone regions (APRs), yellow.  
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Fig. 9. Potential metal binding residues, aromatic residues, auto / metal catalyzed hydrolysis sites 
and predicted aggregation prone regions (APRs) are mapped on to heavy and light chain 
sequences of the IgG2 mAb in this study. Single letter amino acid code is used. Metal 
binding residues C, D, E, H are shown in bold and red. Potential APRs predicted by 
Tango/Page and Waltz are shown in yellow and sky blue backgrounds. CDRs are 
underlined. Auto and metal catalyzed clipping sites, DP, DY, HS, SH and KT, are shown 
in grey background. Aromatic residues, W, F and Y, are shown in big bold and blue.  
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Fig. 10. Potential aggregation prone regions (APRs) in the heavy chain of IgG2 mAb. The APRs 
were predicted using a combination of Tango and Page. X-axis shows residue number. 
There are two Y-axes in this figure. The one in blue shows Z-score calculated from 
PAGE’s aggregation propensity values. The horizontal line in cyan shows a cut off value 
for Z-score (1.96). The Y-axis in green shows Tango’s β- aggregation score. The 
horizontal magenta line shows cut off value for Tango score (10%). These cut off values 
were used to identify predicted APRs. The APRs detected by this method are: 47-
WVAVIWY-53, 92-AVYYC-96, 103-ALTYYYYYG-111, 243-SVFLFP-248, 263-
VTCVVV-268, 306-VVSVLTVV-313, 369-LTCLV-373 and 406-GSFFLYS-412. Note 
that these are not Kabat numbering positions. 
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Fig. 11. Potential aggregation prone regions (APRs) in the light chain of IgG2 mAb. The APRs 
were predicted using a combination of Tango and Page. This figure was plotted in the 
same was as Fig 10. The APRs detected by this method are: 46-LLIYAA-51, 71-FTLTI-
75, 87-YCQQYY-92, 114-SVFIFP-119 and 131-SVVCLL-136. Note that these are not 
Kabat numbering positions. 
 
166 
 
 
 
 
Fig. 12. Co-localization of Fe3+ binding residues, aromatic residues and APRs in the Fv portion 
of the IgG2 mAb is shown. The solvent accessible Fe3+ binding residues, Glu46, Asp54 
and Asp 62 in the heavy chain, are depicted in ball and stick representation along with 
their proximal aromatic residues, Trp47, Trp52, Tyr53, Tyr60 and Tyr106. Note the 
residues are numbered according to their position in the sequences. The following color 
code was used: green for heavy chain; red for light chain and yellow for APR.   
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5.1 Introduction 
Monoclonal antibodies, like other proteins, are generally marginally stable in solution 
and subject to physical/chemical degradation, such as aggregation, oxidation, fragmentation and 
deamidation. To gain an understanding of the stability of a biotherapeutic protein candidate, real-
time stability studies at various temperatures are generally performed. To save time and 
resources in protein candidate development, characterization of the conformational stability of a 
protein using circular dichroism (CD) [1], intrinsic/extrinsic fluorescence [1-2], differential 
scanning calorimetry (DSC) [3-4], high resolution UV absorbance spectrometry [5], and 
differential scanning fluorescence (DSF) [3] has gradually gained recognition and acceptance. 
The acquired information helps the formulation scientist to understand the factors affecting 
protein stability from the structural perspective and thus provides a basis to identify appropriate 
components and conditions to stabilize the protein. 
During drug substance and/or drug product processing, manufacturing and storage, metal 
ions, especially iron, are inevitably introduced into the final drug product with the risk for 
inducing protein degradation [6-8]. One generally accepted degradation mechanism induced by 
iron is the Fenton reaction [9-13]. However, an alternative degradation mechanism has also been 
proposed, that is, degradation as a consequence of protein conformational changes induced by 
metal ion binding to the protein [14-17]. The study in Chapter 4 indicates that ferric ions bind to 
a therapeutic immunoglobulin monoclonal antibody (IgG2 mAb), and induce mAb degradation. 
All four major degradation mechanisms, oxidation, aggregation, fragmentation and deamidation 
were observed. To further characterize and understand the impact of ferric ions on mAb structure 
and stability, here we focus on investigating the mAb thermal stability. Far-UV CD was 
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employed to characterize the protein secondary structural change with increasing temperatures. 
Intrinsic fluorescence was used to study impact on tertiary structure while (bis-ANS) extrinsic 
fluorescence was utilized to monitor changes in exposure of hydrophobic patches/areas. High-
resolution UV second derivative absorbance spectroscopy was used to track the impact of ferric 
ions on the protein tertiary structure by monitoring peak position thermal shift of six 
characteristic negative peaks arising from aromatic amino acid residues (Phe, Tyr and Trp) [19]. 
The impact of ferric ions on protein intrinsic melting points was studied by DSC and the thermal 
transitional temperature of hydrophobic exposure changes was studied by DSF with SYPRO® 
Orange dye. SYPRO® Orange dye has been reported to be a sensitive tool to monitor protein 
unfolding and protein stability under thermal stress because of its distinct fluorescent properties, 
that is, interactions with hydrophobic regions exposed due to protein conformational changes 
[19-23]. Our results provide further evidence that the binding of ferric ions perturbs the mAb 
structure. The gradually decreasing melting points, thermal transition temperature of 
hydrophobic exposure, and/or SYPRO® Orange intensity with increasing molar ratios of ferric 
ions to mAb, provide a reasonable explanation for the reduction in protein stability induced by 
ferric ions from a structural perspective.   
The study presented in this chapter was undertaken as part of our ongoing efforts to 
elucidate the impact of leached metal ions on mAb structure and stability.  We used the strategy 
of “exaggerating” a factor to understand its impact, similar to that used by Hoehne et al. [25], 
when assessing the impact of glass particles, and by Thirumangalathu et al. [26] for silicone oil. 
Metal ions, especially, ferric ion, can be present in raw materials but a primary source is stainless 
steel manufacturing and storage equipment. Our practical experience suggests that actual levels 
of metal ions tend to be low (generally less than 1- 5 ppm; i.e. molar rations of approximately 
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0.6-3 for a mAb with a molecular weight of ca. 150 kDa at 5 mg/mL) when working with well 
maintained and passivated equipment, especially at large–scale.  Higher levels of ferric ions may 
be obtained when working with surrogate small-scale tanks which present a high surface area 
compared to the volume parameter. An example where such tanks may be found is in long-term 
stability studies designed to mimic large-scale bulk solution storage.   
5.2 Materials and Methods 
5.2.1 Materials 
A therapeutic quality immunoglobulin (IgG2) mAb in 20 mM histidine (pH5.5) was 
obtained from Pfizer Inc. (Saint Louis, MO). USP/EP grade L-histidine, analytical grade ferric 
chloride (FeCl3), and bis-ANS (4,4’-dianilino-1,1’-binaphthyl-5,5’-disulfonic acid, dipotassium 
salt) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). The SYPRO® orange 
dye, supplied as a 5000x concentrated solution in dimethyl sulfoxide (DMSO), was purchased 
from Invitrogen, Inc. (Carlsbad, CA, USA). The molecular details of SYPRO® orange are not 
available to users due to intellectual property considerations. 
5.2.2 Protein formulations 
The mAb solution in 20 mM histidine buffer at pH5.5 was first concentrated to 31.7 
mg/mL using a lab-scale tangential flow filtration unit with 50 kDa cut-off membrane (Millipore 
Inc., Barrington, IL, USA). An appropriate amount of 31.7 mg/mL mAb stock solution and 1 
mg/mL FeCl3 stock solutions in 20 mM histidine at pH 5.5 were compounded to obtain a series 
of test solutions at discrete molar ratios of ferric ions to mAb of   0, 10, 20, 40, 60 and 80. The 
mAb concentration in all test solutions was 5 mg/mL. Other mAb formulations tested in this 
study were prepared by diluting the test solutions to appropriate mAb concentration. 
5.2.3 Circular dichroism spectroscopy (CD) 
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Far UV-CD spectra and thermal transition curves for all samples were acquired on a 
Jasco J-720 spectrophotometer (Tokyo, Japan) with the temperature controlled by a Peltier 
temperature controller. Samples were diluted to 0.2 mg/mL using milliQ water with similar 
dilution for the blanks. A 400 µL sample was aliquoted into 1 mm quartz cuvette with a Teflon 
stopper for measurement. The ellipticity at 218 nm was acquired from 10oC to 80oC with a 
thermal ramp rate of 1oC per minute. Prior to and post-thermal transition, full spectra from 200 to 
260 nm were acquired for the sample and its respective blank with a scan rate of 20 nm/min, step 
of 0.5 nm, bandwidth of 0.5 nm and sampling time per point of 6s. The reported spectra are the 
average of three accumulations. Each sample spectrum was corrected by subtracting the 
respective blank spectra to eliminate buffer contributions.  
5.2.4 Intrinsic and extrinsic fluorescence spectroscopy 
A Cary Eclipse Fluorescence Spectrometer (Varian Inc, Lake Forest, CA, USA) with a 
Peltier based cuvette holder was employed to collect both intrinsic and extrinsic fluorescence 
spectra. A rectangular micro-cuvette (sample volume of 100 µL) with a Teflon stopper was 
employed with a path length of 1 cm. For both intrinsic and bis-ANS extrinsic fluorescence, the 
mAb samples were diluted to 0.2 mg/mL using 20 mM histidine (pH5.5) for intrinsic 
fluorescence or 20 mM histidine (pH5.5) containing 50 µM bis-ANS for extrinsic fluorescence 
measurement. The Trp-dominated intrinsic fluorescence was acquired by exciting samples at 295 
nm and recording the emission from 300 to 450 nm. The bis-ANS extrinsic fluorescence spectra 
were acquired from 400 to 600 nm with an excitation at 385 nm. The excitation and emission 
slits were set at 5 nm and full spectra were collected every 2oC from 10oC to 80oC. The 
respective blanks for both intrinsic and extrinsic fluorescence were collected in the same way as 
the protein samples and then subtracted from the active samples to eliminate any potential 
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background interference. Microcal Origin 10.0 (Piscataway, NJ, USA) was employed to process 
all background-corrected spectra for the maximal wavelengths and corresponding maximal 
intensities at each temperature.  
5.2.5 Derivative UV absorbance spectroscopy 
An Agilent 8453 diode array UV- visible spectrometer (Palo Alto, CA, USA) was 
employed to study the temperature perturbation of UV absorbance. Spectra were collected every 
2oC from 20 to 80oC with an equilibration of 2 minutes for each temperature. Prior feasibility 
experiments had demonstrated that an equilibration time of 2 minutes was sufficient to record a 
stable spectrum. The samples were diluted to 0.2 mg/mL with 20 mM histidine at pH5.5 in a 1 
cm cuvette, sealed with a Teflon stopper (sample volume of 200 µL). Blanks were processed 
similar to the active samples and their UV absorbance was subtracted from the active spectra to 
eliminate any potential formulation matrix interference. An Agilent Chem-Station was used to 
analyze the spectra and the second-derivative was acquired using a nine-point data filter, fifth-
degree Savitzky-Golay polynomial. The spectra were subsequently fitted to a cubic function with 
99 interpolated points per raw data point as described by Dr. Middaugh [19], permitting 0.01 nm 
resolution.  
5.2.6 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) (VP-Cap, GE HealthCare, Pittsburgh, PA, USA) 
was used to monitor the thermal transition temperatures (Tms) of the mAb at different molar 
ratios of ferric ions to mAb by measuring the heat capacity associated with gross conformational 
changes. A scan rate of 200oC/hr was used to record the heat capacity at the temperature of 25 to 
110°C. The mAb concentration was diluted to 1.0 mg/ml with the buffer for all samples. The 
same dilution was used for the corresponding blanks in all experiments.   
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5.2.7 Differential scanning fluorescence (DSF) 
SYPRO® orange dye was supplied in concentrated stock solutions. Prior to use, the dye 
was diluted into 20 mM histidine buffer at pH5.5. SYPRO orange was first diluted 200 times and 
then added to the protein solution to achieve a final dilution level of 1:2000 in the assay samples. 
The final concentration of SYPRO® orange was 2.5 times higher than the recommended gel stain 
concentration because the fluorescence intensity obtained from an earlier feasibility experiment 
using a 1:5000 dilution was only 2-fold higher than baseline. To improve the accuracy, a dilution 
of 1:2000 was utilized for all the tested solutions. The protein solutions were prepared in BioRad 
multiplate® PCR platesTM low 96-well clear plate (BioRad Laboratories, Hercules, CA, USA). 
Each cell contained an aliquot of 25 µL solution. The plate was sealed with optically clear 
adhesive PCR SealersTM Microseal® ‘B’ film and the fluorescence monitored by a Bio-Rad 
CFXTM Real Time System, C1000TM Thermal Cycler (BioRad Laboratories, Hercules, CA, 
USA). With an excitation at 488 nm using an argon laser, SYPRO® orange was detected with 
FRET (FÖrster resonance energy transfer) as fluorophore. The sample plate was subjected to 
thermal stress from 20 to 95oC with an increment of 1oC. At each temperature, the plate was 
equilibrated for 1 minute prior to measurement. The fluorescence data and the 1st derivatives 
obtained from the built-in software were exported as CSV file into Microsoft Excel (Microsoft 
Corporation, Redmond, WA, USA) for further data analysis. The addition of the dye (at 1:5000 
to 1:500) did not change the thermal transition points of the proteins determined by DSF using 
the same thermal stress parameters.  
5.3 Results and Discussion 
Protein solutions with various molar ratios of ferric ions to mAb of 0, 10, 20, 40, 60 and 
80 were prepared. The actual molar ratios of ferric ion to mAb were measured as 0, 8, 18, 35, 54 
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and 75 due to the compounding deviation. Solution containing no ferric ions served as a negative 
control.  
5.3.1 Far-UV circular dichroism (Far-UV CD) 
The impact of ferric ions on the mAb secondary structure was explored by Far-UV CD. 
The full scan spectra prior to and post melting are presented in Fig. 1. At 10oC, as previously 
observed, the protein exhibited typical β-sheet pattern with a minimum peak at 218 nm and ferric 
ions did not produce any impact on the mAb secondary structure. Post melting at 80oC, 
compared to the spectra prior to melting, the ellipticity decreased and the minimum at 218 nm 
broadened and shifted to a lower wavelength. However, similar spectra were observed for all the 
solutions containing different molar ratios of ferric ions to mAb, suggesting ferric ions did not 
produce any impact on mAb secondary structure observable by this technique. Meanwhile, there 
was also no significant difference in Tm values and thermal transition patterns observed (data not 
shown) in the secondary structure at different molar ratios of ferric ions to mAb.  
5.3.2 Intrinsic and extrinsic fluorescence 
The impact of ferric ions on the protein tertiary structure was studied by intrinsic and 
extrinsic fluorescence in last Chapter. The same strategy was employed in this study to 
investigate the impact of ferric ions on mAb tertiary structure thermal stability. No difference in 
the thermal transitions of maximal fluorescence intensity and wavelength were observed by both 
intrinsic and bis-ANS extrinsic fluorescence (data not shown), suggesting that either the intrinsic 
and extrinsic fluorescence are not sufficiently sensitive to detect the subtle changes in thermal 
transition induced by ferric ions or that ferric ions did not perturb the thermal transition of the 
mAb tertiary structure.  
5.3.3 High resolution derivative UV absorbance spectroscopy 
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Second-derivative UV absorbance can permit small changes in tertiary structure to be 
readily detected compared to other spectroscopic approaches since the three aromatic residues, 
Phe, Trp and Tyr are dispersed throughout the mAb primary sequence [19]. Six distinct negative 
peaks, three from Phe, and one each from Tyr, Trp/Tyr and Trp were observed in the second-
derivative UV absorbance spectra of the test solutions containing different molar ratios of ferric 
ions to mAb at 20oC. The six peak positions at 20oC for all test solutions are summarized in 
Table 1 along with the peak position values from the literature [19]. The six peak positions of the 
negative control solution containing no ferric ions are slightly different from the values reported 
for bovine granulocyte colony stimulating factor (bGCSF), that is, peak 1 (Phe 1), 2 (Phe 2), 3 
(Phe 3), 5 (Trp/Tyr) and 6 (Trp) moved to a higher wavelength while peak 4 (for Tyr) moved to 
lower wavelength. The differences are possibly induced by the differences in microenvironment 
between bGCSF and the IgG2 mAb. The peak positions for these six peaks were monitored as a 
function of temperature, as shown in Fig. 2. At lower temperature, before transition, a quasi-
linear continuous wavelength increase with temperature increase was observed for all six 
negative peaks, reflecting the intrinsic response of the spectra of the aromatic amino acid side-
chains to temperature. Similar to bGCSF at pH2 and pH3, three Phe peaks (peak 1, 2 and 3) 
responded differently to the temperature change. Phe-1 (peak 1, Fig. 2A) and Phe-2 (peak 2, Fig. 
2B) exhibited a quasi-linear continuous wavelength increase with temperature without transition. 
Phe-3 (peak 3, Fig. 2C) and Tyr (peak 4, Fig. 2D) in the negative control solution exhibited a 
clear transition but in the solutions containing ferric ions no transitions were observed. For 
Trp/Tyr (peak 5, Fig. 2E) and Trp (peak 6, Fig. 2F), clear transitions were observed for all the 
solutions. As shown in Fig. 2, the presence of ferric ions in the solutions clearly disturbed two 
out of three microenvironments that Phe residues are located in, and also the Trp and Tyr 
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microenvironments. Furthermore, the presence of ferric ions disturbed Phe-3 (Fig. 2C) and Tyr 
(Fig. 2D) thermal transition pattern. While the negative control solution exhibited a clear 
transition, the solutions containing ferric ions exhibited continuous wavelength increase with 
temperature without clear transitions. These observations imply that the mAb tertiary structure is 
sensitive to the presence of ferric ions.           
5.3.4 Differential scanning calorimetry 
The melting point of a protein is an indication of its relative thermal stability. DSC was 
performed on the solutions containing different molar ratios of ferric ions to mAb and two well 
separated thermal melting transitions (Tm1 and Tm2) were observed, as shown in Fig. 3. The 
thermal transitions were irreversible. The data indicate that the presence of ferric ions shifts Tm1 
(summarized in Table 2) to lower temperatures and broadens the transition at Tm2. An increase 
in the molar ratios of ferric ion to mAb decreased Tm1 proportionately, as well as the enthalpies 
of each transition. The DSC profile suggests that Tm1 corresponds to the unfolding or melting of 
the CH2 domain and Tm2 corresponds to the Fab and CH3 domains [27]. Addition of ferric ions 
destabilizes the Tm1 melting domains, lowering the onset and peak temperature as well as the 
melt enthalpy. The Tm2 temperature is not significantly impacted but the melt enthalpy is 
reduced. Ferric ions destabilize the structure in a domain specific manner with a greater impact 
on the CH2 domain. 
5.3.5 Differential scanning fluorescence 
SYPRO® Orange is an environment sensitive probe which on binding to hydrophobic 
regions shows a significant increase in fluorescence emission [4]. A feasibility experiment 
suggested that 5 mg/mL stock protein solution containing discrete molar ratios of ferric ions to 
mAb exhibited reasonable fluorescence intensity. Thus, DSF was performed with 5 mg/mL mAb 
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instead of diluting to 0.2 mg/mL, as was done for the Far-UV CD, fluorescence and high 
resolution UV absorbance studies. Since the aggregation rate, one of the major protein 
degradation pathways, is often directly related to its concentration [5, 28-30], the advantage of 
using the original solution without dilution is that the acquired properties are more representative 
of the actual formulation conditions.  
As shown in Fig. 4A, the fluorescence spectra of all test solutions exhibited a sigmoid-
shape. During the thermal melting process, temperature-dependent unfolding results in 
increasing exposure of hydrophobic residues and binding of SYPRO® Orange. The fluorescence 
intensity is maximal when the protein is molten but the hydrophobic residues are still continuous 
creating a patch for the dye to bind to. Subsequently, the fluorescence intensity decreases, 
possibly due to the formation of aggregates which could reduce the number of hydrophobic 
regions available for SYPRO® Orange binding and/or due to completion of denaturation / 
unfolding such that the hydrophobic residues are moved apart reducing the size of the binding 
regions. However, simple quenching due to increased temperature has also been shown to be 
significant and the peak may therefore be a result of the balance between increasing intensity due 
to hydrophobic exposure and decreasing intensity due to quenching. The spectra in Fig. 4A and 
the derivative spectra in Fig. 4B clearly show that increasing molar ratios of ferric ions to mAb 
gradually shift the onset of unfolding to lower temperatures. The hydrophobic-melt temperature 
(Th) is taken as the first peak in the derivative spectra, and is summarized in Table 2 [4]. The 
observed reduction in the Th indicates that ferric ions destabilize the corresponding domain 
structure allowing the fluorescence probe to bind at lower temperatures. Increasing the ferric ion 
to mAb ratio especially above 54, makes the first transition less and less distinct, indicating 
almost complete destabilization of the corresponding domain structure. The second peak in the 
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derivative spectra also moves to lower temperatures although the domains corresponding to this 
peak seem more resistant to unfolding by ferric ions compared to the first. This is in agreement 
with the DSC results presented above. The reduction in transition temperatures (listed in Table 2) 
that result from exposure of hydrophobic regions, demonstrates that the different molar ratios of 
ferric ions to mAb exert significantly different impact on mAb stability, consistent with our 
previous observations on the protein in real-time stability studies. Furthermore, even though the 
transition temperatures by DSF for the first transition are consistently lower than the melting 
transitions obtained by DSC (as shown in Table 2), the trend with ferric ion content is similar. 
The difference in absolute transition temperatures between DSC and DSF is due to the nature of 
the techniques, and is in agreement with observations by Goldberg, et al. [31]. More importantly, 
DSF was not only able to detect the impact of ferric ions on the first transition, but also on the 
second transition corresponding to the melting of more stable domains of the mAb. Other 
techniques, such as CD, fluorescence and DSC, were not able to detect this effect suggesting that 
the effect of ferric ions on these more stable domains is quite subtle. The interaction results in 
changes in surface hydrophobicity or hydration without (appreciable) changes to the tertiary 
structure and relatively unperturbed secondary structure. Compared to the impact on the less-
stable domain represented by the first transition temperature (Th), the impact on the second 
transition is thus less significant. 
To further explore the impact of increased molar ratios on the mAb stability, a higher 
protein concentration of 22 mg/mL with the same molar ratios of ferric ions to mAb was 
prepared and analyzed by DSF. As shown in the fluorescence spectra (Fig. 5A) and the first 
derivative spectra (Fig. 5B), only one hydrophobic-exposure related transition could be observed. 
The fact that the transition temperatures are lower than that observed in 5 mg/mL solutions (as 
179 
 
shown in Table 2) indicates that the increased protein concentration also reduced the protein 
conformational stability. This effect of high protein concentration on Th has been also reported 
by He et al [4] and Harn et al. [1] to increase (secondary structure) stabilization due to molecular 
crowding (by DSC and CD), but decreased tertiary structure stability (by UV and fluorescence) 
with increasing concentration. Destabilization of tertiary structure could occur due to increased 
self-association (reversible and irreversible) resulting in reduction in solvent exposed surface 
area [31]. Addition of ferric ions to these higher concentrated solutions (22 instead of 5 mg/mL) 
caused a steeper decline in the Th (see Table 2), in agreement with the mechanistic explanation 
that ferric ions destabilize the tertiary structure. The combined effect of ferric ions and higher 
concentration seems to reduce the onset temperature at which the hydrophobic regions become 
exposed. 
5.4 Conclusions 
The impact of ferric ions on the thermal stability of an IgG2 mAb was characterized by 
Far-UV CD, intrinsic fluorescence and (bis-ANS) extrinsic fluorescence, DSC and DSF using 
SYPRO® Orange. The results of Far-UV CD and intrinsic/bis-ANS extrinsic fluorescence did not 
demonstrate any detectable impact of ferric ions on the thermal stability of the mAb. However, 
the observed impact on the six negative peaks resulting from aromatic residues in the second 
derivative UV spectra suggested that the presence of ferric ions in the solution disturbed the 
mAb tertiary structure. This is in agreement with the decreased melting points measured by DSC. 
The spectra acquired by DSF using SYPRO® Orange dye at high and low protein concentrations 
provided further evidence that the increased molar ratios of ferric ions to mAb destabilized the 
mAb, primarily through the less stable domain by perturbing the tertiary structure. At low 
concentrations, the impact of ferric ions on the more stable domains was small (by DSF). 
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However, at the higher mAb concentration, a combination of destabilization by possible self-
association as well as by ferric ion, resulted in a steep decline in the temperature of hydrophobic 
exposure. This study of the impact of ferric ions on mAb thermal stability provides further 
evidence that the earlier observed physical and chemical instability of the studied mAb on long-
term storage, was a consequence of the ferric ion binding / interaction. 
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Table 1. Second derivative UV-spectra peak positions of aromatic residues in the test solutions 
containing different molar ratios of ferric ions to mAb at 20oC compared to the reference 
values in bGCSF at 10oC 
 
Peak 1: 
Phe-1 
Peak 2: 
Phe-2 
Peak 3: 
Phe-3 
Peak 4: 
Tyr 
Peak 5: 
Trp/Tyr 
Peak 6: 
Trp 
Reference 
values in 
bGCSF 
252.7 258.8 265.5 277.6 283.9 290.6 
Neg Ctrl 253.1 259.1 268.5 276.5 284.5 292.0 
Molar 
ratios of 
ferric 
ion to 
mAb 
8 253.2 259.3 269.0 276.9 284.8 292.3 
18 253.2 259.3 268.8 276.8 284.8 292.4 
35 253.2 259.3 268.6 276.8 284.8 292.3 
54 253.1 259.3 268.8 276.8 284.8 292.3 
75 253.2 259.3 268.9 276.8 284.8 292.2 
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Table 2. First transitional temperatures (Tm1 for DSC and first transition temperature of 
hydrophobic exposure for DSF) for the test solutions at different molar ratios of ferric ion 
to mAb 
Techniques 
mAb conc. 
(mg/mL) 
Neg Ctrl 
 
Molar ratios of ferric ion to mAb 
8 18 35 54 75 
DSF 
5 62.0 61.1 59.8 57.8 50.5 46.6 
22 60.0 57.0 46.5 NA NA NA 
DSC 1 67.97 67.19 67.02 65.93 65.62 65.32 
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Fig. 1. Secondary structure examined by Far-UV circular dichroism (CD) for the solutions 
containing discrete molar ratios of ferric ions to protein pre and post melting at 10oC and 
80oC: the spectra of upper group represent the secondary structure at 10oC and the spectra 
in the lower group represent the secondary structure at 80oC. 
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Fig. 2. Comparison of solution thermal stability containing discrete molar ratios 
of ferric ion to the protein investigated by high-resolution second derivative 
absorbance at a function of temperature: (a) Phe-1, (b) Phe-2, (c) Phe-3, (d) Tyr, 
(e) Tyr/Trp, and (f) Trp. The experiment was performed on the diluted solution 
containing 0.2 mg/mL protein.    
a 
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Fig 2. Continued 
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 Fig 2. Continued 
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Fig. 3. The impact of ferric ions on the thermal unfolding of the solutions containing discrete 
molar ratios of ferric ions to the protein investigated by DSC. The experiment was 
performed on the diluted solution of 1 mg/mL protein in 20 mM histidine at pH5.5 
containing discrete molar ratios of ferric ions to mAb at 0, 8, 18, 35, 54 and 75.   
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Fig. 4. The impact of ferric ions on the protein thermal stability examined by differential 
scanning fluorescence (DSF) using SYPRO® Orange dye in the solutions containing 
discrete levels of molar ratios of ferric ions to protein at 0, 8, 18, 35, 54 and 75. The 
experiment was performed on the 5 mg/mL stock solutions without dilution: (a) the 
fluorescence intensity as a function of temperature and (b) the first derivatives of the 
fluorescence intensity.  
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Fig. 5. The impact of ferric ions on the protein thermal stability examined by differential 
scanning fluorescence (DSF) using SYPRO® Orange dye in the solutions containing 
discrete levels of molar ratios of ferric ions to protein at 0, 8, 18, 35, 54 and 75. The 
experiment was performed on the 22 mg/mL stock solutions without dilution: (a) the 
fluorescence intensity as a function of temperature and (b) the first derivatives of the 
fluorescence intensity.  
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6.1 Introduction 
It is well known that transition metal ions such as Fe(II)/(III), Cu(II), Zn(II), Co(II) and 
Ni(II) etc., can bind to protein molecules to stabilize their structure and play a critical role in 
modulating physiological functions [1–7]. Iron, an essential constituent of proteins involved in 
many cellular processes, is crucial for the growth and viability of almost all organisms. However, 
excessive iron may become toxic or even fatal due to its ability to induce oxidation of lipids and 
other cellular constituents [8–10]. It has been reported that iron can induce protein degradation 
via different mechanisms [11–15]. Since iron is only regulated by uptake [6], iron chelators have 
been introduced into clinical practice to protect patients from toxicity caused by iron overload. 
Various chelators such as cell-impermeable chelators like ethylenediaminetetraacetic acid 
(EDTA), dipicolinic acid (DPA), diethylenetriaminepentaacetic acid (DTPA) [16], cell-
permeable chelators of hydroxypyridiones such as b-[N-(3-hydroxy-4-pyridone)]-a-
aminopropionic acid (L-mimosine) [17], catecholates such as 1,5,10-N, N’, N’-tris (5-sulfo-2,3-
dihydroxybenzoyl) triazadecane (3,4-LICAMS) [6], and pyrophosphates [6] have been widely 
studied, although (salts of) EDTA (Fig. 1A) and to a lesser extent DTPA (Fig. 1B) are the most 
commonly used. EDTA is a hexadentate chelator capable of complexing stoichiometrically with 
virtually every transition metal in the periodic Table [18]. The effectiveness of EDTA as a 
chelator for a particular metal ion is governed by the stability constant of the resulting metal 
complex. The stability constants (log K) of EDTA (acid form) metal complexes for the most 
commonly observed trace metal ions in parenteral formulations are 25.1 for Fe(III) and 14.6 for 
Fe(II) [19]. The stability constant for DTPA-Fe (III) is 27.3 and that for DTPA-Fe (II) is 16.0 at 
20oC, 0.1M ionic strength [20]. 
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Many parenteral biologics drug products include metal chelators to improve product 
stability, with salts of EDTA being the most common. These chelators are generally used to 
complex trace amount of metals (especially iron ions) which may be introduced into the drug 
solution from formulation excipients and/or leachables from contact with stainless steel 
equipment utilized in production and storage. Both disodium edetate (Na2EDTA) and calcium 
disodium edetate (CaNa2EDTA) have been approved for human use by the FDA [21, 22]. 
Analysis of drugs approved through the year 2000 reveal that 48 parenteral drugs contain EDTA 
in various salt forms [23]. Nine contain CaNa2EDTA, 38 contain Na2EDTA, and 1 product 
(Folvite®) contains sodium edetate [23]. 
Na2EDTA is generally used in pharmaceutical preparations as a chelating agent at 
concentrations between 0.005 – 0.1% w/v (0.05 – 1mg/mL). CaNa2EDTA is used in 
formulations as a chelating agent in the range 0.01% – 0.1% w/v (0.1 – 1 mg/mL). Na2EDTA 
readily chelates calcium and can, in large doses, cause calcium depletion (hypocalcemia) if used 
over an extended period or if administered too rapidly by IV infusion. CaNa2EDTA does not 
chelate calcium. For Na2EDTA the LD50 (mouse, IV) = 0.056 g/kg, and LD50 (rabbit, IV) = 
0.047 g/kg. For CaNa2EDTA the L50 (rat, IV) = 3.0 g/kg. The toxicity is significantly dependent 
on the salt form used [24]. 
Disodium edetate is not a first-line agent for any indication; it is approved for use in 
emergency treatment of severe hypercalcaemia and in the treatment of arrhythmias secondary to 
digitalis toxicity. In adults with normal renal function, about 50% is excreted in the first hour in 
the urine and over 95% is excreted with 24 hours. Disodium edetate is almost entirely excreted in 
the urine unchanged within 24 hours. Therapeutically, a dose of 50 mg/kg Na2EDTA, as a slow 
infusion over a 24 hour period, with a maximum daily dose of 3 g, has been used as a treatment 
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for hypercalcemia. For the treatment of lead poisoning, a dose of 60–80 mg/kg of CaNa2EDTA, 
as a slow infusion in two daily doses, for 5 days has been used [22, 25]. 
Use of the generic term EDTA for all its various salt forms has had fatal consequences. 
Children and adults have died from overdose of disodium edetate mistakenly administered in 
place of calcium edetate, or when disodium edetate was used for ‘‘chelation therapies’’ [21]. A 
Public Health Advisory was issued by the FDA in January 2008 concerning this use and the 
misleading abbreviation EDTA [22, 26]. 
A recombinant human granulocyte macrophage colony stimulating factor product 
(Leukine®), was marketed as a lyophilized form without disodium edetate. However, Leukine® 
was reformulated in 2006 as a liquid containing disodium edetate. An increase in spontaneous 
reports of adverse events such as syncope and hypotension was noticed, which appeared to 
coincide with the introduction of the liquid formulation [27]. This increase in adverse event 
reports was not associated with the lyophilized formulation of Leukine®  which did not contain 
disodium edetate [28]. The liquid Leukine® was voluntarily withdrawn from the market in 
January 2008 [27]. A new formulation of liquid Leukine® without disodium edetate was 
approved by the FDA in May 2008 [28]. The dose of disodium edetate through Leukine is about 
1.9 mg/day for a 2 m2 patient via the IV or SC routes. Interestingly, in the same time frame, a 
new IV formulation of fosaprepitant demelgumine (Emend®) was approved with a disodium 
edetate dose of up to 14.4 mg per injection. Caution is required when using Na2EDTA in 
developing new biopharmaceutical products due to these safety concerns. EDTA also has been 
reported to accelerate protein oxidation in some cases even though the intention was to stabilize 
proteins in the presence of iron [12, 13, 29]. Considering the safety and possible stability issues 
around EDTA, it is important to evaluate the use of alternate chelators. 
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DTPA is one of the synthetic polyamino polycarboxylic acids that can form stable 
complexes with a large number of metal ions, such as Cu(II), Ni(II), Co(II), Zn(II), Cd(II), 
Mn(II) and Ca(II) [30]. Free DTPA contains five carboxylic acid and three amine groups, and 
five pKa values of 1.79, 2.56, 4.42, 8.76 and 10.42 have been reported [31]. Similar to EDTA, 
DTPA chelates iron ions at equimolar ratio [31, 32] over pH 2.5–11.0. It has been used in some 
approved drug products. For example, Magnevist® contains 0.40 mg DTPA/mL (0.04%; dose 
0.08 mg DTPA/kg) and Kinevac contains 0.04 mg/mL DTPA (0.004% DTPA; dose 0.008 – 
0.048 mg DTPA/kg). Calcium trisodium pentetate is used in the treatment of poisoning by heavy 
metals while both calcium trisodium pentetate and zinc trisodium pentetate are used in case of 
poisoning with radioactive metals such as plutonium, americium, and curium. In heavy-metal 
poisoning, calcium trisodium pentetate has been given in a dose of 1 g daily by intravenous 
infusion for 3 to 5 days, with further treatment, if necessary, after an interval of 3 days [25, 33–
37]. The reported LD50 of DTPA (rat, IP) is 0.59 g/kg [38]. DTPA is hydrophilic and is unlikely 
to penetrate cells to any great extent [39]. Early pharmacokinetic studies in animals [40-41] and 
in humans [42] showed that DTPA is very poorly distributed into tissues and is rapidly 
eliminated from the body via urine excretion after either intravenous injection or inhalation. 
The safety profile of DTPA suggests that it can be a viable alternative to the more 
commonly used (salts of) EDTA in biologics formulations. There is limited information and 
experience with the use of DTPA in protein formulations. This study therefore focuses on 
comparing the ability of Na2EDTA or DTPA (acid form) to influence the physical / chemical 
stability and biophysical properties of an IgG2 mAb in the presence of various levels of iron. 
6.2 Material and Methods 
6.2.1 Materials 
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An IgG2 monoclonal antibody produced by Pfizer Inc. was used as a test molecule in this 
study. The mAb was formulated in 20 mM histidine buffer at pH 5.5 containing 84 mg/mL 
trehalose dihydrate, and 0.2 mg/mL polysorbate 80. USP/EP grade L-histidine, L-histidine mono 
hydrochloride, analytical grade FeCl2, FeCl3, acetate acid (97.7%), disodium EDTA dihydrate 
and DTPA were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). USP/EP 
grade polysorbate 80 was obtained from J.T. Baker (Meriden, CT, USA). 
6.2.2 Preparation of the test solutions and experimental design 
The mAb in the formulation buffer was concentrated to 20 mg/mL using a tangential flow 
filtration (TFF) unit. The protein concentrations were determined using an extinction coefficient 
of 1.43 (1 mg/mL at 280 nm; 1 cm path-length) determined by the Edelhoch method [43]. The 
appropriate amounts of Na2EDTA and DTPA stock solutions were added to mAb in formulation 
buffer according to the matrix described in Table 1. The pH of the final formulations was 
controlled to 5.5 using 20 mM histidine /histidine-HCl buffer. At this pH, DTPA (H5A) exists in 
equilibrium between H2A
3-and H3A
2-; however, in the presence of iron, DTPA forms the 
complexes of FeA3-/ FeA2- at equimolar ratios [31]. For simplicity, the term DTPA is used in the 
text, regardless of its ionization form. 
Various levels of iron were spiked (as concentrated FeCl2 stock) into the formulated mAb 
solutions containing the defined molar amount (0.134 mM) of Na2EDTA or DTPA. Both a 
negative control (absence of chelator and iron) and a positive control (absence of chelator but 
presence of iron at a level of 24 ppm) were used. Table 1 summarizes the complete experimental 
design. The amounts of Na2EDTA and DTPA in the formulations were confirmed by RP-HPLC. 
The concentrations of spiked iron were measured by ICP-MS during the evaluation of real time 
stability data. The formulations were filtered through a 0.22 µm PVDF filter, 1 mL aliquots were 
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filled into 2-mL type I glass vials, and then placed in stability chambers maintained at either 2–
8oC, 25oC, or 40oC. The formulations were stored at various temperatures (5oC, 25oC and 40oC) 
for thirteen weeks. Biochemical and biophysical data were collected at different time intervals to 
assess the mAb degradation.  
6.2.3 RP-HPLC analysis for mAb oxidation and chelator concentration 
RP (reversed phase)-HPLC was employed to monitor the oxidation of the mAb by means 
of proteolytic mapping with a limit of quantitation of 1.6%. Methionine-containing peptide 
fragments and their respective oxidized forms (containing methionine sulfoxide) were 
chromatographically monitored, and their percent oxidation was reported relative to the 
methionine containing parent peptides. The mAb samples were digested with LysC enzyme for 
18±2 hours at 37oC. The oxidized peptide fragments were separated on an Agilent 1100 system 
equipped with a binary pump and UV detector set at 214 nm. A GraceVydac protein C4 
analytical column (5 µm, 4.6 mm x 250 mm) was used to separate peptide fragments with two 
mobile phases consisting of (A) 0.1% (v/v) TFA (trifluoroacetic acid) in water and (B) 0.085% 
(v/v) TFA in acetonitrile. The following binary gradient was adjusted at a flow rate of 1 mL/min: 
(1) 79% mobile phase (mp) A and 21% mobile phase B held for the first 10 mins; (2) mp A 
decreased to 70% and mp B increased to 30% within 32 mins; (3) mp A decreased to 5% and mp 
B increased to 95% within 3 mins and held for an additional 4 mins; (4) mp A and B returned to 
their initial composition (mp A: 79% and mp B: 21%) within 2 mins and held for an additional 8 
mins. The final mAb concentration was diluted to 1 mg/mL and 100 µL was injected to separate 
the oxidative products. Results are reported as % oxidization. The concentrations of both 
Na2EDTA and DTPA in the formulations were determined using the Agilent 1100 system 
coupled to a diode array detector. The separation was achieved isocratically on an Agilent 
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Eclipse XDB-C18 column (5 µm, 4.6 x 150 mm) at a flow rate of 1 mL/min at ambient 
temperature. The mobile phase consisted of 30 mM sodium acetate, 2 mM tetrabutylammonium 
hydroxide, and 5% (v/v) methanol in water (pH 3.15). Excessive FeCl3 (5 mM in final) was 
added to both samples and standards. External calibration was established with varying levels of 
Na2EDTA and DPTA simultaneously. 20 mL of the sample were injected onto the column and 
the separation was monitored by UV detection at 254 nm. 
6.2.4 Size exclusion HPLC 
Size exclusion HPLC was employed to monitor mAb aggregation. The chromatography 
was performed on an Agilent 1100 system equipped with G3000SWXL and G2000SWXL 
columns (7.8 x 300 mm, Tosoh Biosciences, Montgomeryville, PA, USA or equivalent) in 
tandem using 200 mM phosphate at pH 7.0 as the mobile phase. An isocratic elution method (0.7 
mL/min) was used. The injection volume was adjusted such as to inject 20 mg mAb onto the 
columns and the elution was monitored at 214 nm. The quantities of the monomer, low 
molecular weight species (LMMS) and high molecular mass species (HMMS) were reported 
after integration. 
6.2.5 Imaged capillary isoelectric focusing (iCE) 
Changes in charge heterogeneity were used to detect deamidation of the mAb. iCE 
profiles of the monoclonal antibody were obtained using an iCE280 Analyzer equipped with an 
Alcott 719 AL autosampler (Convergent Bioscience, Toronto, OH, USA). The test solutions 
were prepared using various amounts of pI markers, Pharmalyte, 1% methyl cellulose, 5 M urea, 
20% sucrose and monoclonal antibody samples. A sample volume of 35 µL was injected and the 
analysis was performed using a sample transfer time of 100 seconds, pre-focusing at 1500 V for 
duration of 1 min followed by focusing 5 mins at 3000 V. The samples were detected at 280 nm 
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and the relative abundance of the resolved peaks was calculated. Results are reported as % acidic 
species. 
6.2.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was employed to quantify the intact and degraded products of the 
monoclonal antibody. The separation was performed on precast polyacrylamide gels (NuPAGE 
4-12% Bis-Tris, Invitrogen, Carlsbad, CA, USA) using a mini-gel apparatus (Invitrogen Cell 
SureLockTM). The bands were analyzed using the Molecular Dynamics Personal Densitometer 
(PDQC-90) with FragmeNT software. Results are reported as% Total impurities. 
6.2.7 Inductively coupled plasma – mass spectrometry (ICP-MS) 
Spiked iron concentrations in the formulations were confirmed by an ICP-MS method 
which utilized an Agilent 7500 CX ICP-MS system equipped with an autosampler. 50 mL of 
mAb samples and blanks were digested using 70% nitric acid (Omnitrace-NX0407) (EMD 
Chemicals Inc, Gibbstown, NJ, USA) at a volume ratio of 1:3 (sample: nitric acid) on a heated 
water bath (80–90oC) for 15 minutes. Samples were cooled to room temperature after digest 
completion and diluted to 5 mL with 1% nitric acid before analysis. Samples were analyzed in 
the ‘‘hydrogen mode’’ and scandium (45) was used as the internal standard. An external 
calibration curve was established before running the digested samples. A 50 ppb standard was 
analyzed between every 6 samples to ensure the system performance. 
6.2.8 Isothermal titration calorimetry (ITC) 
Thermodynamic binding measurements were made using an isothermal titration 
calorimeter (VP-ITC, GE-Healthcare, Piscataway, NJ, USA) at 25oC. The mAb and FeCl3 
samples were degassed at 23oC (Thermo-Vac, GE-Healthcare, Piscataway, NJ) before loading 
into the ITC cell and syringe. Titration in the presence of chelator anions included mixtures of 
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equimolar concentrations of either Na2EDTA or DTPA with mAb in the cell and FeCl3 in the 
syringe. Reference titrations were carried out by injecting FeCl3 into placebo buffer which did 
not contain mAb. The reference was subtracted from the heat of interaction with mAb. Iron 
binding measurements for both DTPA and Na2EDTA were not feasible via the ITC method due 
to the very large binding constants (>1012M). The concentrations of mAb, FeCl3, Na2EDTA and 
DTPA used were 33.5 µM, 6 mM, 268 mM, and 268 mM, respectively. The binding isotherms 
were best fit to a single class binding site model by Marquardt using non-linear least-squares 
analysis to obtain stoichiometry and thermodynamic parameters. 
6.2.9 Differential scanning calorimetry (DSC) 
The thermal stability of the antibody was measured by monitoring the heat capacity 
associated with gross conformational changes in the antibody using DSC (VP-Cap, GE 
healthcare). A scan rate of 200oC/hr, scan range of 25–110oC, and a mAb concentration of 1.0 
mg/mL was used in all experiments. 
6.2.10 Circular dichroism (CD) spectroscopy 
Far UV-CD spectra for various samples were acquired by using a Jasco J-810 
Spectropolarimeter (Jasco Inc, Easton, MD, USA) equipped with an autosampler. Samples were 
diluted to 0.25 mg/mL using the formulation buffer. The spectra were acquired for samples and 
respective buffers from 190 to 260 nm. Sample spectra were subtracted from respective buffer 
spectra to eliminate buffer contributions. Data acquisition and analyses were performed by using 
inbuilt Spectra ManagerTM software. 
6.2.11 Intrinsic fluorescence 
Intrinsic fluorescence measurements were performed on a Cary Eclipse Fluorescence 
Spectrophotometer (Varian Inc, Lake Forest, CA, USA) using 0.2 mg/mL mAb for all iron 
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concentrations. The mAb was excited at 295 nm and the tryptophan-dominated emission was 
monitored between 305 to 405 nm to avoid iron interference. The excitation and emission slits 
were set at 5 nm. All the spectra were analyzed using the Microcal Origin 7.0 (Piscataway, NJ, 
USA) software. The sample spectra were subtracted from respective blank control spectra to 
eliminate the formulation matrix contribution. 
6.3 Results and Discussion 
The ability of Na2EDTA or DTPA to protect the IgG2 mAb from metal (iron)-induced 
degradation was studied by holding the formulations at various temperatures and evaluating the 
physical and chemical changes to the mAb at different time intervals. 
6.3.1 Real-time biochemical analysis 
Metals, present even in trace amounts in protein solutions, can induce oxidation [12, 44, 
45], fragmentation [44–46], aggregation [12], and/or possibly contribute to other pathways of 
protein degradation such as deamidation or the formation of insoluble particles. Protein 
oxidation, aggregation, fragmentation and deamidation are major indicators of product stability. 
There are also concerns for the potential alteration of pharmacology, immunogenicity, and 
toxicology as a consequence of these degradants [12, 47, 48]. Therefore, these degradation routes 
serve as indicators of the stability of biologic drug products to support the development of 
products with adequate shelf life and were closely monitored in this study to differentiate mAb 
stability among the formulations. 
6.3.2 mAb degradation 
The real time stability data at 2–8oC for oxidation, soluble aggregates, total impurities 
and deamidation are shown in Fig. 2–5, respectively. The data for the samples stored at higher 
temperatures exhibited similar trends (data not shown). For iron concentration less than 4 ppm 
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(equivalent to 0.0715 mM), the molar ratio of the chelators Na2EDTA or DTPA to iron is greater 
than 1:1, i.e. above stoichiometric ratio. Here, both Na2EDTA and DTPA containing 
formulations showed stability profiles similar to the negative control. At iron levels more than 15 
ppm (equivalent to 0.268 mM), the molar ratio of the chelator to iron is less than 1:1, i.e. sub-
stoichiometric ratio. Under such conditions, both Na2EDTA and DTPA containing formulations 
exhibited a similar or less severe degree of degradation compared to the positive control but 
significantly more severe degradation compared to the negative control. At the initial time point, 
oxidation and aggregation do not correlate directly with the spiked iron levels, probably due to 
the difference in actual analysis timing for the individual samples since these samples had to wait 
for a few days to be sequenced for analysis after being stored for two weeks at 2–8oC. Clearly, 
the iron-catalyzed degradation of mAb can be effectively inhibited at chelator to iron molar 
ratios of greater than 1:1. Fig. 6 summarizes the degradation data for the thirteen week time point 
which illustrates again that a molar ratio of chelator to iron above 1:1 leads to efficient 
stabilization. 
6.3.3 Statistical analysis of real-time data 
Statistical analyses were performed by using design expert software to gain more insight 
into the real time stability data obtained and thereby elucidate any subtle differences present. 
Chelator type, iron levels in the formulations, storage temperature and time were the four major 
parameters considered in this analysis. The responses from the real-time data analyzed were 
soluble aggregates (i.e., high molecular mass species - HMMS) and oxidation levels. Analysis of 
HMMS / oxidation, and two factor interaction response surface model fit to the actual data 
suggested that un-chelated iron level, time and temperature were major factors to impact the 
mAb degradation. This observation was in line with the observations in the previous section. No 
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difference in soluble aggregate levels was observed when comparing formulations containing 
either DTPA or Na2EDTA. Fig. 7A and Fig. 7B display response-surface plots for the 13 week 
time point for Na2EDTA and DTPA, respectively. These plots demonstrate that higher un-
chelated iron levels and higher temperatures increase the amount of soluble aggregates. 
Furthermore, contour plots (not shown) revealed no notable differences in soluble aggregates for 
the two chelator types.  
Oxidation level analysis for the available data of up to 13 weeks are illustrated in 
response-surface plots displayed in Fig. 8A (Na2EDTA) and Fig. 8B (DTPA),  respectively. 
There was no apparent difference between Na2EDTA and DTPA. Both of them worked 
effectively at the intended storage condition of 2–8oC. Further analysis of surface plots and 
contour plots (not shown) suggested that there was a slight difference in the oxidation levels as a 
function of chelator type at elevated temperature when the chelator to iron molar ratio was less 
than 1:1. At these sub-stoichiometric levels of chelator, the contour plots (not shown) indicated 
that Na2EDTA may be a better stabilizer than DTPA under accelerated storage (40
oC) 
conditions. No significant differences were observed under these accelerated conditions with 
adequate (greater than stoichiometric) amounts of chelator. Therefore, both DTPA and 
Na2EDTA can be effective chelators for the studied mAb as long as an adequate amount of 
chelator is present. 
6.3.4 Biophysical analysis 
Biophysical methods were used to evaluate the effect of spiked iron and chelators on 
mAb structure and stability. The binding of iron ions to the mAb was also measured by ITC in 
the presence and absence of Na2EDTA and DTPA. DSC, Far UV circular dichroism (CD) and 
intrinsic fluorescence were used to probe protein intrinsic thermal stability, secondary structure 
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and tertiary structure changes using the real time stability samples stored at 2–8oC over eight 
weeks. 
6.3.4.1 ITC evaluation of iron binding to mAb in the presence and absence of chelator 
The binding of iron to the mAb was investigated by ITC in the presence and absence of 
chelator. Analysis of ITC spectra shown in Fig. 9 indicated that there was a stoichiometry of 20:1 
ferric ions bound per mAb molecule with a Kd of 0.18 mM in the absence of the chelator. In 
contrast, no significant binding of iron to the mAb was observed in the presence of chelator of 
Na2EDTA or DTPA (spectra not shown). Affinity of iron to mAbs is very weak (Kd in mM) and 
the stoichiometry of ~20 obtained could vary between antibodies. This affinity is significantly 
lower than the EDTA/DTPA affinity to iron (Kd’s in the nM to fM ranges). We have not 
explored assigning the binding of iron atoms to different structural regions of the mAb. 
Combined with the observations from chemical analyses, it is reasonable to believe that the weak 
binding of free (un-chelated) iron to the mAb, catalyzed the degradation pathways of the mAb by 
decreasing its intrinsic thermodynamic stability which were further confirmed by other 
biophysical analysis discussed later. 
6.3.4.2 Impact of iron on mAb thermal stability analyzed by DSC 
DSC has been used to probe energetics of protein folding/unfolding transitions and 
thermodynamic mechanisms [49, 50]. The melting point of a protein can be used as an indicator 
of its relative thermal stability. The DSC data for the real-time stability samples, obtained under 
non-reducing conditions with the disulfides intact, are shown in Fig. 10. Two thermal melting 
transitions (Tm1 and Tm2) for this mAb are observed in the DSC scans of the various 
formulations evaluated. The thermal transitions are irreversible. The data indicate that the 
formulations with 0.134 mM Na2EDTA or DTPA and less than or equal to 4 ppm spiked iron, 
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i.e., with sufficient chelator present to chelate all iron, exhibited comparable sharp transitions. 
However, a significant shift of Tm1 and broadening for the transition Tm2 were observed for the 
formulations with spiked iron at the level of greater than or equal to 15 ppm. Due to the 
difficulty in assigning the melting peaks to specific structural regions/domains on the IgG2, 
specific explanations for the changes cannot be provided. However, it is clear that addition of 
iron perturbs the structure such that the Tm1 decreases indicating a destabilization of the 
structure. Similarly, while Tm2 seems to show an apparent increase most likely due to a 
broadening of the transition, the heat capacity and enthalpy values of this transition decrease 
significantly, again illustrating the destabilizing effect of the added iron. A summary of the Tm1 
data shown in Fig. 11 was used for the mAb formulation stability comparison. The significant 
shift of Tm1 to lower temperatures for the formulations with spiked iron levels of ≥ 15 ppm 
indicated that the formulations were less stable than the formulations spiked with ≤ 4 ppm iron. 
Meanwhile, the similarity in values of Tm1 for the formulations with adequate amount of 
Na2EDTA or DTPA to chelate iron, suggest that both chelators behaved equivalently in 
stabilizing the formulations. This observation was consistent with the thirteen week real-time 
stability data which indicated that the mAb can be protected from degradation with sufficient 
chelator present in the formulations. 
6.3.4.3 Impact of iron on mAb secondary structure analyzed by CD 
Circular dichroism has been generally used to probe protein secondary structure since its 
spectra are sensitive to the protein conformation [49]. Far-UV CD spectroscopy was employed to 
qualitatively probe the iron induced secondary structure changes of the mAb. Analysis of the 
spectra obtained for all the samples (not shown) indicate that no significant changes in secondary 
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structure were observed for any of the real time stability samples stored at 2–8oC over eight 
weeks. 
6.3.4.4 Impact of iron on the mAb tertiary structure analyzed by fluorescence 
spectroscopy 
Fluorescence spectroscopy can be used to probe the effect of additives on protein tertiary 
structure [50]. Tryptophan fluorescence spectroscopy was used to evaluate the effect of metals 
and chelators on mAb tertiary structure. A summary of the data is shown in Fig. 12. The 
fluorescence was monitored over the wavelength range of 300 – 450 nm to eliminate iron 
interference. There are 22 tryptophan residues in this mAb and the average emission maximum 
was at the wavelength of 330 nm which suggested that most of them were buried. Identical 
protein concentrations were used in these experiments with varying concentrations of iron. There 
was no significant change in the emission intensity at 330 nm for the formulations with ≤ 4ppm 
iron and Na2EDTA or DTPA, similar to the negative control. However, the intensity decreased 
significantly (~58%) for the formulations with ≥ 15 ppm iron. The positive control exhibited an 
even further decrease in intrinsic fluorescence intensity to 47%. However, no notable red-shift in 
the emission maximum was observed to indicate mAb gross conformational change for all the 
formulations studied. The significant intrinsic fluorescence quenching of tryptophan emission 
without a shift in the emission maximum indicates [49, 51] only subtle changes in the tertiary 
structure are induced by any un-chelated iron present. The quenching effects could also be local 
and solvated tryptophan specific. This subtle change in structure was apparently still significant 
enough to lead to the changes in the thermal melting profiles, and cause the mAb degradation as 
described in the previous sections, indicating a reduction in the intrinsic thermodynamic stability 
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of the molecule. A similar phenomenon was observed by Derrick et al. for recombinant human 
factor VIII which was induced to aggregate in the presence of Al(III) [52]. 
6.4 Conclusions 
This study investigated the ability of metal chelators, Na2EDTA and DTPA to impact the 
stability of mAb formulations which were spiked with iron at different levels. A weak binding of 
the iron to the IgG2 mAb was measured. No gross changes in the secondary or tertiary structure 
were observable with the techniques employed. The free (un-chelated) iron ions by interacting 
with the mAb result in a decrease in its intrinsic thermodynamic stability, probably through 
subtle impact on the folding forces and thereby causing minor perturbations to the tertiary 
structure. Apart from the expected transition metal-catalyzed oxidative degradation, this decrease 
in intrinsic stability also resulted in significant increases in soluble aggregate levels, 
deamidation, and total impurities. Both Na2EDTA and DTPA exhibited equivalent capacity to 
inhibit the iron induced mAb degradation when adequate amounts were present to chelate the 
iron. Analysis of real time and accelerated oxidation data suggested that only in the situation 
when un-chelated iron ions were present in the formulations stored at higher temperatures, 
Na2EDTA performed slightly better. However, the two chelators appeared to be equivalent for 
solutions stored at the more common mAb storage temperature of 2–8oC. DTPA can therefore be 
used as an alternative chelator to improve mAb solution formulation stability. 
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Table 1. Formulations studied with Na2EDTA or DTPA: the matrix is 5 mg/mL mAb in 20 mM 
histidine buffer, 0.2 mg/mL polysorbate 80 at pH 5.5 
 
Protein  
(mg/mL) 
Fe2+ 
(ppm) 
Na2EDTA 
(mg/mL) 
Na2EDTA 
(mM) 
DTPA 
(mg/mL) 
DTPA 
(mM) 
5 0 0 0 0 0 
5 0 0.050 0.134 NA NA 
5 4 0.050 0.134 NA NA 
5 15 0.050 0.134 NA NA 
5 24 0.050 0.134 NA NA 
5 0 NA NA 0.053 0.134 
5 4 NA NA 0.053 0.134 
5 15 NA NA 0.053 0.134 
5 24 NA NA 0.053 0.134 
5 24 NA NA NA NA 
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Fig. 1. Schematic structures of (A) EDTA and (B) DTPA and the binding mechanism to metal. 
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Fig. 2. Oxidation of the mAb over thirteen weeks when stored at 2–8oC for the formulations with 
(A) Na2EDTA and (B) DTPA. 
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Fig. 3. Aggregate formation in the mAb over thirteen weeks when stored at 2–8oC for the 
formulations with (A) Na2EDTA and (B) DTPA. 
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Fig. 4. Total impurities generated in the mAb over thirteen weeks when stored at 2–8oC for the 
formulations with (A) Na2EDTA and (B) DTPA. 
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Fig. 5. Acidic species generated in the mAb over thirteen weeks when stored at 2–8oC for the 
formulations (1st bar for T0 and 2nd bar for T13weeks) with (A) Na2EDTA and (B) 
DTPA. 
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Fig. 6. Comparison of degradation data for the formulations with Na2EDTA or DTPA when 
stored at 2–8oC at 13 weeks: oxidation, aggregation, acidic species and total impurities. 
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Fig. 7. (A) Response surface plot for soluble aggregate levels for Na2EDTA at 13 weeks over 
temperature range of 5–40oC and iron levels of 0–24 ppm. The diagonal line represents 
contour grid. (B) Response surface plot for soluble aggregate levels for DTPA at 13 
weeks over temperature range of 5–40oC and iron levels of 0–24 ppm. The diagonal line 
represents contour grid. 
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Fig. 8. (A) Response surface plot for oxidation levels for Na2EDTA at 13 weeks over 
temperature range of 5–40oC and iron levels of 0-24 ppm. The diagonal line represents 
contour grid. (B) Response surface plot for oxidation levels for DTPA at 13 weeks over 
temperature range of 5–40oC and iron levels of 0–24 ppm. The diagonal line represents 
contour grid. 
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Fig. 9. Iron binding to the mAb by ITC: Iron binding to mAb in absence of chelator, 6 mM of 
FeCl3 was titrated with 33.5 µM of mAb (blue in upper panel) and 6 mM of FeCl3 was 
titrated with the placebo (black in upper panel). The resulting binding isotherm is shown 
in lower panel. Iron binding to mAb was curve fit to obtain thermodynamic parameters. 
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Fig. 10. DSC spectra for the real time stability samples at T8 weeks stored at 2–8oC with A) 
Na2EDTA and B) DTPA at spiked iron levels of 0, 4, 15 and 24 ppm, and negative 
control formulation (absence of chelator and iron), and the positive control formulation 
(absence of chelator but presence of iron at a level of 24 ppm). 
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Fig. 11. Tm1 data for the real time stability samples at T8 weeks stored at 2–8oC with Na2EDTA 
or DTPA at spiked iron levels of 0, 4, 15 and 24 ppm, the negative control formulation 
(absence of chelator and iron), and the positive control formulation (absence of chelator 
but presence of iron at a level of 24 ppm). 
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Fig. 12. Fluorescence spectra for the real time stability samples at T8 weeks stored at 2–8oC A) 
Na2EDTA and B) DTPA at spiked iron levels of 0, 4, 15 and 24 ppm, negative control 
formulation (absence of chelator and iron), and the positive control formulation (absence 
of chelator but presence of iron at a level of 24 ppm). 
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Chapter 7: Mechanisms of IgG photo-degradation: 
The Photolysis of Disulfide Bonds in IgG1 and IgG2 Leads to Selective Intramolecular 
Hydrogen Transfer Reactions of Cysteinyl Thiyl Radicals, Probed by Covalent H/D 
Exchange and RPLC-MS/MS analysis 
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7.1 Introduction 
Immunoglobulin G (IgG) monoclonal antibody (mAb) biotherapeutics have gained 
significant attention and become a fast growing biotherapeutic class in the pharmaceutical 
industry [1-3]. These protein therapeutics are subject to ultra-violet (UV) and/or visible light 
exposure during development, manufacturing, transportation, storage and administration to the 
patients. Antibodies contain multiple disulfide bonds, and, similar to many other proteins, are 
sensitive to light-induced degradation [4]. Light testing is defined as an integral part of stress 
testing for submission in registration application for new molecular entities and associated drug 
products by the Food and Drug Administration (FDA) under The International Conference on 
Harmonization (ICH) Tripartite guideline [5]. The guideline clearly notes that the intrinsic 
photostability characteristics of new drug substances and products should be evaluated to 
demonstrate that, as appropriate, light exposure does not result in unacceptable change. A 
systematic approach to photostability testing is recommended covering, as appropriate, studies of 
i) tests on the drug substances, ii) tests on the exposed drug product outside of the immediate 
packing, and, if necessary, iii) tests on the drug product in the immediate packing, and, if 
necessary, iv) tests on the drug product in the marketing packing. The resulting instability 
information is an important element in the quality assurance for drug therapy, e.g., in 
determining the shelf life, storage instructions, and use life (i.e. stability in an opened container). 
For photo-labile drug substances and drug products, the formal labeling requirements are 
established by national/regional requirements.  
IgG monoclonal antibodies contain multiple Cys residues, forming inter- and intrachain 
disulfide bonds. These inter- and intrachain disulfide bonds play an important role for protein 
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stability. On the other hand, disulfide bonds are subject to light-induced degradation [4, 6, 7]. 
Photo-irradiation at λ = 253.7 nm results in the homolytic dissociation of disulfide bonds, leading 
to the formation of a cysteinyl thiyl radical (CysS•) pair [8-12]. This CysS• radical pair engages 
in disproportionation (to thiol and thioaldehyde) as well as reversible hydrogen atom transfer 
reactions with C-H bonds of surrounding amino acids [13-16]. Intramolecular hydrogen transfer 
reactions were confirmed by the covalent incorporation of deuterium into specific amino acid 
residues when peptides and protein thiyl radicals were generated in D2O [15, 16]. These 
intramolecular hydrogen transfer reactions generate carbon-centered (C-centered) radicals, which 
ultimately may result in the formation of protein hydroperoxide, protein aggregates and/or 
protein fragmentation [17]. In specific model peptides and proteins, such as insulin, we have 
demonstrated that reversible hydrogen transfer reaction between CysS• radicals and C-H bonds 
led to covalent hydrogen/deuterium (H/D) exchange [16], as outlined in Scheme 1 [15]. Such 
reversible hydrogen transfer can also result in L- to D-amino acid conversion, as shown for L-
Ala in a model peptide [14].  
IgG1 and IgG2 represent two important subclasses of IgG. They exhibit differences in the 
number and connectivity of interchain disulfide bonds. In IgG1, the interchain disulfide bonds 
link the light chain (LC) and the heavy chain (HC) at the hinge region, whereas in IgG2, the 
interchain disulfide bonds linking the LC and the HC are located to the junction between the 
variable and the constant region [18].  Based on these different locations of the disulfide bonds, 
CysS• radicals generated through disulfide bond photolysis may react selectively with different 
amino acid residues in different domains of IgG1 and IgG2, generating intermediary carbon-
centered protein radicals at different locations. Through covalent H/D exchange, we have probed 
232 
 
in this paper the reactivity of disulfide bonds, and specifically CysS• radicals in IgG1 and IgG2 
toward reversible intramolecular hydrogen transfer.  
7.2  Experimental 
7.2.1 Materials 
IgG1 (37 mg/mL) and IgG2 (30 mg/mL) mAb stored as frozen solutions (-80oC) were 
supplied by Amgen Inc. (Seattle, WA, USA). Dithiothreitol (DTT, >99%) and diethylmaleate 
(DEM, 97%) were obtained from Sigma-Aldrich (Saint Louis, MO, USA). N-ethylmaleimide 
(NEM, >99%) and ammonium bicarbonate (NH4HCO3) were obtained from Fluka (Saint Louis, 
MO, USA). Sequencing-grade trypsin and Glu-C were obtained from Promega Corp. (Madison, 
WI, USA). Deuterium oxide (D2O, 99.9%) was obtained from Cambridge Isotope Laboratories 
Inc. (Andover, MA, USA).  
7.2.2 Reactions 
7.2.2.1 UV irradiation 
The IgG1 and IgG2 stock solutions were exchanged into MilliQ H2O or D2O at room 
temperature in a nitrogen (N2) box using an Amicon
® ultra-0.5 centrifugal filter device equipped 
with a 10 kDa filter membrane (Millipore Inc., Bedford, MA, USA). The samples were 
centrifuged by means of a mini-centrifuge (Southwest Science, Roebling, NJ, USA) for 15 mins. 
An aliquot (200 µL) of each protein stock solution in H2O or D2O was transferred to a quartz 
tube and sealed with a rubber stopper. The sealed quartz tubes containing protein solutions were 
transferred from the N2 box and irradiated at room temperature for 1 hour with UV light at λ = 
253.7 nm by means of four UV lamps (RMA-500, Southern New England, Branford, CT, USA) 
in a Rayonet Photo-chemical reactor (Southern New England, Branford, CT, USA). 
7.2.2.2 Thiol derivation reactions and digestion 
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The protein solutions in D2O were exchanged into H2O by means of an Amicon
® ultra-
0.5 centrifugal filter device as described above. An aliquot of 100 µL of each protein solution in 
H2O was added to 0.9 mL of NH4HCO3 buffer (50 mM, pH 7.8). The proteins were denatured by 
ramping the temperature from 35oC to 80oC using a water bath. Heat denaturing of the proteins 
was terminated when the solution turned cloudy. Thiol groups produced during photo- irradiation 
were derivatized with NEM (0.2 mM) for 1 hour at 37oC. The remaining, intact disulfide bonds 
were reduced by DTT (2 mM) for another 30 mins at 37oC. Then DEM was added at a final 
concentration of 20 mM to the samples to derivatize the thiol residues resulting from the 
reduction of disulfide bonds by DTT. That is, the thiol residues produced by photo-irradiation 
were labeled with NEM whereas DEM was used to alkylate the thiols generated from the 
disulfide bonds through reduction by DTT. The solutions containing the derivatized proteins 
were subsequently transferred into 15-mL FalconTM tubes (BD, Franklin Lakes, NJ, USA) 
containing 9 mL ethanol and stored at -20oC overnight. The solutions were then centrifuged at 
14,000 rpm to precipitate the proteins. After removal of the supernatant, the protein pellet was 
re-dissolved in 1 mL NH4HCO3 buffer (50 mM, pH 7.8). An aliquot of 100 µL of the derivatized 
protein solutions was digested first with sequencing-grade trypsin (15 μg) (two doses with an 
interval of 2 hours). Then, the digestion was continued by the addition of sequencing-grade Glu-
C (8 μg) by incubating the sample at 37oC overnight.  
7.2.2.3 UPLC-MS and nano-ESI-TOF MS analysis 
The samples were injected onto a Vydac MS C18 column (25 cm X 1 mm, 3.5 μm) from 
Grace (Deerfield, IL, USA). The mobile phases A and B were composed of water, acetonitrile 
and formic acid at 99:1:0.08 (v/v/v, %) for A and 0:99:0.06 (v/v/v) for B. The samples were 
eluted on an Acquity ultra-performance liquid chromatography (UPLC) system (Waters Corp., 
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Milford, MA, USA) by gradient elution at a flow rate of 12 μL. The gradient elution was 
composed of three segments defined by increasing contents of solvent B: 1% B for 1 min, 10 to 
30% B increased within 8 mins, followed by an increase of B to 70% within 3 mins.  
ESI mass spectra were acquired on a SYNAPT G2 high definition mass spectrometer 
(Waters Corp. Milford, MA, USA). Electrospray ionization mass spectra of the proteins were 
acquired by operating the SYNAPT G2 for maximum resolution with all lenses optimized on the 
[M + 2H]2+ ion from the [Glu]1-fibrinopeptide B and Ar was admitted to the collision cell. The 
capillary voltage was set at 2.9 kV. The cone voltage was set at 45 V and then ramped to 85 V. 
The voltage of the extraction cone was maintained at 6 V. Source and desolvation temperatures 
were set at 95oC and 200oC, respectively. The gas flow at the cone and for desolvation was set at 
40 L/h and 250 L/h, respectively. The spectra were acquired within a mass range of 100-2000 
amu (amu: atomic mass unit). The data were accumulated for 0.5 sec per cycle and processed 
using the software MassLynx (Waters Corp. Milford, MA, USA). 
7.2.2.4 MS/MS analysis 
Collision-induced dissociation (CID) spectra were acquired by setting the MS1 
quadrupole to transmit a precursor mass window of ± 0.2 amu centered on the most abundant 
isotopomer. MS/MS spectra were acquired with collision energies between 20 eV and 50 eV 
depending on the mass-to-charge ratio (m/z) of the parent ions.  
7.2.2.5 Identification of covalent H/D exchange 
The covalent incorporation of deuterium into the proteolytic peptides and their fragments 
was determined by the variation of base peak intensity (BPI) of the isotopic distribution peaks 
between the covalently deuterated peptide and the corresponding fully protonated peptide. The 
isotopic distribution peaks were normalized to the most abundant isotopic peak.  
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7.3 Results 
After photo-irradiation, LC-MS analysis of the proteolytic peptides from IgG2 in H2O 
and D2O was performed in order to identify peptides which have covalently incorporated at least 
one deuterium. Peptide sequence mapping was achieved by searching against a custom-built 
database of IgG2. A similar analysis was performed for IgG1. The sequence coverage was 87% 
and 82%, respectively for the HC and LC of IgG2, whereas the sequence coverage was 90% and 
92%, respectively, for the HC and LC of IgG1. Two peptides displaying covalent incorporation 
of deuterium were identified for IgG2, peptide A, VVSVLTVVHQDWLNGK [294:309], located 
in the constant region (Fc) of the heavy chain (HC), and peptide B, VTVLGQPK [109:116], 
located in the light chain (LC). For IgG1, only peptide A was identified, which exhibited the 
same isotopic distribution profile as peptide A originating from IgG2. Therefore, the detailed 
discussion below will focus on the two peptides A and B originating from IgG2. For simplicity, 
any peptide analyzed by LC-MS and MS/MS originating from the non-irradiated or the photo-
irradiated solutions which were prepared in H2O, will be referred to as proteo-samples, and the 
ones prepared in D2O as deutero-samples. 
 Peptide A: VVSVLTVVHQDWLNGK [294:309, HC] (m/z = 598.75, z = 3) 
The comparison of the isotopic distributions of peptide A after photo-irradiation of IgG2 
at λ = 253.7 nm in H2O or D2O reveals a mass shift towards higher masses for IgG2 photo-
irradiated in D2O compared to H2O (Fig. 1A). In contrast, a comparison of the isotopic 
distributions of peptide A originating from non-irradiated IgG2 in H2O and D2O shows a perfect 
overlap (Fig. 1B). The isotopic distribution of this triply charged peptide ion in H2O and D2O, 
the BPIs and their BPI variations are presented in Table 1. These BPI variations at the same m/z 
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isotopic distribution peaks suggest that during the photo-irradiation of IgG2 in D2O, peptide A 
covalently incorporates deuterium. 
MS/MS experiments were performed on peptide A originating from the proteo and 
deutero samples. MS/MS spectra of peptide A generated the following ions: b3-b4 (Fig. 2), and 
y1-y3, y5, y7-y9 and y11-y14 (Fig. 3). The isotopic distributions of these ions, originating from 
the UV-irradiated proteo and deutero samples were analyzed. The isotopic distributions of the b3 
and b4 fragments overlap (Fig. 2). We, therefore, exclude that the amino acid residues VVSV 
[294:297, HC] incorporate any deuteron (Fig. 2). A comparison of the isotopic distributions of 
the y1, y2, y3, and y5 fragment ions of the proteo and deutero samples also shows no difference. 
Thus, none of the amino acid residues WLNGK [305:309, HC] incorporates a deuteron. Further 
analysis of the fully protonated fragment ion y7 (QDWLNGK [295:309, HC]) originating from 
the proteo sample shows that its isotopic distribution displays ions with m/z 860.5, m/z 861.5 and 
m/z 862.5 with a relative abundance of 82%, 100%, and 21%, respectively. After photo-
irradiation of IgG2 in D2O, the y7 fragment ion of peptide A shows an isotopic distribution 
composed of the same ions with a relative abundance of 12%, 100% and 36%, respectively. 
Hence, the relative abundance of the ion with m/z 860.5 for the y7 fragment originating from 
peptide A of the photo-irradiated IgG2 in D2O is ca.15% of that in H2O, and the relative 
abundance increased significantly, ca. 70%, for the isotopic peak with m/z 862.5. This difference 
in isotopic distributions between the fully protonated peptide A and peptide A originating from 
photo-irradiated IgG2 in D2O indicates that deuterium is covalently incorporated into the amino 
acids composing fragment ion y7. The analysis of the isotopic distributions of the y8, y9, and 
y11-y14 fragment ions do not reveal any significant shifts toward higher masses. Hence, we 
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conclude that deuterium incorporation occurred largely in the amino acids Q [303, HC] and/or D 
[304, HC].  
Peptide B: VTVLGQPK [109:116, LC] (m/z = 841.64, z = 2) 
Like for peptide A, a comparison of the isotopic distributions of peptide B after photo-
irradiation of IgG2 in H2O and D2O at λ = 253.7 nm exhibites a mass shift towards higher 
masses for photo-irradiated IgG2 in D2O (Fig. 4A). The comparison of the isotopic distributions 
of peptide B originating from non-irradiated IgG2 in H2O and D2O shows no mass shift (Fig. 
4B). The isotopic distribution of peptide B in H2O is composed of ions with m/z 421.3, m/z 421.8 
and m/z 422.3 with a relative abundance of 100%, 46% and 13%, whereas the same peptide after 
irradiation in D2O is composed of the same ions with a relative abundance of 80%, 100% and 
40%, respectively. The most intense peak in D2O shifts to the ions with m/z 421.8, compared to 
the most intense ion with m/z 421.3 in H2O. The relative abundances of the isotopic peaks for the 
peptide in D2O are ca. 110% higher for m/z 421.8, and ca. 200% higher for m/z 422.3 compared 
to the ones in H2O. These results indicate that during the photo-irradiation of IgG2 in D2O, 
peptide B covalently incorporated deuterium. 
To specify the location of covalent deuterium incorporation in peptide B, MS/MS 
analysis was performed (Fig. 5). The isotopic distribution of the fully protonated y1 fragment is 
composed of ions with m/z 147.1 and m/z 148.1 with a relative abundance of 100% and ca. 10%. 
After photo-irradiation of IgG2 in D2O, the corresponding fragment shows an isotopic 
distribution with a relative abundance of ca. 18% and 100%. The fact that the most intense peak 
shifted from m/z 147.1 to m/z 148.1 Da for a singly charged fragment ion indicates that nearly 
100% of peptide B has covalently incorporated one deuteron into the y1 fragment. Therefore, K 
[116, LC] represents a site for deuterium incorporation during the photo-irradiation of IgG2 in 
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D2O. Further analysis of the fully protonated fragment of y7 (TVLGQPK [110:116]) originating 
from the proteo sample shows an isotopic distribution for ions with m/z 742.5, m/z 743.5 and m/z 
744.5 with a relative abundance of 100%, 42% and 10%, respectively. After photo-irradiation of 
IgG2 in D2O, the fragment ion y7 shows an isotopic distribution for ions with m/z 743.5, m/z 
744.5 and m/z 745.5, with the same relative abundance of 100%, 42% and 10%, respectively, 
however 1 Da higher in mass than their corresponding ions in H2O. This result indicates that one 
deuterium is incorporated into the sequence TVLGQPK [110:116]. Meanwhile, no significant 
change is observed for the isotopic distributions of the fragment ion b2 between the proteo and 
deutero samples. However, the b3-H2O fragment ion shows an isotopic distribution for the ions 
with m/z 282.2 and m/z 283.2 with a relative abundance of 100% and 16%, whereas the fragment 
b3-H2O originating from photo-irradiation in D2O shows a relative abundance of 100% and 60% 
for the same ions, respectively. Variation of isotopic distributions for the fragment b3-H2O 
towards the higher masses is observed for the deutero sample compared to the proteo one. We 
can, therefore, hypothesize that the residue V [111, LC] has incorporated deuterium during 
photo-irradiation of IgG2 in D2O. In conclusion, the MS/MS analyses of the fragment ions of 
peptide B generated after photo-irradiation of the IgG2 in H2O and D2O, allow us to determine 
that V [111, LC] and K [116, LC] are two amino acid residues which covalently incorporates a 
deuteron during photo-irradiation of IgG2 in D2O. 
7.4 Discussion 
It was recently demonstrated that UV-irradiation (λ = 253.7 nm) of an IgG1 monoclonal 
antibody could lead to the formation of dithiohemiacetal and thioether products, originating from 
the photolytic cleavage of selected disulfide bonds [17]. Specifically, the formation of the 
dithiohemiacetal required disproportionation of a pair of CysS• radicals. An alternative reaction 
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of CysS• radicals is a hydrogen transfer reaction, as illustrated in Scheme 1 [15], which can 
generate carbon-centered radicals on surrounding amino acid residues. The intermediary 
formation of carbon-centered radicals can be monitored by covalent H/D exchange when 
photolysis reactions are carried out in D2O. Here, we have identified the selective incorporation 
of deuterium into two peptides in IgG2 and one peptide in IgG1. These two deuterated sequences 
are adjacent to disulfide bonds. The difference in deuterium incorporation in IgG1 and IgG2 
suggests an influence of IgG structure and sequence on CysS• radical formation and reactivity. 
Importantly, the observation hydrogen transfer reaction occurs very selectively, i.e., only involve 
a few amino acids in the HC and LC, respectively. The high sequence coverage of our HPLC-
MS/MS analysis, especially for IgG2, ensures that this observed selectivity is not the result of 
missed peptides but is an inherent feature of IgG conformation and radical reactivity. More 
importantly, preliminary data on photolytic fragmentation of IgG1 (unpublished results) indicate, 
that peptide B (VTVLGQPK) is located in a domain of IgG1, which is sensitive to 
fragmentation. The actual mechanisms of photolytic fragmentation of IgG1 are currently under 
investigation. However, radical pathway, such as initiated through radical-dependent formation 
of carbon-centered radicals on specific amino acids of IgG1 may well be at the origin of 
fragmentation reaction. 
7.5 Significance 
The intermediary formation of carbon-centered radicals after homolytic disulfide cleavage is 
critical since it may permit the epimerization of amino acids and, consequently, conformational 
changes. Moreover, carbon-centered radicals can serve as the origins for the formation of 
covalent crosslinks and fragmentation of proteins.  
7.6 Conclusions 
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The formation of intermediary carbon-centered radicals in IgG1 and IgG2 after UV-
irradiation (λ = 253.7 nm) has been documented through the covalent incorporation of 
deuterium. This observed covalent deuterium incorporation into IgG1 and IgG2 irradiated in 
D2O can be rationalized by intramolecular hydrogen transfer upon the formation of CysS• 
radicals. The formation of intermediary carbon-centered radicals in IgG monoclonal antibodies 
may lead to significant degradation, a major concern of biotherapeutic product development. 
Further understanding of degradation pathways induced by photo-exposure would provide 
valuable insight for regulatory agency and industry in evaluating protein photo-instability. 
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Table 1. The isotopic distribution of the identified triply charged peptide A 
(VVSVLTVVHQDWLNGK [294:309, HC]) originating from IgG2 after photo-
irradiation at λ = 253.7 nm in H2O or D2O, and the base peak intensities (BPIs) and their 
relative variations. 
m/z 598.7 599.1 599.4 599.7 600.1 
BPI in H2O (%) 32 100 88 43 16 
BPI in D2O (%) 22 100 97 53 21 
BPI variations (%) -10 0 +11 +10 +5 
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Scheme 1: proposed reaction mechanism to explain the formation of carbon-centered (C-
centered) radical. The mechanism proceeds through an intra-molecular hydrogen atom 
transfer reaction between αC and CysS•.   
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Fig. 1. MS spectra of peptide A, VVSVLTVVHQDWLNGK [294:309, HC], originating from 
IgG2 after proteolytic digestion: A) photo-irradiated IgG2, B) non photo-irradiated IgG2; 
IgG2 in H2O (empty peaks) or in D2O (filled peaks). 
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Fig. 2. MS/MS analysis and comparison of the isotopic distributions of the b fragment ions 
originating from peptide A, VVSVLTVVHQDWLNGK [294:309, HC], to localize the 
amino acid residues with covalently incorporated deuterium.   
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Fig. 3. MS/MS analysis of the y fragment ions originating from peptide A, 
VVSVLTVVHQDWLNGK [294:309, HC], to localize the amino acid residues with 
covalently incorporated deuterium.   
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Fig. 4. MS spectra of peptide B, VTVLGQPK [109:116, LC] originating from IgG2 after 
proteolytic digestion: A) photo-irradiated IgG2, B) non photo-irradiated IgG2; IgG2 in 
H2O (empty peaks) or in D2O (filled peaks). 
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Fig. 5. MS/MS analysis of the b and y fragment ions originating from peptide B, VTVLGQPK 
[109:116, LC], to localize the amino acid residues with covalently incorporated 
deuterium.   
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Chapter 8: Methodology development to detect and characterize IgG1 photo-degradants: 
Simultaneous Separation and Characterization of IgG1, IgG1 Fragments and 
Photodegradation Products by Reverse Phase Liquid Chromatography/ Mass 
Spectrometry (RPLC/MS) 
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8.1 Introduction 
Reverse phase liquid chromatography (RPLC) combined with mass spectrometry (MS) is 
an established method to identify and characterize proteins and their degradation products. An 
increased demand for fast and sensitive analysis has fostered the development of new liquid 
chromatography techniques accelerating chromatographic separation and reducing the protein 
amount needed for analysis. Non-porous columns have been utilized for protein separations, 
especially with particles of 2 µm or less in diameter [1-4] due to their unique advantages. 
Compared to conventional column stationary phase packing with porous particles, non-porous 
particles potentially increase the column efficiency by reducing Eddy diffusion, mass-transfer 
resistance and diffusional broadening due to the lack of pore structures. The use of non-porous 
packing also reduces the possibility of protein loss inside the pores of the porous packing 
material, improving resolution and protein recovery.  
In current practice, protein separation and the following desalting step are needed prior to 
protein analysis by LC/MS due to solvent incompatibility and sample complexity. Protein 
separation is typically achieved by reverse phase liquid chromatography (RPLC), size exclusion 
chromatograph (SEC), 1-D or 2-D sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and/or the combination of these techniques. The separation of intact monoclonal 
antibodies (mAbs) and their degradation products by traditional RPLC with porous columns has 
been intractable because of large size, structural complexity and hydrophobicity of the mAb. 
MAb separation by RPLC with porous columns typically results in low recovery, poor resolution 
and irreproducibility. The separation and desalting process is very labor-intensive and time-
consuming, which also increases risks of introduction of undesired modification(s), degradation 
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and material loss. Detection and characterization of mAb modifications and/or degradation 
products has remained a challenging analytical task because of product complexity and low 
abundance. Separation with online characterization of intact proteins and large fragments will 
pose an unambiguous advantage in the rapidly developing field of proteomics and 
biopharmaceutical product analysis.  
Non-porous columns have been explored for some time [5-9]. Dauly et al. demonstrated 
that matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-
MS) analysis of each collected  and desalted fraction of proteins from a non-porous column was 
a feasible method for sensitive and reproducible protein characterization [2]. Protein profiles of 
normal and malignant whole cell lysates of human breast cancer cell lines were also generated by 
using non-porous silica bead packing material, followed by further protein identification of each 
separated and desalted protein fraction from PRLC [3]. The challenges with the reported 
application of RPLC/MS for protein analysis are that prior to protein analysis by MS, the 
proteins of interest had to be separated by RPLC for fraction collection, and desalted.   
To the best of our knowledge, the separation with online characterization of an intact 
mAb and large mAb fragments by RPLC connected to a MS using non-porous columns without 
the need of pre-separation by other methodologies and desalting has not been reported. Here, we 
focus on developing a RPLC/MS method capable of separation with online characterization of an 
IgG1 and its photo-degradation products, especially fragments, without the need for additional 
separation and desalting. The separation of the proteins and fragments is achieved by RPLC 
using a non-porous column. The sensitivity and resolution of the mass spectrometer as well as 
the chromatographic separation were optimized with an in-house prepared mixture containing 12 
ng lysozyme, 60 ng bovine serum albumin (BSA), 200 ng IgG1 heavy chain (HC), 600 ng IgG1 
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light chain (LC), 400 ng IgG1 Fab-HC, 400 ng IgG1 constant HC (Fc-HC) and 800 ng IgG1. 
Excellent reproducibility in retention time (%RSD < 0.4) and reasonable reproducibility in peak 
area (total ion counts,) of %RSD < 16 are demonstrated. The limit of detection (LOD) of the 
proteins and IgG1 fragments ranged between 1.2 and 80 ng dependent on the nature of the 
analytes. Analysis of IgG1 photo-degradation products further confirmed that this developed 
RPLC/MS method using a non-porous column is a fast and highly sensitive analytical tool, 
allowing us to characterize the degradation products, especially fragments, with very limited 
material of 3 µg IgG1. The detected fragments were confirmed by SDS-PAGE. Combination of 
the information obtained from our developed RPLC/MS method with in-gel digestion of the 
fragments resolved by SDS-PAGE allowed us to determine the potential fragment sequence, 
providing valuable insight into IgG1 photo-instability. Thus, a fast and highly sensitive 
separation with online characterization method to analyze intact proteins and fragments would 
provide a novel and powerful approach in proteomic and biopharmaceutical analysis to greatly 
improve efficiency.    
8.2 Experimental 
8.2.1 Materials 
Recombinant monoclonal immunoglobulin (IgG1, 35 mg/mL) was supplied by Amgen 
Inc. (Seattle, WA, USA). The purified protein was stored in formulation buffer at -80oC. Other 
commercially available proteins, such as lysozyme (pI: 11.0, MW: 14.388 kDa) and bovine 
serum albumin (BSA) (pI: 4.7, MW: 66,463 Da) were purchased from Sigma Aldrich (St. Louis, 
MO, USA). Dithiothreitol (DTT), iodoacetamide (IAM), sodium phosphate, dibasic (Na2HPO4), 
sodium phosphate, monobasic (NaH2PO4) and sodium chloride (NaCl) were also purchased from 
Sigma Aldrich (St. Louis, MO, USA). FabRICATOR® was purchased from Bulldog Bio, Inc. 
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(Portsmouth, NH, USA), a distributor of Genovis (Lund, Sweden) in the USA. All organic 
solvents (analytical and HPLC grade) were purchased from Sigma Aldrich (St. Louis, MO, USA) 
or VWR Scientific (West Chester, PA, USA). SDS-PAGE running buffer (100 mM tris, 1.92 M 
glycine and 0.1% (w/v) SDS at pH 8.3) and Precision Plus Protein dual color standards were 
obtained from Bio-Rad (Hercules, CA, USA). Sequencing grade trypsin and Glu-C were 
purchased from Promega Corp. (Madison, WI, USA). SYPRO® orange dye, supplied as a 5000x 
concentrated solution in dimethyl sulfoxide (DMSO), was purchased from Invitrogen, Inc. 
(Carlsbad, CA, USA). 
8.2.2 Sample preparation 
8.2.2.1 Formation of light chain (LC) and heavy chain (HC) from IgG1. 
The stock solution of IgG1 was dialyzed at 2-8oC in milliQ H2O using a dialysis cassette 
with a 10 kDa cut-off membrane (Pierce, Rockford, IL, USA). After dialysis, IgG1 was diluted 
to 1 mg/mL in milliQ H2O. 4 µL of a DTT stock solution (100 mM in H2O) were added into the 
solution prior to incubation at 37oC for 30 min. The reduction of the disulfide bonds of IgG1 
results in the separation of the LC and HC chains. The final concentrations of both LC and HC 
were 2 µg/µL. 
8.2.2.2 Formation of the Fab-HC, Fc-HC, and LC from IgG1 
   IgG1 was prepared at 1 mg/mL in 50 mM sodium phosphate buffer in the presence of 
NaCl (150 mM) at pH 6.6. An aliquot of 10 µL reconstituted FabRICATOR® solution in H2O 
(20 unit/µL in H2O) was added to the solution prior to incubation at 37
oC for 30 mins. After 
cleavage of IgG1 between the residues Cys 225 and Cys 257 of the HC, the disulfide bonds 
present in the resulting protein fragments were reduced according to the procedure described 
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above to form Fab-HC, Fc-HC and LC as shown in Fig. 1. The final concentrations of LC, Fab-
HC and Fc-HC were 2 µg/µL. 
8.2.2.3 Preparation of protein mixture standard 
BSA, lysozyme, intact IgG1 and its LC, HC, Fab-HC and Fc-HC were mixed to achieve 
the final concentrations listed in Table 1. The protein mixture was prepared in milliQ H2O with 
0.5% formic acid (v/v).    
8.2.2.4 Photo-degradation of IgG1 
IgG1 was prepared at 10 mg/mL in 20 mM sodium phosphate buffer at pH 6.5. The 
sample was placed in a quartz tube and irradiated for either 30 or 45 minutes with ultra-violet 
(UV) light (λ = 253.7 nm) by means of a Rayonet photochemical equipped with four UV lamps 
(RMA-500) (Southern New England Ultraviolet Company, Branford, CT, USA). Photo-
irradiated IgG1 was cleaved and reduced into LC, Fab-HC, and Fc-HC according to the protocols 
described in the sections of 8.2.2.1 and 8.2.2.2.  
8.2.2.5 Reverse phase liquid chromatography/mass spectrometry (RPLC/MS) 
Mass spectrometry data acquisition was achieved on a SYNAPT G2 high definition mass 
spectrometer (Waters Corp. Milford, MA, USA). Electrospray ionization (ESI) mass spectra of 
the proteins were acquired by operating the SYNAPT G2 for maximum resolution with all lenses 
optimized on the [M + 2H]2+ ion from the [Glu]1-fibrinopeptide B and Ar was admitted to the 
collision cell. The capillary voltage was set to 2.9 kV. The cone voltage was set at 45 V and 
ramped to 85 V. The voltage of the extraction cone was maintained at 6 V. Source and 
desolvation temperatures were set at 95oC, and 200oC, respectively. Gas flows at the cone and 
for desolvation were set at 40 L/h, and 250 L/h, respectively. The spectra were acquired using a 
mass range of 900-3000 amu (amu: atomic mass unit). The data were accumulated for 0.7 sec per 
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cycle and processed using the software MassLynx (Waters Corp. Milford, MA, USA).  ESI 
generates a series of multiply charged ions for a single protein. To characterize the proteins 
present, the mass-to-charge (m/z) ratio distributions were analyzed by maximum entropy 
(MaxEnt) processing. MaxEnt disentangled the m/z distribution of each mass spectrum produced 
by the mass spectrometer to present the proteins in the mixture as single peaks on a molecular 
mass scale [10-12].  
  The proteins were chromatographically separated after injection of an aliquot of 2 μL of 
each sample onto a non-porous column, Presto FF-C18 (15 cm x 0.5 mm C18, 2 µm), packed 
with octadecyl silane (ODS) from Imtakt Corp. (Philadelphia, PA, USA). The column was 
maintained at 65oC and the solvents were eluted through the column by an Acquity 
Chromatography System (Waters Corporation, Milford, MA, USA). Mobile phases consisted of 
H2O/acetonitrile (ACN)/formic acid at a ratio of 99%, 1%, 0.08% (v/v/v) for solvent A and a 
ratio of 1%, 99%, 0.06% (v/v/v) for solvent B. The column was equilibrated with 15% B at a 
flow rate of 5 µL/min. Between 0 - 3 min, and 3 – 20 min the eluent composition was linearly 
increased to 25% B and 35% B, respectively, at a constant flow rate of 5 µL/min. Between 20 - 
35 min and 35 – 45 min, the eluent composition was modified to reach 65% and 95% B, 
respectively, through a non-linear gradient (chromatographic curve # 3) at a flow rate of 7 
µL/min. Elution at 95% B was held for 2 min. After 47 min, the flow rate was gradually 
increased to 10 µL/min and held for 10 mins with 95% B for column washing. The column was 
re-equilibrated with 15% B at 5 µL/min for 10 mins.  
8.2.2.6 SDS-PAGE  
The photo-irradiated IgG1 was treated according to the protocol described in section 1.2. 
After reduction of the disulfide bonds, the reduced Cys residues were alkylated. An aliquot (100 
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µL) of the cleaved and reduced photo-irradiated IgG1 sample was mixed with 5 µL of 
iodoacetamide stock solution (100 mM in H2O) and incubated at ambient room temperature for 
30 mins in the dark. The alkylated sample was mixed with SDS-PAGE sample buffer containing 
100 mM Tris, 100 mM Tricine, and 0.1% (w/w) SDS at pH 8.25. The sample was heated at 
100oC for 1 min after mixing and subsequently, 20 µL were loaded onto a polyacrylamide gel 
Novex 4-20% (Invitrogen, Carlsbad, CA, USA). Molecular Weight Standard, precision plus 
protein dual color standards from Bio-Rad (Hercules, CA, USA), was loaded onto the same gel 
as a molecular weight reference. The gel electrophoresis was run under a difference of potential 
of 250 V for 60 min using diluted (1/10) running buffer. During electrophoresis, the temperature 
was maintained at 6oC.  
8.2.2.7 Fluorescence visualization of the IgG1 and its degradants 
SYPRO® Orange dye was used as a fluorescence probe to visualize IgG1 and its 
degradation products. The gel was first rinsed with 2 mM EDTA twice and then incubated in 
diluted acetic acid (1.7 M) containing 5000x diluted SYPRO® Orange dye for 1.5 hours. The gel 
was rinsed three times with 1.7 M acetic acid prior to gel imaging. The fluorescence was 
recorded at 580 nm with the excitation wavelength at 488 nm by TyphoonTM and 
ImageQuantTM Laser Imager from GE HealthCare (Fairfield, CT, USA).  
8.2.2.8 In-gel digestion 
The separation of IgG1 and its degradation products was visualized with Coomassie blue 
(Coomassie R250/acetic acid/MeOH/H2O (0.2/7.5/30/62.5%, v/v/v/v)) obtained from BioRad 
(Hercules, CA, USA). Destaining was performed in acetic acid/MeOH/H2O (10/40/50, v/v/v). 
The fragments of interest were excised from the Coomassie blue-stained gel. The protein present 
in the gel slice was digested according to the in-gel digestion protocol described by Shevchenko 
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et al [13]. Briefly, the gel slice was washed twice with NH4HCO3 (100 mM in H2O) in 50% 
ACN (v/v) for 15 min at room temperature. After removal of the solvent, the gel slice was 
washed twice with 100% ACN for 15 mins at room temperature. The gel slice was dried under 
SpeedVac (Labconco Corp. Kansas City, MO, USA). The dried gel slice was placed in 200 µL of 
a Promega® reconstitution buffer for trypsin, containing 8 µg of trypsin and 4 µg of Glu-C. The 
sample was incubated at 4oC for 1 hour for the gel absorption of tryptic enzymes. Prior to 
digestion incubation 37oC overnight, an aliquot of 300 µL NH4HCO3 (100 mM in H2O) was 
added to the sample. The solution was transferred into new vials upon the completion of 
digestion. The gel slice was washed in ACN and centrifuged for 2 mins at 14000 g. The washed 
solution was transferred into the same new sample vials. Solvent was vacuum dried to reach a 
final volume of 20 µL. 
8.2.2.9 LTQ-FT-MS 
The following procedure was applied to analyze the peptides resulting from the 
proteolytic digestion of the protein isolated by SDS-PAGE. Collision induced dissociation (CID) 
of fragment ions was performed by means of an LTQ-FT hybrid linear quadrupole ion trap 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (ThermoFinnigan, 
Bremen, Germany) [14]. MS/MS data were acquired with an attenuation of the parent ion in the 
range of 25%-35%. The mass window to collect the parent ion was fixed to ±0.2 Da.  
The data were processed using the ThermoElectron BioWorks 3.2 software followed by 
peptide identification using the Mascot database-searching program based on the custom-defined 
IgG1 primary sequence. The peptide assignments obtained were validated using a statistical 
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method of the Scaffold 1.7 software (Proteome Software Inc., Portland or 
http://www.proteomesoftware.com). 
8.3 Results and Discussion 
This work focused on the development of a fast and sensitive analytical tool without the 
need of additional separation and desalting processes to simultaneously separate and characterize 
proteins and their fragments. The non-porous packing material of the Presto-FF C18 column 
allows efficient separation of intact proteins and large protein fragments by reducing mass 
transfer [1]. The separation of macromolecules on a non-porous column has already been 
reported [3-8]. However, to the best of our knowledge, simultaneous separation with online 
characterization of intact proteins and large fragments with RPLC/MS using a non-porous 
column without having to resort to additional fractionation was never documented. In the present 
work, we demonstrate that proteins in the range of 14–150 kDa can be well separated with high 
sensitivity. Analysis of the photo-induced IgG1 degradation products with this developed method 
further confirmed that it is a highly sensitive and rapid method capable of simultaneous detection 
and characterization of the degradation products, especially fragments. The acquired structural 
modifications will also provide valuable insight to understand the possible degradation 
mechanism and the liable region(s) prone to degradation.  
8.3.1 Separation and characterization of proteins by RPLC/MS 
BSA, lysozyme, intact IgG1 and its LC, HC, Fab-HC and Fc-HC were separated and 
identified by mass spectrometry (Fig. 2a-h). The nature of the protein present in each 
chromatographic peak was determined after MaxEnt processing of the respective mass spectra 
(Fig. 2b-h, right panels).  
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8.3.1.1 Constant heavy chain (Fc-HC) of IgG1. The mass to charge (m/z) distribution 
pattern (Fig. 2b, left panel) for the first elution peak at 17.28 minutes indicates the presence of 
two species and the mass deconvolution yielded two main species with a mass of 25,202 Da and 
25,364 Da (Fig. 2b, right panel), corresponding to IgG1 Fc-HC which was glycosylated. The 
number of monosaccharide residues coupled to a protein is estimated by a mass increase of 162 
Da per attached monosaccharide [15, 16]. Thus, the observed mass difference between the two 
Fc-HC species is rationalized by the loss of a monosaccharide.  
8.3.1.2  Lysozyme. The same approach was used to identify the other chromatographic 
peaks. Lysozyme eluted after IgG1 Fc-HC at 18.45 min (Fig. 2a). The deconvoluted mass 
spectrum (Fig. 2c, right panel) shows a mass of 14,306 Da, matching its reported molecular 
weight of 14,307 Da (from chicken egg white) within an accuracy of 1 Da [17]. 
8.3.1.3  Light chain (LC) of IgG1. The reduced but not alkylated LC eluted at 19.49 min 
(Fig. 2a). After deconvolution only one mass of 22,927 Da (Fig. 2d right panel) is observed and 
this mass matches the theoretical molecular weight of the reduced LC. The observation of two 
sets of charge state distributions centered at m/z 1,433.90 and 2,085.20 (Fig. 2d, left panel) for a 
single species indicates the presence of two different conformational states [17-20]. In a first 
approximation, we can consider that the distribution of ions centered at m/z 2,085.20 
characterizes the folded (native) state and the one centered at m/z 1,433.90 represented a partially 
unfolded, or loosely folded, state [21, 22].   
8.3.1.4  Heavy chain (HC) of IgG1. The reduced but not alkylated HC eluted at 21.57 min 
(Fig. 2a). The mass spectrum (Fig. 2e, left panel) indicates the presence of two HC with masses 
of 49,636.04±8.36 Da and 49,475.95±10.57 Da. Based on the uncertainty of ± (8.36-10.57) Da, 
the variation of mass between the two HC is about 161 Da which would correspond to a 
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monosaccharide. The latter is confirmed after MaxEnt data processing (Fig. 2e, right panel). 
Indeed, after deconvolution of the charge state into a mass scale spectrum, the molecular weights 
of 49,475 Da and 49,636 Da are observed as the most probable components of the charge state 
ion distribution presented in the mass spectrum (Fig. 2e, left panel). With a difference of mass of 
161 Da, we assume that the observation of these two masses is related to the presence of 
different glycosylation forms of the IgG1. This is consistent also with our observation of two 
glycosylated forms of IgG1 during the analysis of the IgG1 Fc-HC region (see above). Together, 
the results are consistent with the fact that the glycosylation site of IgG1 is located in the Fc-HC. 
8.3.1.5  Fab region of IgG1 heavy chain (Fab-HC). The reduced but not alkylated Fab-
HC region eluted at 23.12 min (Fig. 2a). Charge state distributions of the ions were observed 
analogous to those for the IgG1 LC, centered at m/z 1,429.63 and m/z 2,024.91 (Fig. 2f, left 
panel) corresponding to a single species. These two charge state distributions indicate the 
presence of two different conformational states. The distribution of ions centered at m/z 2,024.91 
indicates a folded (native) state and the one centered at m/z 1,429.63 likely a partially unfolded 
state, allowing the protonation of more amino acid residues. The sum of the masses of IgG1 Fab-
HC and Fc-HC (as reported above) are ca. 18-20 Da higher than those observed for intact HC, 
i.e., 49,636 Da (Fig. 2e). This mass difference of ca. 18 Da is rationalized by the additional 
peptide bond between the IgG1 Fab-HC and the Fc-HC fragments to form the intact HC. 
8.3.1.6  BSA. BSA eluted at 26.24 min (Fig. 2a). The deconvoluted mass spectrum (Fig. 
2g) shows a molecular weight of 66,438 Da, matching its reported molecular weight of ca. 66 
kDa provided by the supplier. 
8.3.1.7  Intact IgG1. Surprisingly, two peaks eluting at 21.96 min and 27.79 min (Fig. 2a) 
were observed. Both chromatographic peaks show similar charge state distributions (Fig. 2h, left 
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panel, top and bottom). The deconvoluted mass spectra (Fig. 2h, right panel) show a major mass 
of ca. 144,950 Da along with masses of 142,093 Da and 147,691 Da. The measured mass of 
142,093 Da matches the average calculated mass of deglycosylated IgG1 based on its primary 
sequence. The major species, glycosylated intact IgG1 with a mass of 144,950 Da, is ca. 2,726 
Da heavier than the theoretical average mass. The mass difference of 2,726 Da matches the 
average mass of glycans (ca. 2,750 Da) reported for such immunoglobulins [23]. The species 
corresponding to the mass of 147,961 Da likely represents also glycosylated IgG1, demonstrating 
same glycosylation heterogeneity. The fact that the intact IgG1 was separated into two discrete 
populations indicates the existence of two conformational states, consistent with our analysis of 
the Fab-HC and the LC, denoted above. At this point, we cannot conclude that the discussed 
conformers are originally present in the IgG1 stock solution. Rather, we believe that the use of 
acetonitrile and elevated temperature during reverse phase chromatography may lead to partial 
unfolding of the protein. The presence of two conformers of IgG1, and the observation of the 
combination of two charge state distributions produced during the MS analysis of its LC (Fig. 
2d) and Fab-HC (Fig. 2f)  indicate that the observed two conformers of IgG1 (Fig 2h) are the 
result of conformational modifications of its Fab region. Hence, our method is not only capable 
of allowing simultaneous separation and characterization of proteins and fragments but also 
capable of providing some information on the conformational stability of the protein. For 
convenience, we will refer to the two conformers as conformer A (eluted at 21.96 minutes) and 
conformer B (eluted at 27.79 minutes). 
8.3.2 LOD and reproducibility  
Each protein in the standard mixture was individually analyzed under the same 
chromatographic conditions to explore if the presence of other proteins and fragments in the 
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mixture would interfere with the separation and detection. The consistency in retention time 
between the chromatograms of the individual components and the mixture (as shown in Fig. 3) 
demonstrates that the separation and detection of the individual components in the mixture is not 
compromised by the presence of the other proteins and fragments. The chromatogram of intact 
IgG1 (Fig. 3e) exhibits two well separated peaks with identical mass spectra, confirming the 
presence of two conformers.  
The reproducibility of the method was evaluated by three consecutive injections of the 
same protein mixture under identical conditions. Retention time and peak area averages, as well 
as standard deviation (SD) and relative standard deviations (RSD) were calculated for each 
analyte as listed in Table 2. Excellent reproducibility in retention time (< 0.4%) with detectable 
peak area (total ion counts) is demonstrated. Peak area (total ion counts) showed an increased 
variation with RSDs of < 5% except for IgG1 HC, IgG1 conformer A (6.5% of RSD) and IgG1 
Fab-HC (16.26% of RSD). The partial resolution of IgG1 HC, its conformer A, and Fab-HC may 
contribute to the increased variation in peak area.  
The LOD was evaluated by diluting the protein mixture standard by ten-fold and one 
hundred-fold. The same volume, an aliquot of 2 µL, was injected under identical conditions. An 
amount of 20.0 ng IgG1  Fc-HC, 1.2 ng lysozyme, 30.0 ng IgG1 LC, 10.0 ng IgG1 HC, 20.0 ng 
IgG1 Fab-HC, 6.0 ng BSA and 80 ng intact IgG1 in the mixture exhibit acceptable peak intensity 
for detection and quantification (as shown in Fig. 4). After dilution by 1/100 of the original 
mixture, the signal-to-noise ratios for 2.0 ng  Fc-HC, 0.12 ng lysozyme, 3.0 ng LC, 1.0 ng HC, 
2.0 ng Fab-HC, 6.0 ng BSA and 8.0 ng whole IgG, were too low for detection (data not shown 
here).  
8.3.3 Analysis of photo-induced IgG1 degradation  
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The photo-induced degradation of the IgG1 was analyzed by our developed RPLC/MS 
method. The photo-irradiated samples were first diluted ca. 7-fold to 1.5 mg/mL and then an 
aliquot of 2 µL was injected. A representative chromatogram of IgG1 after exposure to UV light 
is displayed in Fig. 5a. The analyte present in each chromatographic peak was analyzed by 
processing the respective mass spectrum with MaxEnt. A new protein fragment with a mass of 
13,210 Da (Fig. 5b), and modified IgG1 Fc-HC with masses of 25,233 Da and 25,396 Da (Fig. 
5c) respectively were detected. Each new component is discussed in detail below. 
8.3.3.1 Fragment with a mass of 13,210 Da. A fragment with the mass of 13,210 Da (Fig. 
5b), which is not present in the control (non-photo irradiated IgG1), eluted at 14.95 minutes. A 
fragment with the same mass was also formed during photo-irradiation of IgG1 under Ar (Fig. 
5d). SDS-PAGE analysis followed by Coomassie blue staining did not allow the visualization of 
this fragment due to its extremely low abundance even after application of a ca. 80-fold 
increased protein load. However, the production of this new protein fragment with a mass of 
13,210 Da was confirmed by SDS-PAGE combined with fluorescence imaging using SYPRO® 
Orange after application of a 15-fold increased protein load. The left panel of Fig. 6 clearly 
exhibits the IgG1 Fab-HC, Fc-HC, LC and protein species of higher mass (lane 1 and 2 were 
loaded with IgG1 samples irradiated for 30 and 45 minutes, respectively). The right panel of Fig. 
6 generated by lower γ correction using Adobe Photoshop (Adobe, San Jose, CA, USA) enables 
us to visualize a fragment band with a mass of ca. 13 kDa. This further demonstrates that our 
developed LC/MS method using the non-porous column is highly efficient and sensitive to 
separate, detect and characterize protein fragments, at least 80-fold more sensitive than SDS-
PAGE stained by Coomassie dye. We also note that this new RPLC/MS method only takes 60 
minutes instead of at least several hours necessary to complete SDS-PAGE analysis. The 
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corresponding ca.13 kDa band area in the gel stained with Coomassie dye was excised for in-gel 
digestion and peptide mapping.  
After mass determination of the fragment by mass spectrometry (Fig. 5b), we searched 
the possible peptide sequences which would match any sequence in our IgG1 by using the web-
based software FindPept (ExPasy; Bioinformatics Research; http://web.expasy.org/findpept). 
The search criteria used were: mass variation of ±0.5 Da and oxidation of Trp (+16 and/or 32 
Da) and Met (+16 and/or 32 Da). Two candidate peptide sequences located in the IgG1 LC 
region (Table 3) matched the fragment mass of 13,210 Da within ±0.5 Da. These are overlapping 
sequences originating from the sequence LC15-LC52. To confirm the sequence of the fragment, 
peptide mapping by LC/MS/MS of the in-gel digested fragment was performed. The detected 
peptides for the two candidate fragments (Table 3) are listed in Table 4a-b, respectively. The 
amino acids in the identified peptide sequences by LC/MS/MS covered 86% and 89% of the 
amino acids in the respective candidate peptide sequences obtained from FindPept. The 
formation of the fragment (a mass of ca.13,210 Da) in both air-saturated and Ar saturated 
solution suggests that the fragmentation between Ser and Asn, Val and Ala, Pro and Gly, and 
Cys and Leu does not involve oxygen and oxygen-centered radicals. Thus, this identified 
fragment is probably due to hydrolytic cleavage. We also note that during the photo-irradiation 
of IgG1, the peptide bond between the amino acid residues His [36, LC] and Trp [37, LC] is 
cleaved leading to the formation of the peptide WYQQLPGTAPL (Table 4a, first entrance). The 
understanding of the mechanism leading to such hydrolytic cleavage is out of the scope of this 
study. However, we may hypothesize that during the photo-irradiation of IgG1, the formation of 
the radical cation of Trp [37, LC] could be at the origin of the fragmentation of the peptide bond 
[24]. 
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8.3.3.2. Modified IgG1 Fc-HC. Mass analysis indicates that the modified IgG1 Fc-HC 
with masses of 25,233 Da and 25,396 Da (as shown in Fig. 5c) was eluted at 15.21 minutes 
before the elution of non-modified Fc-HC. A mass increase of 32 Da and 33 Da within ca. ±1 Da 
accuracy compared to their corresponding non-modified ones (Fig. 2b), respectively, indicates 
the modifications may be due to oxidation. Fc-HC is the region responsible for its biologic 
properties, which include activation of the complement system which leads to enhanced 
phagocytosis, placental transfer, and binding to cell-surface receptors [25]. Thus, any 
modifications to this region may produce impact in its functionality. A detailed analysis of all 
modifications is currently in progress. 
8.4 Conclusions 
In this study, we focused on developing a fast and highly sensitive method using RPLC 
combined to MS for simultaneous separation and characterization of intact proteins and large 
fragments, eliminating the need of additional fractionation and protein desalting. The separation 
was achieved by using a non-porous column with a combination of two non-linear gradients of 
H2O and ACN. We demonstrate that this method exhibits excellent retention time reproducibility 
of %RSD < 0.4 and a fair reproducibility in peak area (total ion counts) of %RSD < 16. The 
LOD of the tested proteins ranged between 1.2 and 80 ng, dependent on the nature of the analyte. 
In addition, this method was capable of not only separating two conformers of IgG1 but also 
providing conformational information, that is, identifying the Fab-region responsible for intact 
IgG1 two conformational states. The analysis of photo-induced IgG1 degradation further 
demonstrates that this developed RPLC/MS method is a highly sensitive analytical method to 
detect and characterize fragments, at least 80-fold more sensitive than that of SDS-PAGE stained 
by Coomassie blue. The information acquired from our developed RPLC/MS method allowed us 
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to detect and characterize the fragment(s) originating from the IgG1 light chain due to photo-
irradiation, providing a valuable tool for studying the photo-instability of antibodies.  
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Table 1. Compositions of the protein mixture for RPLC/MS method development using a non-
porous column    
Compositions Lysozyme BSA LC Fab-HC Fc-HC HC Intact IgG 
Conc. (ng/µL) 6 30 300 200 200 100 400 
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Table 2. Retention time and peak area (ion counts) reproducibility of RPLC/MS method 
evaluated by three consecutive injections under identical conditions  
Components 
Fc-
HC 
Lysozyme LC 
HC/IgG 
conformer 
A 
Fab-
HC 
BSA 
IgG 
conformer 
B 
Retention 
time 
(min) 
Avg 15.60 16.68 19.14 21.96 22.90 26.41 27.84 
SD 0.00 0.06 0.06 0.00 0.005 0.061 0.05 
% RSD 0.00 0.37 0.32 0.00 0.021 0.23 0.21 
Peak area 
(ion 
counts) 
Avg 2043 5634 7515 1831 2149 732 1616 
SD 73 82 177 119 349 29 68 
% RSD 3.58 1.45 2.35 6.50 16.26 4.02 4.18 
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Table 3. Identified peptide fragments (highlighted in bold font) by FindPept in the IgG1 sequence 
for the fragments with a mass of 13,210 Da detected by RPLC/MS using the following 
criteria: mass variation of ±0.5 Da, oxidation of Trp (+16 and +32 Da) and Met (+16 and 
+32 Da). (The cleavage sites are indicated by *).  
Frag
ment 
# 
Fragment 
Mass 
Matched 
peptide 
mass 
(Da) 
Mass 
differe
nce 
(Da) 
Peptide sequence 
Peptide 
position 
in mAb 
1 13210.00 13209.56 -0.464 
(S)NIGAGYDVH*WYQQLPGTAPK*L
LIYGNSNRPSGVPDRF*SGSKSGTSA
SLAITGLQAEDE*ADYYCQSYDSSLS
GLYVFGTGTK*VTVLGQPK*ANPTV
TLFPPSSEE*LQANKATLVCLISDF*
YPGAVTV(A) 
LC 28-
152 
2 13210.00 13210.49 0.468 
(P)GQR*VTISCTGSSSNIGAGYDVHW
YQQLPGTAPK*LLIYGNSNRPSGVP
DRF*SGSKSGTSASLAITGLQAEDE*
ADYYCQSYDSSLSGLYVFGTGTK*V
TVLGQPK*ANPTVTLFPPSSEE*LQA
NKATLVC(L) 
LC 15-
140 
 
274 
 
Table 4a. Peptides identified by LC/MS/MS for fragment #1 listed in Table 3 with the PP, 
PP2, PPtag, mass accuracy and locations in IgG1 light chain (LC). (PP, PP2, PPtag are 
three statistical scores to evaluate the quality of a peptide match. A peptide match 
with max (PP, PP2) > 4.5 and PPtag > 1.3 is considered to be significant with p value 
< 0.05). 
Peptide sequence PP PP2 PPtag ±Mass (Da) Location 
WYQQLPGTAPK 22.6 22.7 4.6 -0.0035 LC37-47 
LLIYGNSNRPSGVPDR 11.1 12.0 1.8 -0.0121 LC48-63 
SGTSASLAITGLQAEDE 25.1 25.2 2.0 -0.0075 LC69-85 
ADYYCQSYDSSLSGLYVFGTGTK 20.6 23.9 5.1 -0.0083 LC86-108 
VTVLGQPK 28.6 31.5 7.3 0.0007 LC109-116 
ANPTVTLFPPSSEE 8.0 11.7 2.2 0.0006 LC117-130 
ATLVCLISDF 13.1 16.2 2.1 0.0069 LC136-145 
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Table 4b. Peptides identified by LC/MS/MS for fragment #2 listed in Table 3 with the PP, PP2, 
PPtag, mass accuracy and locations in IgG1 light chain (LC). (PP, PP2, PPtag are three 
statistical scores to evaluate the quality of a peptide match. A peptide match with max 
(PP, PP2) > 4.5 and PPtag > 1.3 is considered to be significant with p value < 0.05). 
Peptide sequence PP PP2 PPtag ±Mass (Da) Location 
VTISCTGSSSNIGAGYDVHWYQQLPGTAPK 10.5 10.3 1.5 -0.0035 LC18-47 
LLIYGNSNRPSGVPDR 11.1 12.0 1.8 -0.0121 LC48-63 
SGTSASLAITGLQAEDE 25.1 25.2 2.0 -0.0075 LC69-85 
ADYYCQSYDSSLSGLYVFGTGTK 20.6 23.9 5.1 -0.0083 LC86-108 
VTVLGQPK 28.6 31.5 7.3 0.0007 
LC109-
116 
ANPTVTLFPPSSEE 8.0 11.7 2.2 0.0006 
LC117-
130 
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Fig. 1. Cartoon of IgG1 monoclonal antibody structure 
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Fig. 2. RPLC/MS analysis of protein mixture standard containing lysozyme (12 ng), bovine 
serum albumin (BSA) (60 ng), IgG1 LC (600 ng), IgG1 Fab-HC (400 ng), IgG1 Fc-HC 
(400 ng), IgG1 HC (200 ng) and IgG1 (800 ng). RPLC-MS chromatogram (a), mass 
spectrum for IgG1 Fc-HC at tR = 17.28 min (b), lysozyme at tR = 18.45 min (c), IgG1 LC 
at tR = 19.49 min (d), IgG1 HC at tR = 21.57 min (e), IgG1 Fab-HC at tR = 23.12 min (f), 
BSA at tR = 26.24 min (g) and intact IgG1 at tR = 21.96 min and tR = 27.79 min (h)
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Fig. 3. RPLC/MS chromatograms for individual analyzed lysozyme (12 ng/µL) (a), BSA (60 ng) 
(b), reduced IgG1 (100 ng) (c), cleaved and reduced IgG1 (200 ng) (d) and intact IgG1 
(800 ng) (e)  
 
 
a 
b 
c 
d 
e 
Mixture 
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Fig. 4. RPLC/MS chromatogram of the protein mixture standard for limit of quantitation: IgG1 
Fc-HC 20 ng, 1.2 ng lysozyme, 30 ng IgG1 LC, 10 ng IgG1 HC, 20 ng IgG1 Fab-HC, 6 
ng BSA and 80 intact IgG1  
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Fig. 5. Analysis of IgG1 photo-degradation products for photo-irradiation in the air: RPLC/MS 
chromatogram (a), mass spectra for the fragment (b) and mass spectra for modified IgG1 
Fc-HC (c), and mass spectra for the fragment when IgG1 photo-irradiation under Ar (d)  
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Fig. 6. SYPRO® Orange dye labeled reduced SDS-PAGE gel fluorescence image recorded at 
emission wavelength of 580 nm with the excitation wavelength at 488 nm by TyphoonTM 
and ImageQuantTM Laser Imager (left panel at γ correction factor of 2.0 and right panel 
at γ correction factor of 0.2 by Photoshop). Lane 1 and 2 were loaded with IgG1 samples 
irradiated for 30 and 45 minutes, respectively.   
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Part IV: Future Work 
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In this study, chemical and physical instability of several IgG mAbs due to metal 
catalyzed oxidation were investigated. The impact of Fe3+ on IgG physical instability, 
conformational change, formation of soluble aggregates, and intrinsic thermal instability was 
systematically studied. Chemical instability, oxidative modifications of IgG primary sequences 
by redox-active metal ion (Cu2+) coupled with L-ascorbic acid were investigated. Oxidation of 
Phe and Tyr in IgG1 was first identified by fluorogenic derivatization using fluorescence 
spectrometry besides the known oxidation of His, Met and Trp. The oxidation of amino acids in 
IgG is impacted not only by their intrinsic properties, such as location in primary sequence and 
high order of structure, but also the external factors, such as temperature, contact materials, etc. 
The identification of critical determination factor(s) will or should greatly help scientists to 
design a more and/or robust drug product for patients.  
The fluorogenic derivation developed in this study can only qualitatively detect the 
oxidation of Phe and Tyr residues in antibodies. Quantification of their oxidation using 
fluorescence is going to be the focus in next study. The oxidized amino acid residues may 
jeopardize protein function(s). The implication of the oxidized Phe and Tyr residues in IgG1 
antibody’s bioactivity is not clear which needs investigation. The quantitation of the levels of 
oxidized Phe and Tyr residues will help us understand the significance of the oxidation in 
affecting IgG antibody’s bioactivity. 
Even though both physical and chemical instability of proteins induced by redox-active 
ions were studied individually, the correlations and inter-relationships between physical and 
chemical instability pathways of protein degradation due to MCO have not been established. In 
addition, the metal ions of iron, chromium, nickel and tungsten are often seen in biotherapeutic 
284 
 
products instead of Cu2+ due to leaching from the contact materials and/or residues present in 
excipients. Whether the metal ions behave similarly in inducing IgG chemical and/or physical 
instability has not be explored. 
Besides physical and chemical instability of IgG induced by redox active metal ions, 
photo-instability of IgG was also studied since photo stability testing is an integral part of the 
overall stability testing program required by regulatory agencies. The H/D exchange study in this 
work identified the formation of carbon-centered radical in IgGs due to photo-irradiation, and 
opens a door to better understand photo-degradation mechanism. With the aid of the developed 
RPLC-MS method with a non-porous column, we are currently investigating the origin of 
photolytic fragmentation of IgG. 
 
